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Nanomaterials such as quantum dots and polymeric nanoparticles have found a variety of applications 
in biology including bioimaging and drug delivery. Despite tremendous progress, applications of these 
materials for disease detection and treatment are restricted by several limitations such as lack of a 
multiplexed platform for molecular imaging and low targeting efficiency. This thesis focuses on using 
advanced polymer science and nanotechnology to address some of the major challenges associated with 
molecular profiling and targeted drug delivery.  
The first goal of this thesis is to engineer quantum dot surfaces to make a quantum dot with minimal 
hydrodynamic size, negligible nonspecific interactions, chemical functionality and long stability for 
imaging cells and tissues. Toward this goal, a new polymer surface coating methodology is developed for 
making small (7.4-12 nm), stable (over months in storage), and bio-functional quantum dots. The approach 
is shown to be robust and applicable for different shapes of nanocrystals and many other types of ligands 
including small molecular ligands, silica and polymeric ligands with different binding groups. The 
structure-property relationship is investigated and surface coatings are optimized to minimize nonspecific 
binding to cells. Two bioconjugation strategies are introduced to efficiently attach quantum dots to a wide 
range of molecular targets such as DNA and proteins without altering their functions. The performance as 
probes for immunofluorescence staining is further optimized for anti-tubulin antibody conjugates.  The 
combination of polyhistidine-driven self-assembly with protein A-mediated antibody immobilization yields 
the highest density of specific tubulin labeling.  
The second goal of this thesis is to understand the interaction of dextran polysaccharides with cells and 
tissues in the physiological state of obesity and to develop a targeted therapy for obesity-induced insulin 
resistance based on dextran nanocarriers. Depending on the dextran size and administration route, obesity 
is observed to significantly change the biodistribution pattern of dextran, shifting from liver to visceral 
adipose tissue. Twenty-four hours after post intraperitoneal administration of 500 kDa dextran, up to 63% 
of the injected dose remain in visceral adipose tissue. Further mechanistic study shows that macrophages 
in adipose tissue play a critical role in the uptake of dextran in obese mice. A new targeted drug delivery 
system is developed based on this mechanism and a single-dose treatment of anti-inflammatory dextran 
conjugates results in a significant decrease of pro-inflammatory markers in adipose tissue of obese 
mice. This study provides a promising translational nanomaterials-based delivery strategy to target adipose 
tissue macrophages to inhibit the origin of the comorbidities of obesity, and potentially for other 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction to Nanomaterials for Bioimaging and Therapy 
Nanomaterials (NMs) are defined as materials in which at least one dimension is less than 100 nm. 
These nanoscale materials have gained increasing attention because of their unique optical, magnetic, 
electrical and other properties emerge. These emergent properties provide unprecedented opportunities for 
addressing the problems in a vast range of areas ranging from electronic, medicine to energy[1, 2]. Due to 
the similarity to nanometer-scale components of biology, NMs have found wide use in biomedical sciences 
and clinical medicine. The most advanced applications of nanomaterials in biology are imaging, diagnostics 
and therapeutics[2]. NMs can be designed and engineered to upgrade the current medical paradigm of “see 
and treat” to “detect and prevent”[3]. Over the last decade, NMs have emerged as important players in 
modern medicine and the market size of nanomedicine is projected to be USD 350.8 billion in 2025. NMs 
used for diagnostic/therapeutic applications are colloids whose general structures are shown as Scheme 1-
1. They have an organic or inorganic core and usually are stabilized in aqueous solution by hydrophilic 
ligands. Decorated with special functionalities, NMs allow for targeted delivery and molecular imaging 
using modalities such as positron emission tomography and fluorescence. This introduction focuses on 
recent development of quantum dots (QDs) as labeling probes for molecular imaging and polysaccharides 
as drug delivery vehicles for targeted therapy.  
 
Scheme 1-1. Typical structure of drug encapsulating nanoparticles decorated with different ligands 





1.2 Quantum Dots for Molecular Imaging 
1.2.1 Introduction to Quantum Dots 
QDs, tiny light-emitting nanocrystals, show great potential as alternative fluorescent probes due to 
several significant advantages over conventional molecular fluorophores, including size and composition 
tunable light emission, improved brightness, excellent photo-stability, and multicolor fluorescence with a 
single-wavelength excitation[4]. The unique optical properties of these nanocrystals have made them very 
attractive for use in molecular imaging such as tissue imaging, cellular labeling and disease diagnosis[5]. 
Section 1.2 is focused on discussion of the physical origin of size-tunable fluorescence of QDs and the 
challenges of using QDs in molecular profiling.  
1.2.1.1 Quantum Confinement Effect 
Bulk semiconductors are characterized by a bandgap energy (Eg) which is the energy difference 
between the valence band and conduction band. Upon illumination by a photon of light with energy greater 
than Eg, the electrons can get excited and transition to the conduction band after absorption of the photon, 
leaving an orbital hole in the valence band. This pair of a negatively charged electron and a positively 
charged hole is called the exciton which has a finite size within the crystal that is dependent on the materials 
and dictated by the Bohr exciton radius spanning from 1 nm to more than 100 nm[6]. When the particle 
size approaches the Bohr exciton radius, excitons can “sense” the presence of the particle boundaries and 
adjust their energy states according to the particle size. This quantum confinement effect (or quantum size 
effect) can lead to an increase in excitonic transition energy and a collapse of the continuous energy bands 
of a bulk material into quantized levels. Depending on the degree of confinement, a quantum confined 
structure can be quantum well, quantum wire or quantum dot. Figure 1-1 illustrates the density of electronic 
states of a bulk semiconductor, a 2D thin film quantum well, a 1D quantum wire and a 0D quantum dot. In 
a quantum dot, the exciton is confined in three dimensions dense electronic states become discrete atomic-
like states. The relationship -between quantum confinement effect and nanocrystal size is well established 
and described by the Brus equation[7]. 






                               
where ∆𝐸 is the change in bandgap due to quantum confinement, 𝐸𝑏𝑢𝑙𝑘 is the bandgap of a bulk 
semiconductor, 𝐸𝑔 (𝑞𝑑)is the bandgap of a quantum dot, µ is the reduced effective mass of the 
electron and hole, e is the elementary charge, ε is the dielectric constant of the material, ħ is the 





It should be noted that this equation does not take account of the contribution from the 
permittivity of the crystal and its surrounding medium as this effect is usually close to zero. 
According to the Brus formula, when the particle size is comparable with the Bohr exciton radius, 
the band gap energy of the QD is proportional to r-2. Thus, as the QD becomes smaller, its bandgap 
energy increases causing a blue shift in the absorption and luminescent spectra. This fascinating 
size-tunable feature endows QDs with unique optical properties that are not available with organic 
fluorophores as discussed in Section 1.2.1.2.   
 
Figure 1-1. Illustration of the density of states of a semiconductor as a function of dimensionality. 
 
1.2.1.2 Comparison Between QDs and Organic Dyes as Fluorescent Labels 
While atomic-like energy levels are present near the band edge, QDs also exhibit bulk-like properties. 
For instance, their electron bands become more continuous far away from the band edgeIn contrast to 
organic dyes which have well-defined molecular orbitals and narrow absorption features, QDs can absorb 
a wide range of wavelengths of light depending on the nanocrystal size. In the case of CdSe, which is the 
primary focus of this thesis, with the increase of size from 1.8 nm to 20 nm, the absorption spectrum 
becomes wider and red-shifts up to 720 nm as shown in Figure 1-2a. Such broad absorption features 
provide researchers an opportunity to select a desirable excitation source within a wide range of 
wavelengths.  In semiconductors, when an electron gains energy greater than or equal to the bandgap energy, 
the excited electron will be promoted to the conduction band. However, the resulting excited state is not 
stable. The conduction-band electron may lose its energy quickly by dissipating heat to lattice vibrations 
and stabilize at the in the conduction band edge through a relaxation process. Due to the Coulombic 
interaction in the electron-hole pair, the electron may recombine and annihilate with the hole through 
radiative recombination with the emission of a photon. The energy of this photon is equal to the nanocrystal 





vast range of wavelength of light, the fluorescence emission only occurs at a single wavelength of light. As 
shown in Figure 1-2a, the fluorescence color of a monodisperse CdSe nanocrystal is very narrow and 
becomes more red as the size increases.[6] The wide absorption spectra and narrow emission spectra allow 
researchers to detect multiple targets simultaneously by applying a single excitation wavelength. Such 
multiplexed imaging capabilities holds great potential in molecular profiling for precise diagnosis of cancer 
(see more discussion about molecular profiling in section 1.2.4)[8, 9].   
 
Figure 1-2. (a) Size-dependent absorption and fluorescence of CdSe semiconductor nanocrystals. AU = 
arbitrary units[10]. (b) Photostability comparison of QDs and Texas Red under continuous light 
illumination[11]. (c) Size comparison of fluorescein (0.8 nm), green fluorescent protein (GFP) (2.4 nm by 
4.2 nm) and QD (4 nm).  
 
QDs are composed of 200 – 10,000 atoms and thus have high absorption cross-sections with molar 
extinction coefficients about 1-5 × 106 M-1 cm-1, compared with organic dyes with 2.5 × 104 ~ 2.5 × 105 M-
1 cm-1 extinction coefficients[12]. The fluorescence quantum yield (QY) of QDs is usually comparable to 
that of organic dyes, but recent progress has enabled synthesis of QDs with near-unity QY at room 
temperature[13]. Since the brightness is the product of the molar extinction coefficient at the excitation 





crystalline semiconductor nature and strong ionic-like bonding yield a large density of electronic states with 
negligible atomic rearrangement during excitation. As a result, QDs are typically hundreds to thousands of 
times more photostable than organic dyes as shown in Figure 1-2b[11]. Bright and photostable probes are 
beneficial for many biomedical studies that requires continuous monitoring of biological processes for long 
term at the single-particle level[14]. 
However, compared to the rapid progress of quantum dots in optoelectronic application, the clinical 
translation of quantum dots for bioimaging applications is relatively slow. One major disadvantage for use 
of QDs in vivo and biomedical applications is their relatively large hydrodynamic sizeSmall sizes are 
needed to minimize steric hindrance and maximum diffusion in porous biological media. Figure 1-2c is a 
rough schematic showing size differences between quantum dots, green fluorescent protein, and the organic 
dye fluorescein. Quantum dots are about an order of magnitude larger than organic dyes. Minimizing the 
hydrodynamic size is the major research focus of Chapter 2.   
 
1.2.2 Synthesis of Quantum Dots 
The most popular approach for synthesis of high quality QDs is the hot-injection method developed 
by Murray, Norris and Bawendi in 1993[15]. Over the past 25 years, advances in precursor chemistry make 
it possible for researchers to synthesize a large library of monodisperse binary QDs composed of group III-
VI and II-V elements with exceptionally narrow emission spectra.[16] As shown in Figure 1-3a, the 
synthesis involves three stages: (1) burst-like nucleation introduced by a rapid injection of room-
temperature precursor B solution into the high-temperature solution of precursor A. The introduction of 
precursor B leads to the generation of a large quantity of free monomers with a concentration above the 
nucleation threshold [M]C and initiates formation of a large population of nuclei simultaneously. As the 
monomer is rapidly consumed during this nucleation process, the concentration of monomer drops below 
[M]C and nucleation is arrested. The injection of cold precursors also lowers the mixture temperature further 
arresting nucleation to minimize the possibility of inhomogeneous nucleation that potentially broaden the 
size distribution. (2) homogeneous growth of nanocrystals. Upon the cessation of nucleation,  nanocrystals 
stabilized by coordination ligands continues to grow homogeneously until the monomer concentration 
drops close to the solubility limit of monomers [M]∞[17]. High temperature growth usually favors the 
synthesis of highly crystalline particles in this process. (3) Ostwald ripening. Once the monomer 
concentration is close to [M]∞, Ostwald ripening occurs as small particles are dissolved into monomers to 
support the growth of larger particles. Ostwald ripening is detrimental to the size distribution of particles. 





achieve monodisperse particles, usually by lowering the reaction temperature until crystal growth is 
negligible.  
 
Figure 1-3. Synthesis of core/shell colloidal nanocrystals. (a) Synthesis of a QD core through hot-injection 
method (left) and heat-up method (right). (b) Shell growth on a QD core through simultaneous addition 
method (upper) and SILAR method (bottom).   
 
Although hot-injection remains the most common method to synthesize monodisperse QDs, the 
inherent drawbacks of this approach associated with the cold injection have greatly limited its use for scale-
up preparation of QDs with high reproducibility and high quality[17]. For instance, it is impractical and not 
safe to inject large volume of cold precursors into hot solution in industrial-scale reaction. Also, the 
injection speed varies between users and varies from batch-to-batch. This eventually leads to the variation 
in different batches and a challenge in reproducibility. The urgent demand of requiring large quantities of 





developing more efficient method for reliable and controllable production of QDs on large scales. An 
alternative solution to this problem is using heat-up method to synthesize nanocrystals[18]. Figure 1-3a 
illustrates the essential stages of QD formation in a typical a heat-up synthesis. Instead of injection, all 
reagents are mixed first in a single pot and then heated to initiate the monomer conversion from precursors, 
growth and formation of QD. The underlying particle formation mechanism of heat-up method is in 
principle similar to that for hot-injection methods. The key in the heat-up approach for obtaining high 
quality QDs is to select optimal precursors and ligands that enable rapid nucleation upon heat-induced 
decomposition and appropriate decoupling between nucleation and growth stages. 
As-prepared QD core cannot be readily used in many practical light-emitting applications because of 
their low QYs. The surface atoms of QD core samples are incompletely bonded within the crystal lattice. 
The non-passivated bonding orbitals yield surface traps that can localize charge carriers, leading to a 
quantum efficiency drop through non-radiative pathways. Overgrowth of a large bandgap shell such as ZnS 
or CdS can enhance the QY by serving as an electron insulator to confine the charge carriers away from the 
nanocrystal surface, and reduce electron and hole overlap within surface traps. A crystalline shell is also 
beneficial for improving the photo-oxidation stability by limiting interaction of the QD core with 
surroundings[19]. 
Two strategies have been developed to grow an inorganic shell over a QD core as shown in Figure 1-
3b. The first method is to add the shell precursor mixture slowly to the QD core solution at elevated 
temperature. By finely tuning the reaction temperature, epitaxial crystalline shell growth can be obtained 
while homogeneous nucleation can be eliminated. This may be because the barrier to homogeneous 
nucleation is much higher than that of heterogeneous growth as the former requires the formation of a new 
phase[17]. Up to ~ 7 monolayer of CdS can be homogeneously grown on CdSe core samples through 
controlling the production rate of monomers[20]. However, simultaneous addition shell growth method 
rarely fully prevents homogeneous nucleation, yielding contaminating nanocrystal impurities in QD batches. 
In 2003, Peng et al introduced an alternating addition method called successive ion layer adsorption and 
reaction (SILAR) to provide more homogeneous shell formation with minimized chance of shell material 
nucleation[21].  As shown in Figure 1-3b, one precursor is introduced at a time to passivate the surface 
sites followed by addition of another precursor to achieve a layer-by-layer epitaxial growth of a high-quality 
shell. This approach allows for synthesis of bright QDs with controlled shell thickness by iterating step 1-
2 and with a gradient shell composition by changing the precursor components. Extensive research has 
demonstrated the importance of lattice match in shell growth for synthesis of high quality core/shell QDs. 





an interim layer with intermediate lattice constant is usually used to balance the internal strain and enhance 
QY[23]. 
 
1.2.3 Water-dispersion and Surface Functionalization of QDs 
1.2.3.1 Phase Transfer and Ligand Exchange 
As discussed in section 1.2.2, high-quality semiconductor QDs prepared by hot colloidal methods are 
stabilized by hydrophobic ligands such as trioctylphosphine oxide (TOPO), oleic acid, oleic amine. It is 
imperative to make QDs water dispersible for its use in biological environments. Although aqueous 
synthesis and bio-synthesis of QDs have advanced much in the past few years, QDs made through these 
methods usually suffer from polydispersity and poor optical properties, and the synthesis is hard to scale 
up [24]. There are typically two ways for transferring QDs from organic phase to water phase: encapsulation 
and ligand exchange, as shown in Figure 1-4a. Lipids or amphiphilic polymers can form micelle-like 
structures to encapsulate QDs within hydrophobic cores, stabilized by a hydrophilic shell [25, 26]. 
Amphiphilic polymer encapsulated QDs can be extremely stable and highly bright in water[27]. But these 
particles always have relative large sizes (20-30 nm) due to the hydrophobic layer, which limit their broad 
applications. For small ligand coatings, the resulted QDs have a relatively small overall size, but the QY 
typically drops to 30～50 % of the original value upon water solubilization [28]. The exception is using a 
silica coating which has been reported to maintain over 50% of original QY after phase transfer [29]. Silica 
shells have great potential for diverse chemical functionalization, however it is a great challenge to 
eliminating contaminating silica particles and to reproducibly control the silica shell thickness within 5 nm 
due to complex and unpredictable silane chemistry[30]. Therefore, progress on silica coating QDs and their 
applications are relatively slow over last few years [31, 32]. 
Thiol groups have a relatively strong binding affinity to metal ions and thus, have been primarily 
applied as the anchoring group to replace the hydrophobic ligands rendering QDs water soluble [33]. 
However, monothiol ligands are susceptible to photo-oxidation and form dithiol products, which have much 
lower affinity to the metal compared to the thiolate counterpart. This decreased binding can cause the peel-
off of surface ligands and particles aggregation [34]. Increasing thiol numbers (anchoring numbers) of the 
ligand can enhance the colloidal stability of QDs, which generally obey the following trend: multidentate 
(>5) thiol > tetra-thiol > trithiol> dithiol> monothiol [28, 35-38]. It should be noted that thiol oxidation 
requires the diffusion of oxygen close to the QD surface to react. Thus, it is expected that having a dense 
hydrophobic layer between the thiol groups and the medium may slow down the oxidation rate of thiols by 





group and others through engineering monothiol ligands containing hydrophobic domains to prevent ligand 
dissociation from surface and the particles stability can be extended up to several months [39].  
 
Figure 1-4.  (a) Two general ways for making water soluble QDs and their typical overall sizes. (b) 
Representative examples of reported ligands with different anchoring numbers as QDs coatings.  
 
Due to their outstanding strong affinity to QDs, multidentate and polymeric ligands have been widely 
explored to yield compact nanocrystals that are both highly stable and compact [28, 40-48]. A variety of 
polymeric ligand structures have now been reported, synthesized via living radical polymerization or 
though post-modification of functionalized polymers like polyacrylic acid or poly(maleic anhydride). These 
polymers usually have random arrangement of anchoring groups in the main chain and form “loops-to-
trans” conformation on the QD surface [28]. Some of these anchoring groups are free and unbound on the 
surface, which raises the concern that these free-standing anchoring groups may be detrimental to colloidal 





in an attempt to minimize the numbers of unbound anchoring groups [47], but the down side of this strategy 
is the relative large size of final QDs due to its long chain of stabilizing groups.  
Compared with small molecules coating process based on the mass-action effect, multidentate polymer 
coating processes are preferable due to the strong cooperative binding that reduces the amount of ligand 
used for phase transfer [28]. Our previous work and others have shown that QDs with multiple thiols can 
be stable for more than one year without noticeable aggregates and size change under ambient environments 
[28, 35]. However, since the thiol groups are in close proximity within the same polymer chain, oxidation 
of thiols are usually inevitable during synthesis or phase transfer of multidentate thiolated ligands resulting 
in particle aggregation. From this aspect, nitrogen based anchoring groups such as imidazole and pyridine 
groups have advantages in terms of easy preparation and enhanced stability against oxidation [40, 44]. The 
major limitation of both imidazole and pyridine is their intrinsic high pKa (imidazole, pKa = 6 [45]; pyridine, 
pKa = 5.6 [44]) making QDs unstable and fluorescence quenched in an acidic environment (pH < 5) [40, 
44]. In an attempt to overcome this problem, Mattoussi et al recently prepared a multidentate ligand with 
both thiol and imidazole groups (L-8) and the QDs coated with this mixed ligand exhibited high stability 
in a wide range of pH (from 3 to 13) compared to QDs coated with multidentate imidazole groups which 
gradually lose fluorescence at pH = 3 [45]. 
 
1.2.3.2 Antifouling Stabilizing Groups  
Surface coating does not only affect the compactness and stability of QDs, but also determine their 
nonspecific binding properties. For biomedical applications, nonspecific binding increases the background 
noise level and reduces the signal-to-noise ratio. Nonspecific binding can also lead to false-positive staining 
for biomarkers in fluids, cells, and tissues. QDs with a charged surface (carboxylic acid or amine) are prone 
to binding to the oppositely charged domain of tissues, cells, and blood proteins through electrostatic 
interaction as shown in Figure 1-5 [5, 49].  
Neutralizing QDs surface charge through polyethylene glycol (PEG) modification is a widely 
employed way to avoid undesired nonspecific binding [27, 50, 51].  PEG can adsorb a large amount of 
water to form a water molecule barrier to prevent protein approach to QD surfaces. To effectively suppress 
nonspecific binding of nanoparticles, the PEG length typically needs to have a molecular weight over 2,000 






Figure 1-5. Surface coating determines the nonspecific binding properties of QDs. QDs with highly 
negative or positive surface charges have strong nonspecific binding to cells or tissue through electrostatic 
interaction with the charged domains on cells or tissue. Neutralization of QD surface charge by either PEG 
or hydroxyls (-OH) can dramatically reduce nonspecific binding. Zwitterionic surfaces can also be used to 
eliminate nonspecific adsorption of QDs to biomolecules, but the spatial configuration of surface charge 
can influence the anti-fouling ability mediated by the outmost layer charge.  
 
Table 1-1. Hydrophilic groups used for QD stabilization and typical zeta potential at physiological pH[19] 
 
significantly increases the overall hydrodynamic diameter of QDs. Kairdolf et al reported that converting 
the carboxylic acid groups to hydroxyl groups can also be an effective method to minimize nonspecific 
binding [53]. These charge-reduced hydroxylated particles showed remarkably reduced nonspecific binding 
to cells or tissues with little change on the overall size. But this efficient surface coating strategy has not 
been widely explored. Another emerging strategy to maintain the negligible nonspecific binding and keep 
QDs small is to use zwitterionic coatings such as sulfobetaine, carboxybetaine, cysteine, and 
phosphorylcholine [38, 42, 54-56]. The net neutral surface charge can effectively reduce the tendency of 





size small after ligand exchange. Table 1-1 compares the zeta-potential of QDs stabilized by different 
hydrophilic groups at pH 7.4. However, compared to the neutral PEG coating, Bawendi et al recently found 
that the spatial charge configuration of zwitterions may initiate a slight nonspecific binding through the 
outmost surface charge [42]. Thus, three-dimensional charge arrangement should be taken into account in 
the design of future zwitterionic coated “stealth” QDs.  
1.2.3.3 Maximizing Monodispersity 
It is essential to have a monodisperse size distribution of QDs for many biomedical applications such 
as quantitative fluorescence staining, in vivo tumor targeting, and single molecule tracking [43, 57]. Small 
populations of aggregates may cause antigen crosslinking during staining, or cause more particles to be 
bound to one antigen, resulting in inaccurate quantitative analysis as shown in Figure 1-6a [58]. Small 
particles (< 6 nm) can efficiently diffuse into the tumor environment targeting the tumor cells and be rapidly 
excreted from body through renal filtration [54, 59, 60], while large clusters (>100 nm) can trigger 
unwanted biological responses in vivo and are more likely to be phagocytosed by the mononuclear 
phagocytic system (MPS) resulting in accumulation of aggregates in liver or spleen as shown in Figure 1-
6b [61-63]. Moreover, for single molecule tracking, large aggregates remain immobile in the cytoplasm 
and have slower diffusion rate compared to the small single particles [64]. Although monodisperse QDs are 
advantageous, achieving a homogeneous size distribution QDs with a multidentate coating ligand has 
proven to be a challenge compared to QDs coated with small molecules.  
The process of attaching a multidentate polymer to a colloidal surface is not as simple as that for small 
molecule ligands. Although the lowest energy conformation of adsorption on the surface is through a flat 
geometry whereby the number of binding groups associated with the nanocrystal surface is maximized, this 
conformation can be kinetically difficult to achieve due to competing processes, such as nanocrystal 
aggregation and polymer crosslinking between particles. The end result is often a heterogeneous mixture 
of small clusters. To resolve this problem, Chapter 2 screened a variety of coating methods to optimize the 
ligand exchange process for making homogeneous and compact QD with multidentate ligand coating. As 
shown in Figure 1-6c, a two-step process was developed whereby the initial hydrophobic ligands are 
removed from the nanocrystal surface and replaced with weakly bound ions (hydroxide ions) [65]. This 
rapid process renders the nanocrystals homogeneously dispersible in polar solvents such as 
dimethylsulfoxide, in which multidentate polymers can readily displace the weakly bound ions without 
destabilizing the dispersion. A critical step is to heat the QD-polymer mixture at high temperature (110℃) 
to dissociate small clusters and boost quantum yield, generating homogeneously coated nanocrystals that 





in quality of the products when using larger nanocrystal cores and is much more rapid than previous 
techniques. With the optimal condition, QDs were coated with polymeric ligands with nearly monodisperse 
size between 7.4 nm to 11.6 nm. It is expected that this work will greatly extend the use of multidentate 
ligand coated QDs in various applications, especially single molecule tracking and quantitative multiplexed 
imaging.  
 
Figure 1-6. (a) Aggregates of QD- antibody conjugates can cross-link cellular antigens due to increased 
antibody valences. (b) Small single particles can efficiently permeate into tissues such as solid tumor and 
label interstitial targets, while large aggregates are more prone to being taken up by the MPS and 
sequestered in the liver and spleen. (c) Schematic illustration of two-step phase transfer process for 
preparing homogeneous and compact multidentate ligand coated QDs (left) and gel permeation 
chromatography result of three monodisperse QDs with different sizes (right).  
 
1.2.3.4 Conjugation to Biomolecules 
To specifically label targets, it is critical to conjugate QDs with a functional biomolecule such as a 
nucleic acid, antibody and peptide. A number of conjugation strategies have been utilized in the literature 
and can fall into two main categories: covalent conjugation and noncovalent interaction (Table 1-2) [5]. 
Carboxylic acid on QDs can be converted to N-hydroxylsuccinimide (NHS)-esters mediated by 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC), and then react with amine groups on the biomolecules [5, 
66]. Biomolecules typically contain more than one amine group, so this method is the most common 
strategy for biomolecule conjugation. However, because of its multivalent nature, activated QDs usually 
have more than one NHS-ester and can cross-link multiple proteins, resulting in insoluble aggregates and 





the protein orientation on surface of QDs. Another common functional groups for the covalent attachment 
is a thiol group for coupling to maleimide to form a thioether bond [67, 68]. This chemistry is particularly 
useful for conjugating QDs to antibodies, which have thiol groups exposed after reduction of interchain 
disulfide bonds which does not disrupt the antigen binding site [69, 70]. However, the maleimide-thiol 
adducts are not very stable and the succinimidayl thioether can be cleaved in thepresence of excess of thiols 
such as cysteine and glutathione (GSH), the abundant intracellular reducing agents. This displacement may 
cause loss of conjugated biomolecules and diminish or eliminate the targeting function of the QD conjugate 
[71].  
Over the last decade, bioorthogonal click chemistry has gained substantial momentum due to unique 
advantages in bioconjugation such as mild reaction conditions, rapid reaction rates, high reaction specificity 
to the functional groups and high product yield [72]. In many examples, click reactions are quantitative and 
require no purification in contrast to conventional EDC-mediated coupling where extensive purification 
steps are always required. Click reactions have been proven to be efficient methods for QD bioconjugation. 
One common click chemistry is copper-catalyzed alkyne-azide cycloaddition. However, Cu(I) ion can 
damage CdSe/ZnS QDs and permanently quench their fluorescence [73, 74] , thus, copper free click 
chemistry has become an attractive alternative for QD bioconjugation [69]. Bawendi et al first applied 
norbornene-tetrazine cycloaddition chemistry to in situ label epidermal growth factor receptor (EGFR) on 
A431 cells surface with QD-EGF conjugates[41]. They further demonstrated the capability of in vivo 
cytometric imaging of endogenous bone marrow cells in mice with this technique [43].  Mulvaney et al 
reported the use of strain-promoted azide-alkyne cycloaddition reactions for attaching cyclooctyne-
modified transferrin to azide QDs and verified the biological activity of QD-transferrin adducts in 
transferrin-receptor expressing tumor cells [75], although compared to dye-transferrin conjugates, they 
found that presence of QDs perturbed the intracellular uptake pathway. This variation may be due to the 
relative large size of the amphiphilic polymer encapsulated QDs highlighting the benefits of using size-
minimized coating for cellular tracking. 
Noncovalent interaction has also been employed for coupling biomolecules to QDs through either 
electrostatic interactions or affinity interactions. The electrostatic interaction strategy suffers various 
drawbacks including possible impaired protein activity and uncontrolled coupling [76]. Therefore, 
electrostatic interaction is not widely used. The strong affinity between streptavidin and biotin (dissociation 
constant Kd = 10-15 M) has made this conjugation methodology one of the most frequently used interactions 
to link biomolecules with QDs [77, 78]. However, wild-type streptavidin is a tetramer protein and has four 
biotin binding sites. It may cross-link two biotinylated molecules when they are in close proximity. 





wild-type streptavidin, but generation of the monomeric streptavidin still challenging and the affinity is 
substantially diminished [79]. For antibody conjugation, molecular adaptors such as protein A/G or Fc 
receptor have unique advantages in controlling the antibody orientation via binding to the Fc region of 
antibody without necessity of modifying the antibody [58, 80, 81]. Gao et al recently developed a multicolor 
multicycle molecular profiling (M3P) technology by engineering a universal QD-protein A platform for 
flexible and fast preparation of a library of functional QD-antibody conjugates [80]. To avoid the formation 
of polymeric protein A- immunoglobulin (IgG) complexes or aggregates, they found it is critical to use 
excess ratio of protein A to the antibody to make the antibody inaccessible to other protein A after reaction. 
However, the excess protein A on one QDs can dramatically increase the overall size of QDs, which limits 
their applications in certain circumstances where small size is preferred. In this context, Fcγ receptor I may 
have more potential of engineering compact QD molecular adaptors as one Fcγ receptor I only bind to one 
IgG avoiding possible aggregation and polymerization [58].  
Table 1-2. Conjugation methods for coupling biomolecules with QDs[19] 
 
Molecular adaptors can be conjugated to QDs by either covalent interaction using the methods 
described above [80] or metal-affinity coordination of polyhistidine (his6-tag) to metal ion on QDs surfaces 
[58]. Compared to covalent conjugation, the use of his6-tag for QD bioconjugation is a powerful and 





toward outward; (2) controlled biomolecules to QD ratio; (3) no need for additional protein modification 
or further purification steps; (4) high product yield. Therefore, his6-tag based self-assembly strategies for 
QD bioconjugation have been widely used in last few years. It is now known that his6-tag self-assembly 
efficiency is sensitive to the thickness of the surface coatings as PEG coating with a repeating unit n > 12 
can inhibit the binding of his6-tag protein on the surface [82]. Thus, size-minimized surface coating would 
be beneficial for attaching his6-tag biomolecules to QDs. A recent review by Medintz et al has summarized 
details about his6-tag mediated assembly of biomolecules with QDs [83].  
 
1.2.4 Molecular Profiling with QDs 
Current clinical cancer diagnosis is based largely on histopathology of the primary tumor tissue which 
has limited diagnostic accuracy. Molecular analysis of the primary tumor tissue is more quantitative than 
histopathology, but single molecular markers alone (e.g. human epidermal growth factor receptor 2) still 
have weak diagnostic accuracy in view of inherent heterogeneity of tumos. Molecular profiling of numerous 
markers has been shown to be highly accurate but large numbers (40-50) are typically needed, which is 
challenging by most analytical approaches. In contrast to the destructive techniques such as reverse 
transcription polymerase chain reaction (RT-PCR), 2D gel electrophoresis, flow cytometry, and enzyme-
linked immunosorbent assay (ELISA), imaging based analytical approaches such as mass spectrometry 
(MS) and fluorescence are capable of providing valuable molecular information without damaging the 
structural integrity, thus increasing the predictive power of cancer diagnostics. In particular, fluorescence-
based methods allow for detection at the single-cell level which is not available with MS imaging (10-20 
µm lateral resolution). However, although immunofluorescence (IF) and fluorescence in situ hybridization 
(FISH) have been proposed for detection of multiple markers in clinical diagnosis for many years, the 
quantitative analysis is heavily compromised by the limitations of organic fluorophores such as rapid 
photobleaching and broad emission spectra. In this regard, QDs are well-suited for quantitative profiling of 
multiple targets at the single cell level because of their bright, photo-stable and narrow emission signals. 
Despite this great promise in revolutionizing bioimaging, current QD-based technologies exhibit a series 
of technical challenges inr multiplexed imaging. The successful use of QDs for IHC or IF has been greatly 
limited by the relative large sizes of commercially available water-soluble QDs, strong nonspecific 
interaction with tissue, and lack of a reproducible method for QD-antibody conjugation. Chapter 2-4 
describes the attempts in addressing these challenges to engineer small, stable QDs with minimum 





1.3 Polysaccharide Nanomaterials for Targeted Therapy 
1.3.1 Overview of Nanomaterials for Therapy 
Conventional cancer treatment mainly relying on chemotherapeutics is suffering from serious adverse 
effects such as hair loss, nausea and impaired immune system due to off-target effects. Nanomaterials based 
medicine or nanomedicine holds great potential for enhanced anticancer efficacy by increasing the 
solubility of hydrophobic drugs, extending the circulating time of drugs in blood, delivering drugs 
specifically to the tumor site and releasing drugs within a tumor tissue or cells in a more controllable way. 
Over last 40 years, tremendous efforts have been made on development of nanoparticles (NPs) for cancer 
targeted therapy[84, 85]. A number of nanoparticle therapeutics have been already approved by FDA or are 
currently in clinical trials[86]. Compared to small molecules, nanomedicine can be designed to optimize 
the biodistribution, pharmacokinetics and pharmacodynamics of single or multiple drugs to improve the 
therapeutic index, reduce systemic toxicity and increase antitumor efficacy. Such unique features of 
nanomedicine are primarily determined by the interactions between colloidal particles the endothelial 
system, altered tumor microenvironment and physicochemical properties of NPs.  
1.3.1.1 Altered Biodistribution 
Most anticancer chemotherapeutics and NPs are delivered through intravascular administration. Once 
they are in the blood circulation, they begin to distribute to the whole body and extravasate into tissues or 
organs through transvascular transport and interstitial transport.  
The endothelium permeability plays a critical role in determining the biodistribution of small 
molecules and NPs[87]. Typically, solutes in fluids can extravasate across the endothelium layer through 
three pathways: intra-endothelial transport, receptor mediated endocytosis and transcytosis[88]. As shown 
in Figure 1-7A, water and small lipophilic molecules are mainly transported across the blood vessels 
through intra-endothelial transport, while the majority of NPs larger than 5 nm are not likely to pass through 
continuous and nonfenestrated endothelium. The kidney glomeruli are composed of a fenestrated 
endothelium, a glomerular basement membrane and podocyte extensions of glomerular epithelium. These 
fenestrations have pore sizes around 60 nm and the gaps between podocytes are about 5 nm. As a result, 
NPs with size smaller than 6 nm and small molecules can be filtrated from the kidney and eliminated in 
urine[54, 89]. The liver sinusoid has four layers: a discontinuous fenestrated endothelium, a basement 
membrane, a space of Disse and lining hepatocyte. Moreover, the liver contains a large number of immune 
cells such as Kupffer cells and motile macrophages. Depending on the NPs type and chemistry, NPs may 
be taken up by macrophages and remain in the liver for a very long time or they can be rapidly degraded 





endothelium of tumor tissue is discontinuous mainly because of uncontrolled angiogenesis. The pore size 
of intercellular space here is about 30 - 200 nm. This highly permeable endothelium combined with poor 
lymphatic drainage (see discussion below) allows NPs smaller than 200 nm to accumulate at the tumor site. 
This enhanced permeability and retention (EPR) effect has been the primary rationale for passive targeted 
delivery of NPs for cancer therapy[84].   
During system circulation, opsonized NPs can be identified MPS followed by sequestration or 
elimination through the liver or spleen.[91] This opsonization caused by nonspecific binding to the plasma 
proteins is detrimental to efficient delivery of NPs to tumor. Surface modification with  PEGlyation is a 
common strategy to effectively minimize the formation of a protein corona due to its hydrating layer[92]. 
Other materials such as CD47 peptides[93] have also been utilized to avoid phagocytic clearance by 
macrophages. If NPs successfully escape from MPS recognition and arrive at the tumor site, they can cross 
the leaky vasculature and be transported to the tumor intersititium. As shown in Figure 1-7B, interstitial 
transport is primarily governed by diffusion and convection[94]. In normal tissues, the pressure in blood 
vessels (PBV) is higher than that in the surrounding interstitium (PI) and this outward pressure drives solutes 
such as small molecules from vessels and through the intersitium to the lymphatic vessels where the 
pressure (PLV) is lower than PI. However, owing to the leaky vessels and enhanced endothelium 
permeability of tumor tissue, PI at tumor tissue is increased to the similar level as PLV. This elevated fluid 
pressure reduces convective transport of NPs into the tumor tissue. As a result, interstitial transport of NPs 
only depends on diffusion. The tumor microenvironment consists of a highly interconnected network of 
extracellular matrix (ECM) which can slow down or trap the movement of NPs depending on size, shape, 
surface charge of NPs[84]. Normalization of tumor microenvironments, vasculature, and ECM has been 
reported to enhance the delivery efficiency of NPs to tumor tissue[95]. 
Another widely explored strategy to increase the accumulation of NPs in tumors is to engineer the NP 
surface with certain targeting ligands such as antibodies, peptides and aptamers that bind to tumor-specific 
cell-surface receptors[96]. BIND-014 is the first targeted polymeric nanoparticle in clinical trial that has 
been reported to provide 10 times more delivery efficiency of docetaxel to tumors compared with free 
docetaxel, an effect attributed to prostate-specific membrane antigen targeting[97]. Although this active 
targeting strategy  has potential, only limited delivery efficiency (less than 1%) has been achieved according 
to a recent comprehensive survey on the literature of NPs for cancer therapy[98]. This highlights an urgent 
need to understand the fundamental mechanisms underlying the poor delivery efficiency of current NPs 
such as the interaction of NPs with biological systems in different animal models for future clinical 






Figure 1-7. Transport processes of nanoparticles and free drugs from the bloodstream to various tissues. 
(A) Interaction of nanoparticles with normal tissue, kidney, liver and tumor tissue. Solutes in blood fluid 
can be transported across the vasculature through transcellular, receptor-mediated, paracellular or 
transcytosis. In normal tissues, small lipophilic molecules can passively transport across the tight and 
continuous endothelium while most nanoparticles cannot transport across the endothelium. In kidney, 
nanoparticles smaller than 5 nm can be filtered out from the blood and excreted in urine. In liver, most of 





Figure 1-7 (continued) endothelium is discontinuous and nanoparticles smaller than 200 nm can penetrate 
through the blood vessel. (B) Compared to normal tissue, interstitial transport of nanoparticles at tumor site 
mainly depends on diffusion due to elevated interstitial pressure. The diffusion rate of nanoparticles may 
be also affected by the altered tumor microenvironment such as poor lymphatic drainage, undeveloped 
tumor vasculature and densely inter-connected extracellular matrix. 
 
1.3.1.2 Tunable Pharmacokinetics and Pharmacodynamics 
Besides the altered biodistribution, another advantageous characteristic using NPs for drug delivery is 
their tunable pharmacokinetics and pharmacodynamics[99]. In contrast to small molecules which can suffer 
from low dose administration and rapid clearance, nanoformulations shows a prolonged circulation time in 
plasma (Figure 1-8 A) and increased tissue exposure time or area-under-the curve (AUC) (Figure 1-8B). 
By tuning the physicochemical properties of NPs, the release profile of free drugs from NPs can be 
controlled to have a wide range of therapeutic indices and adjustable potencies (ie. IC50) for personalized 
medicines as shown in Figure 1-8C. Such sustained release behavior enables a long term efficient antitumor 
activity with a tolerable toxicity to healthy tissues. 
 
Figure 1-8. Tunable pharmacokinetics and pharmacodynamics of NPs. (A) Comparison of drug 
concentration in plasma between NP and free drug. (B) Comparison of bioavailability between NP and free 
drug. AUC: area under curve. (C) Tunable IC50 of NP.   
 
1.3.1.3 Combinational Therapies for Personalized Medicine 
A current problem with cancer chemotherapy is cancer drug resistance, which eventually causes 
treatment failure. Drug resistance involves a diverse range of molecular mechanisms such as overexpression 
of drug efflux pumps, alteration of drug metabolism, and inactivation of a death signaling pathways of 
cancer cells[100]. Combination therapy, which targets multiple signaling pathways simultaneously in a 
synergistic manner, is an emerging treatment to overcome cancer drug resistance for better therapeutic 





is always unpredictable in vivo due to their dissimilar pharmacokinetics, mismatched biodistribution and 
different membrane transport properties. Within this context, nanoparticle formulations offer several 
advantages for combinational therapy[102]. For instance, multiple drugs with different physiochemical 
properties and pharmacological properties can be incorporated into one nanoparticle and released together 
at a desirable ratio. Moreover, the synergistic effect of combinational therapy enables improved antitumor 
efficacy with a lower dose of each drug as well as reduced systematic toxicity. As a result, nanomedicine 
provides a unique platform for clinicians to fine-tune the pharmacological properties of multidrug cocktails 
for personalized medicine.  
 
1.3.2 Polysaccharides as Nanocarriers for Targeted Therapy 
In spite of major advances in engineering nanoparticles as drug carriers, only a few are currently 
approved by the Food and Drug Administration (FDA) for diseases treatment[86]. A major roadblock for 
clinical translation of nanomaterials is the potential safety concern raised by the synthetic components used 
for construction of the nanocarriers. In contrast, natural biopolymers are typically biocompatible and 
biodegradable, and thus possess intrinsic advantages as non-toxic delivery vehicles in vivo[103]. 
Polysaccharides are one important type of natural biopolymer and have been widely explored as either 
coating materials or drug conjugates for a vast number of biomedical applications like controlled drug 
release and targeted imaging [104, 105]. 
Polysaccharides are hydrophilic carbohydrates with a wide range of molecular weight from 1,000 Da 
to 100 million Da. Polysaccharides are present across many different species (bacteria, human and animals) 
serving numerous in biological roles. For example, the secretion of dextran enables bacteria to modulate 
adhesion by changing the softness of bacterial cell surfaces. Natural polysaccharides are typically produced 
by biosynthesis through condensation reactions of monosaccharides. Depending on the structures of 
monosaccharides, polysaccharides may bear varying charged groups such as hydroxyls, amines and 
carboxylic acids. In drug delivery, these moieties are extremely useful because they can act as reaction sites 
for covalent attachment of a variety of ligands to tailor the functionalities of polysaccharides.  Figure 1-9 
provides some representative examples of polysaccharides with different charges. The diversity of 
polysaccharides in molecular weight, structures and charges provides a great platform for researchers to 






Figure 1-9. Chemical structures of representative examples of polysaccharides used in drug delivery 
 
Over the last decade, polysaccharides have been engineered into various nanoformulations including 
cross-linked nanoparticles, micelles and vesicles to efficiently deliver drugs through either crosslinking of 
polysaccharides or self-assembly of hydrophobically modified polysaccharides[105, 106]. For instance, 
acetylation of dextran (Ac-DEX) with 2-methoxypropene has become a facile approach to synthesize acid-
responsive nanoparticles with tunable degradation kinetics as shown in Figure 1-10a[107]. Ac-DEX 
encapsulated payloads such as small hydrophobic drugs, proteins or nucleotides can exhibit controlled 
release at the disease sites upon the hydrolysis of acid-labile acetal groups at lower pH.  The pH-neutral 
degradation species of Ac-DEX minimize potential damage to both payloads and microenvironments in 
vivo[108]. Compared with commonly used nanocarriers such as poly(lactic-co-glycolic acid) (PGLA), Ac-
DEX nanocarriers showed a much higher immunotherapy efficacy by adopting a fast degradation 
chemistry[109]. The compatibility of Ac-DEX with a broad range of encapsulation methods such as 
emulsion, electrospray, and nanoprecipitation has largely advanced the broad applicability of this material.  
 
Figure 1-10. (a) Synthesis and acid triggered degradation of Ac-Dex. (b) Receptor-mediated uptake of 





As mentioned in section 1.3.1.1, surface functionalization of nanocarriers with targeting ligands can 
enhance therapeutic efficacy and reduce side effect through targeted delivery of cargos to specific organs 
or cell types. This active targeting mechanism is also applicable for polysaccharide-based nanoparticles. 
For example, folate decoration of polyethylenimine conjugated dextran exhibited higher efficiency for 
targeted gene delivery to an SKOV-3 xenograft tumor in a mouse model compared with cationic dextran 
conjugates without folic acid[110]. However, the most intriguing feature of using polysaccharides for drug 
delivery is that they can act as not only cargo carriers, but also targeting ligands due to their capability of 
binding with certain cellular receptors[111]. A large library of carbohydrate binding receptors has been 
identified on the surfaces of different cell types. Increasingly, studies have demonstrated that different types 
of polysaccharides may bind specifically to certain carbohydrate binding receptors. For instance, chitosan 
can be selectively recognized by CD44 receptors over-expressed in cancer-stem-like cells. He et al recently 
found that chitosan-modified doxorubicin nanoparticles showed six times higher cytotoxicity of 
doxorubicin compared to that of free doxorubicin and were able to reduce the tumor size with no obvious 
systemic toxicity[112]. Alternatively, dextran is known to be efficiently and selectively internalized by 
macrophage cells due to their expression of scavenger receptors and dextran-binding C-type lectins[113-
115]. Macrophages have emerged as important targets in many human diseases such as atherosclerosis, 
obesity induced insulin resistance, cancer, asthma and rheumatoid arthritis. Selective delivery of drugs to 
macrophages for modulating macrophage phenotypes is a promising strategy[116, 117]. Dextran is an FDA 
approved biomaterial that has been used for decades as a plasma expander. Therefore, dextran based 
nanocarriers hold great promise to engineer fully biocompatible drug delivery systems for targeting 
macrophages as shown in Figure 1-10b. Chapter 5 demonstrates that dextran drug conjugates can be a 
promising translational delivery strategy to target adipose tissue macrophages to inhibit the origin of the 
comorbidities of obesity, and potentially for other inflammatory diseases of visceral organs[118]. 
 
1.4 Dissertation Overview 
In Chapter 2, I developed new polymeric ligands and optimize coating and bioconjugation 
methodologies for core/shell CdSe/CdxZn1-xS quantum dots to generate homogeneous and compact 
products. I demonstrate that “ligand stripping” rapidly displaces nonpolar ligands with hydroxide ions to 
allow homogeneous assembly with multidentate polymers at high temperature. The resulting aqueous 
nanocrystals are 7-12 nm in hydrodynamic diameter, have quantum yields similar to those in organic 
solvents, and strongly resist nonspecific interactions due to short oligoethylene glycol surfaces. Compared 





chromatographic and single-molecule analysis. The effect of polymeric ligand structures was also 
investigated in terms of hydrodynamic size, nonspecific binding and optical properties. 
In Chapter 3, I demonstrate high-efficiency bioconjugation of QDs through azide-alkyne click 
chemistry and self-assembly with hexa-histidine-tagged proteins that eliminate the need for product 
purification. The conjugates retain specificity of the attached biomolecules and are exceptional probes for 
immunofluorescence, cellular imaging and single-molecule dynamic imaging. These results are expected 
to enable broad utilization of compact, biofunctional quantum dots for studying crowded macromolecular 
environments such as the neuronal synapse and cellular cytoplasm. 
In Chapter 4, I describe a facile and effective approach to conjugate antibodies with multidentate 
polymer coated QDs. This strategy takes advantage of the thin surface coating of these QDs and strong 
affinity of polyhistidine to metal surfaces on QDs. QD-His-tagged Protein A conjugates can be incubated 
with antibody to form primary QD-sa-PA-sa-Ab conjugates. The primary immunostaining performance of 
QD-sa-PA-sa-Ab was compared with that of three other QD-Ab conjugates that were prepared using diverse 
methods. The resulting self-assembly-based QD-sa-PA-sa-anti-tubulin antibody complex showed best 
staining results in terms of highest specific signals and best interconnectivity of tubulin structure. 
In Chapter 5, I synthesized a series of dextran conjugates with tunable size linked to contrast agents for 
positron emission tomography, fluorophores for optical microscopy, and anti-inflammatory drugs for 
therapeutic modulation of macrophage phenotype. Larger conjugates efficiently distribute to visceral 
adipose tissue and selectively associate with macrophages after regional peritoneal administration. Up to 
63% of the injected dose remained in visceral adipose tissue 24 hours after administration, resulting in >2-
fold higher local concentration compared to liver, the dominant site of uptake for most nanomedicines. 
Furthermore, a single-dose treatment of anti-inflammatory conjugates significantly reduced pro-
inflammatory markers in adipose tissue of obese mice. Importantly, all components of these therapeutic 
agents are approved for clinical use. This work provides a promising nanomaterials-based delivery strategy 
to inhibit critical factors leading to obesity comorbidities and demonstrates a unique transport mechanism 
for drug delivery to visceral tissues. This approach may be further applied for high-efficiency targeting of 
other inflammatory diseases of visceral organs. 
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CHAPTER 2: ENGINEERING COMPACT, HOMOGENEOUS AND 
STABLE MULTIDENTATE POLYMER COATED QUANTUM DOTS 
WITH MINIMUM NONSPECIFIC BINDING 
 
2.1 Background and Motivation 
Quantum dots (QDs), tiny light-emitting nanocrystals, show great potential as alternative fluorescent 
probes due to several significant advantages over conventional molecular fluorophores, including size and 
composition tunable light emission, improved brightness, excellent photo-stability, and multicolor 
fluorescence with single-wavelength excitation[1, 2]. In the past decade, QDs have been used as fluorescent 
probes to image and detect biological molecules such as proteins and DNA in biological fluids, living cells, 
and living organisms[3, 4]. For these applications, QDs must be coated in ligands compatible with aqueous 
biological media because bare surfaces are highly reactive and adsorb the constituents of biological 
solutions. These ligands are bifunctional: the headgroup chemisorbs to a surface facet and is appended 
through a backbone to a tailgroup that interfaces with the surrounding media, which is composed of water 
molecules, ions, small molecules like sugars, and macromolecules like proteins. It is critical that the surface 
ligands are precisely controlled because they are the primary determining factor of hydrodynamic size, 
optical and chemical stability, nonspecific interactions and functionality. Therefore, ligands are a major 
focus of current efforts for optimizing QDs for molecular imaging and labeling in complex solutions, cells, 
and tissues[5]. 
One of current trends in the field of QDs is size minimization[6]. From commercial suppliers, the 
hydrodynamic diameter is 15-35 nm, which is much larger than typical globular proteins (~5-10 nm) that 
QDs are usually used to analyze. Because of this physical disadvantage, the optical advantages of these 
probes have not yet been fully exploited for many proposed applications. Large QDs cannot access the 
crowded neuronal synapse, a 20-30 nm space between connected cells[7, 8], and are largely immobile in 
the cellular cytoplasm[6, 9], where macromolecular crowding effects dominate the behavior of colloids. 
Extensive efforts have been made to engineer the surface coating to minimize the QDs size. Among of 
those methods, multidentate and polymeric ligands have been used to prepare nanocrystals that are both 
highly stable and compact[10-16]. These coatings are usually based on linear polymers with three types of 
pendant functional groups that (1) bind to the nanocrystal surface, (2) extend away from the surface to 
stabilize the particle in aqueous solution, or (3) enable conjugation to a biomolecule. The resulting colloids 
are stable for months to years and are compatible with harsh purification protocols that destabilize more 





polymerization, peptide synthesis, or though chemical modification of reactive polymers like polyacrylic 
acid or poly(maleic anhydride). Surface-binding groups include thiols[10, 13, 16], imidazoles[11], and 
pyridines[15], and hydrophilic groups include oligo-ethylene glycol (OEG)[17], poly-ethylene glycol 
(PEG)[11, 12, 14, 18] or zwitterionic betaines[19, 20], which minimize nonspecific interactions with 
biological structures such as proteins and cells. The process of attaching a multidentate polymer to a 
colloidal surface is not simple and the end product is often a heterogeneous mixture of small clusters.  
The process of attaching a multidentate polymer to a colloidal surface is not as simple as it is for small 
molecule ligands[10]. Although the lowest energy conformation of adsorption is through a flat geometry 
with a maximum number of binding groups associated with the nanocrystal, this conformation can be 
kinetically difficult to achieve due to competing processes, such as nanocrystal aggregation and polymer 
crosslinking between particles. The product is often a heterogeneous mixture of small clusters. This 
outcome is exemplified in Figure 2-1, demonstrating that QDs coated with multidentate polymers using 
slightly different procedures (different polymer amount and temperature) can yield monodisperse or 
polydisperse QDs that are virtually indistinguishable by inspection under room light or ultraviolet light 
(Figure 2-1a), and in terms of stability and quantum yield. But when examined by gel permeation 
chromatography (GPC, Figure 2-1b) or by analyzing their diffusion coefficients at the single molecule 
level (Figure 2-1c), it is clear that one of the samples is highly aggregated while the other is monodisperse. 
In this Chapter, we characterize products generated through a variety of previously described and novel 
methods and find that nearly all methods yield some degree of nanoparticle aggregation, but importantly 
this heterogeneity may not be evident from dynamic light scattering (DLS) or gel electrophoresis 
measurements which provide insufficient resolution of mixed-size samples (Figure 2-1d and vide infra). 
For many quantitative imaging and single-molecule analysis applications, achieving a homogeneous, 
monomeric population is essential[18, 21, 22], and small populations of clusters skew measurements. 
However, to date, ligand exchange processes have not been optimized to maximize monodispersity of QDs 
coated with multidentate ligands. 
As depicted in Figure 2-2b, we optimized a new methodology for homogeneous and compact 
polymeric assembly on a QD surface using a two-step process whereby the initial hydrophobic ligands are 
removed from the nanocrystal surface and replaced with weakly bound ligands or ions. We found that a 
rapid process using hydroxide ions renders the nanocrystals homogeneously dispersible in polar solvents, 
in which multidentate polymers can readily displace the weakly bound ions without destabilizing the 
dispersion. A critical step is to heat the QD-polymer mixture at high temperature (>100 ℃) to dissociate 
small clusters and boost quantum yield, generating homogeneously coated nanocrystals that are 





of the products and is much more rapid than previous multi-step coating techniques. Using these new 
methods, we demonstrate the generation of small, stable, and multicolor QDs in the range of 7.4-11.6 nm 
with negligible nonspecific association with cells. The effect of polymeric ligand structures on QDs were 
investigated in terms of hydrodynamic size, nonspecific binding and optical properties.  
 
Figure 2-1. Comparison of multidentate ligand-coated quantum dot samples that are monodisperse or 
polydisperse. (a) Photographs of a monodisperse sample (upper) and a polydisperse sample (lower) under 
room light (left) or ultraviolet light (right). (b) Gel permeation chromatogram of the two samples. (c) 
Hydrodynamic size distribution of the two samples measured by single-molecule fluorescence imaging in 
a mixture of aqueous buffer and glycerol. (d) Gel electrophoresis results for the two samples; the well 
position is indicated by the arrow and electrode polarities are indicated as (-) and (+). Detailed synthetic 
methods are provided in the Experimental Section. 
 
2.2 Results and Discussion 
2.2.1 Design and Synthesis of Multidentate Polymeric Ligands 
Multidentate polymer ligands were designed to allow modular control of chemical structure, a variety 
of binding groups, and a high graft density of OEG to minimize nonspecific interactions with biological 
molecules and cells. Polymers were synthesized starting from a linear homopolymer of amine-reactive N-
hydroxysuccinimide (NHS) functional groups, poly(N-acryloyloxysuccinimide) (PNAS). PNAS was 
synthesized via reversible addition fragmentation chain transfer (RAFT) polymerization to yield a polymer 
with 18,900 Da molecular weight, or approximately 110 NHS groups, with a polydispersity index of 1.2 
(assessed through GPC)[23]. As depicted in Figure 2-2a, PNAS was reacted with compounds containing 
primary amines that conjugate to the polymer backbone through an amide bond. The compounds contain 
imidazole (histamine) to bind to QD surfaces, or a monoamine triethylene glycol (NH2-EG3-OH, 3) to 
render stability in aqueous solution and minimal nonspecific interactions with cells and biological 
molecules, and minimal size. The molar feeding ratio of the binding group compound to the hydrophilic 
group was 35:65. The binding groups and hydrophilic groups were probably randomly distributed along 





trans” loop closure on the QD surface. An advantage of this post-modification approach is that a variety of 
amines with different moieties can be easily incorporated into the ligands to manipulate the surface 
properties of QDs.  
 
Figure 2-2. (a) Synthesis of monomer 3 and polymeric ligand PIM through modification of PNAS. (b) 






Figure 2-3. Fluorescence and extinction coefficient spectra (left) and transmission electron microscopy 
images (right) of (a,b) QD525, (c, d) QD565, (e,f) QD600, (g,h) and QD605 
 
 
2.2.2 Quantum Dot Nanocrystals 
Quantum dots composed of CdSe cores capped with CdxZn1-xS shells were synthesized using typical 





were grown in 0.8 monolayer (ML) increments in order to suppress shell material nucleation and were 
graded in composition from higher CdS content on the CdSe surface to outer layers that were entirely ZnS 
to aid in stability of the final particle. By tuning both the core size and the shell thickness, the nanocrystals 
could emit light in the range of 520-610 nm with a fluorescence quantum yield (QY) greater than 40% in 
hexane or chloroform after purification. For this work, we prepared four batches with different nanocrystal 
sizes with emission wavelengths indicated by their names: QD525 with 3.3 ± 0.3 nm diameter, QD565 with 
4.3 ± 0.5 nm diameter, QD600 with 5.7 ± 0.5 nm diameter, and QD605 with 5.5 ± 0.5 nm diameter; sizes 
were determined by transmission electron microscopy (TEM) (see Figure 2-3). After synthesis the 
nanocrystals were coated with aliphatic ligands such as oleylamine and oleic acid, the predominant ligands 
in the shell growth solution. 






Size by DLSa 
(nm) 





28.3 21.7 30.8 ± 11.8 >30c 
M2 S2- 47.0 18.5 14.9 ± 3.3 >30 
M3 Zn2+ 38.6 32.6 53.9 ± 16.4 17.1 
M4 Thioglycerol 65.4 35.8 19.2 ± 5.6 15.2 
M5 mPEG-SH 48.5 29.0 14.6 ± 3.3 14.2 
M6 OH- 66.5 17.8 10.2 ± 2.6 12.5 
aHydrodynamic size measured by DLS is the mean size from the number distribution.  bThe size measured by GPC is 
the minimum size among peaks, calculated from calibration curves of proteins with known size. cSizes above 30 nm 
exceed the GPC column limit. dNo signal detected.  
 
2.2.3 Multidentate Ligand Coating Methods 
We found empirically that the attachment of polymeric ligands to QD surfaces is challenging to control 
and is more difficult for nanoparticles with larger sizes, likely due to lower surface energy compared with 
smaller particles that allows competing aggregation processes to dominate such as interparticle aggregation 
and polymer cross-linking. Here, we focused on maximizing the homogeneity of QD605 coated with PIM 
by tuning the coating conditions as shown in Figure 2-2b. For homogeneous coating, is critical to 





as well as the polymer to prevent aggregation. We have found that the most important parameters are the 
ligands on the surface during exchange and the temperature. First we tuned the ligands on the nanocrystal 
surface and mixed the QDs with the multidentate polymeric ligands PIM in solvents optimized to stabilize 
both the QDs with their initial ligands and the polymer-coated QDs. For each sample, we measured the 
final transfer efficiency to aqueous solution, the fluorescence quantum yield, the hydrodynamic size using 
dynamic light scattering (DLS) and gel permeation chromatography (GPC) calibrated with molecular 
weight protein standards with known diameters, and the homogeneity of migration through an agarose-
polyacrylamide gel via electrophoresis. The six intermediate ligands and methods (M1-6) are summarized 
in Table 2-1 and included native hydrophobic ligands in CHCl3 (M1), hydrophilic monodentate ligands 
that are short-chain (thioglycerol, M4) or long-chain (PEG-SH, M5), or three ligand-free approaches. The 
ligand-free coatings were developed by Talapin and coworkers to “strip” the native hydrophobic ligands 
from the surface, yielding nanocrystals surfaces terminated with sulfide ions (M2), zinc ions (M3) or 
hydroxide ions (M6)[25]. As shown in Table 2-1 and Figure 2-4, all coatings yield stable colloidal 
dispersions of QDs in aqueous solution with substantial QY. The products were lowest in quality for 
methods in which the intermediate coatings were hydrophobic ligands, sulfides, and zinc ions (methods 
M1-M3), which had low transfer efficiencies (<50%), large sizes (>16 nm by GPC), and smeared gel bands 
(data not shown).[17] The products were particularly aggregated using the PIM polymer with hydrophobic 
and sulfide coatings and could not migrate into the gel during electrophoresis. The results were particularly 
improved with the hydroxide surface (M6), which yielded the smallest sizes by DLS and GPC and the 
highest transfer efficiency (>65%).  
Figure 2-5a represents a typical process of method M6. Organic QDs was first transferred from hexane 
phase to NMF phase with addition of tetramethyl hydroxide (TMAH), and then the NMF QDs solution was 
mixed with polymer to form polymer coated QDs. The removal of original hydrophobic ligands was 
confirmed by the TEM images in which hydroxide ion capped QDs were aggregated together due to lack 
of spacious barriers as shown in Figure 2-5b.  This reagent was lowest in cost, and the procedure was air 
stable and much more rapid compared with the ones requiring an intermediate thiol. This can be 
advantageous for future scale up if we want to make a large batch for commercialization of these particles. 
Moreover, hydroxide-coated QDs effectively have bare, ligand-free surfaces[25], with a zeta potential near 
–26 mV, which provides strong electrostatic repulsion for stabilization in polar solvents such as N-
methylformamide (NMF) and dimethylsulfoxide (DMSO). As a result, these intermediate hydroxide ion 
capped QDs are highly resistant to aggregation and stable in NMF for more than three months without 
purification (Figure 2-5c). In Chapter 3, we showed that even when  hydroxide ion capped QDs were stored 





Furthermore, this method did not change the optical spectra and preserved over 80% of quantum yield (QY) 
in aqueous solution (using optimal coating conditions, see Section 2.5) as shown in Figure 2-5d. Therefore, 
we elected to proceed with further optimization using the method M6.   























Figure 2-4. GPC curves of PIM coated QDs using different methods. 
 
2.2.4 A Robust and Universal Approach for Ligand Exchange of Nanocrystals 
Further investigation of method M6 showed that small molecular ligands or polymeric ligands with 
different binding groups can also be readily attached to surface of nanocrystals with different shapes using 
the same procedure to tailor the surface properties of nanocrystals such as charge and stability. Figure 2-
6a lists the thiol-based molecules that we have successfully used to stabilize QDs in water using this 
modular phase transfer and ligand exchange protocol[26-28]. Unlike published generalized ligand-
exchange strategies which usually involves unstable intermediates, hydroxide ion capped QDs are 
extremely stable in polar solvents enabling efficiently homogeneous ligand exchange without aggregation. 
Bi-dentate ligands such as dithiol dihydrolipoic acid (DHLA) derivatives have been extensively 
explored to generate stable QDs dispersions[20, 29, 30]. As shown in Figure 2-6b, hydroxylated DHLA -
coated QDs were stable for three days. However, long-term stability was not comparable to PIM-coated 
QDs due to possible oxidation of the thiols. One limitation of using DHLA is the pre-requirement of 
reducing lipoic acid groups to DHLAs. Reducing agents are not compatible with certain functional groups 





oxidized lipoic acid-based ligands without prior reduction[31, 32]. In our study, we found that this photo-
ligation process can also be conducted with method M6. Lipoic acid based ligands can be photo-reduced to 
DHLAs which further stabilize the particles in the same phase. Such in situ homogeneous ligand exchange 
can potentially minimize the aggregation that may occur in ligand exchange across a biphasic interface.  
 
Figure 2-5. General procedure of phase transfer and ligand exchange for polymeric ligands. (a) Schematic 
illustration of phase transfer and ligand exchange (not to scale); (b) TEM images of as-prepared QDs in 
hexane (upper) and QDs treated with tetra-ammonium hydroxide in NMF (lower). Scale bar: 20 nm; (c) 
Optical spectra before and after phase transfer; (d) stability of hydroxide capped QDs in NMF after one 
month at -20 ℃. 
 
Silica-coated quantum dots (QDs) have shown great promise in multiplexed biological detection and 
imaging due to their relative high brightness, superior stability, cytocompatibility , and diverse chemistry 
for surface functionalization[33-35]. A major ongoing challenge is to achieve an uniform silica shell coating 
with thickness less than 5 nm[36]. With method M6, we were able to reproducibly yield water-soluble 
homogeneous QDs with ultrathin silica coating (1~2 monolayer) and high quantum yield preservation 
(~80%) using (3-aminopropyl)triethoxysilane (APTES). The amine surface of the resulting QDs enables 





Michael addition. Using these techniques we have generated highly stable (over one month) carboxylated 
QDs with only a 4.5 nm increase in hydrodynamic diameter arising from the coating as shown in Figure 2-
6c. Future studies will be focused on controlling the thickness of silica coatings to minimize the effect of 
the environment such as photo-oxidation and acid etching[37, 38].   
 
Figure 2-6. Examples of ligands tested in conjuction with method M6. (a) Chemical structures of thiol-
based ligands and APTES. (b) Particle stability and fluorescence stability of DHLA-TRIS coated QD605 
within three days. (c) Hydrodynamic size of carboxylic acid functionalized monolayer silica coated QD605.  
 
Besides quasi-spherical QDs, nanocrystals with different sizes and different shapes such as 
nanoplatelet and nanorod can also be stabilized by PIM utilizing this robust and universal approach. As 
shown in Figure 2-7, PIM coated nanoplatelets, nanorods and big QDs maintain fluorescence in aqueous 
buffer and were colloidally stable for over one year. These different shaped nanocrystals have many unique 
applications in bioimaging studies. For example, recently we have demonstrated that nanoplatelets are a 
new type of efficient cell penetrating agents, exhibiting rapid penetration of mammalian cells. Nanorods 
have been widely used in polarization microscopy, which takes advantages of the polarized emission of 






Figure 2-7. Phase transfer and ligand exchange using method M6 to coat different-shaped nanocrystals 
with PIM polymers.  
 
2.2.5 Optimization of Coating Conditions to Maximize Size Homogeneity  
In Section 2.4, we demonstrated that hydroxide ions capped QDs provide an ideal substrate for 
adsorption of polymeric ligands. However when the coating procedure was performed at room temperature, 
GPC revealed that despite a small size observed by DLS (10.2 nm), a large fraction of the population was 
present as small aggregates when using the PIM polymer. As shown in Figure 2-8, we further optimized 
the hydroxide-mediated polymeric coating strategy by adjusting specific reaction parameters (solvent, 
reaction time, molar capping ratio, and temperature.  
All particles were stable in aqueous solution after purification and yielded fluorescent, transparent 
dispersions (Figure2- 8a). The major characteristics for optimization were GPC size and homogeneity, 
shown in Figure 2-8b-e. The major peak with smallest size was deemed to be the unaggregated monomeric 
QD population, and we quantified its fraction in the population by fitting the chromatograms to a sum of 
Gaussian peaks, dividing the area of the monomeric QD peak by the total area under the GPC curve. When 
the coating was conducted in different diluting solvents, the final particles have different degree of 
aggregation. This may be because the polymer chain showed different flexibility in those solvents. In good 






Figure 2-8.  Optimization of coating methods for hydroxide-capped QD605 QDs with PIM by changing 
solvents (DMSO, NMF, methanol), reaction time (1 h, 2 h, 4 h), molar capping ratio (MCR; 1:1, 2:1, 5:1) 
and temperature (room temperature, 70℃, 110℃). (a) Fluorescent photographs of aqueous PIM-coated 
QD605 dispersions under UV excitation. Gel permeation chromatograms of aqueous products using 
different coating conditions, adjusting: (b) solvent, (c) reaction time, (d) MCR, and (e) temperature. Note: 
these samples were measured on Superose 6 column. 
 
surface to stabilize the particles (Figure 2-8b). Lengthening the coating time rendered more monodisperse 
particles and this might be because the particles have more reach a thermodynamic equilibrium. A 2 h 
reaction time was found to be optimal, with no benefit provided by longer times (Figure 2-8c). We also 
found that adding excess polymer was beneficial based the result of varying the molar capping ratio (MCR) 
which was calculated as the ratio of the number of imidazole groups on the polymer per the total number 
of QD surface atoms (Figure 2-8d). The reason for this may be  because the excess polymer can prevent 
particle aggregation during coating[10]. However, more than 10% of aggregates remained in the final 
product. To fully minimize the aggregate population, we found it was most important to use high 
temperatures for coating (110℃), which removed small aggregates present, likely due to dissociation of 
weakly bound conformations of the polymer that were not fully adsorbed (Figure 2-8e). Although it is 
energetically favorable for the linear multidentate polymer to wrap around the QDs in a closed configuration, 
this highly ordered structure is kinetically slow to form at room temperature. Thus randomly attached 
polymers may cause polymer crosslinking between different particles and eventually form small clusters at 
room temperature, so, elevating the reaction temperature may facilitate the loop closure and reduce 





study, in which with the reaction goes on, the resulting particles become more compact and homogeneous 
as shown in Figure 2-9.  
 
Figure 2-9. (a) GPC curves of PIM coated QDs synthesized in DMSO using 5: 1 MCR at 110 ℃ at different 
time points: 1 min, 10 min, 1 h and 2 h. These samples were measured on Superose 6 increase column. (b) 
Theoretical calculation of hydrodynamic diameter for QDs with an ideal compact multidentate polymer 
coating that forms a closed “loops-and-trans” conformation.  
 
2.2.6 Optimization of Polymer Structures to Minimize Hydrodynamic Size 
In Section 2.5, I optimized the coating conditions to maximize the homogeneity of PIM-coated QDs. 
When the particles were synthesized in DMSO using 5: 1 MCR at 110 ℃after 2 hours, the particles became 
monodisperse and compact. In theory, for compact multidentate polymer coating, the polymer should form 
a closed “loops-and-trans” conformation. As a result, the final hydrodynamic size of PIM coated QDs 
should be determined by the radius of the loop and the length of the stabilizing group. As shown in Figure 
2-9b, for a 5.8 nm core (QD600), the minimal hydrodynamic size of PIM coated QDs should be about 11 
nm. But the smallest particles we synthesized using the optimal coating condition is 12.5 nm which is 1.5 
nm bigger than the minimal hydrodynamic size. This discrepancy implied there was something wrong with 
our initial polymer design. Compared with the ideal polymer structure in which the half of the side chain is 
imidazole, there was only 35% of imidazole groups in our polymer. This means polymeric ligand can 






Figure 2-10. 1H NMR spectra of PIM with different imidazole percentage on the side chain. The imidazole 
percentage was calculated by the integration ratio of peak b to peak a. 
 
To test this hypothesis, I synthesized a series of PIM ligands with varying percentages of imidazole 
groups on the polymer side chain (0%, 4%, 14%, 28%, 54%, 65%, and 100%). The polymer structures were 
verified by 1H NMR as shown in Figure 2-10. Increasing the imidazole percentage in the polymer should 
form a smaller loop on the QD surface and the resulted PIM coated QDs should become smaller. 
Surprisingly, all the polymers were able to yield stable colloidal dispersion of QDs in aqueous solution 
depending on the buffer pH. For 65% and 100% samples, the corresponding QDs can be dispersed in acidic 
buffer (pH 4.0), not neutral phosphate buffer (pH 7.4). For the other samples, the resulted PIM coated QDs 
were readily dispersed and stable in neutral phosphate buffer (pH 7.4). The distinguishable differences may 
arise from the imidazole percentages in the polymer. When the imidazole percentage is over 50%, it is 
possible that some extra imidazole groups were not anchored to the QD surface and the particles tended to 





protonated and the particles became positive charged. As a result, particles were stabilized by charge-charge 
repulsion. It is noteworthy that PIM with no imidazole groups was also able to stabilize the QDs. This 
polymer may be physically adsorbed onto QDs and provide steric stabilization by entropic repulsion.  
However, these are not uniform, as evident from precipitation with centrifugation.  
 
Figure 2-11. Size characterization of QDs coated PIM with varying imidazole percentages. (a) DLS curves; 
(b) Mean size measured by DLS; (c) GPC curves; (d) Size measured by GPC is the minimum size among 
peaks, calculated from calibration curves of proteins with known size. Note: these samples were measured 
on Superose 6 increase column. 
 
Figure 2-11 shows size characterization of these particles by DLS and GPC. As expected, the particles 
progressively became smaller with increasing imidazole in the polymer as shown in Figure 2-11b. However, 
there was no significant size difference in DLS measurement when the imidazole percentages were 
increased from 14% to 65%. But when these particles were examined by size exclusion chromatography, 
with increasing imidazole content, it can be clearly seen that the particles progressively became smaller 
from 16.2 nm to 11.3 nm close to the theoretical hydrodynamic size minimum. Positively charged particles 
tend to interact with the agarose beads in GPC column. We were not able to measure the size of QDs coated 





group plays a critical role in the final hydrodynamic size. 1: 1 ratio of binding group to stabilizing groups 
can enable the smallest stable particles.  Also, this result implies that in order to further shorten the ligand 
shell thickness, it is necessary to reduce the distance between the binding group and end groups of 
stabilizing part. An ideal design to further minimize the size might be putting the binding groups within the 
main chain rather than on a pendant group .  
 
Figure 2-12.  Extension of the optimized coating method for preparation of PIM-coated QDs and PIMN3-
coated QDs with different sizes and colors. (a) Emission spectra of QDs with different sizes. (b) GPC curves 
of PIM-coated QDs with diferent colors. Note: these samples were measured on Superose 6 column. (c) 
TEM images of PIM-coated QDs. Scale bar 20nm. Inset image: TEM images of tungstic acid stained PIM-
coated QDs. Dashed circle line indicates “crown-like” structure of PIM on QDs. Scale bar: 5 nm. 
 
Using this new methodology, we coated four sizes of QD cores with different emission (Figure 2-12a), 
which yielded high-QY particles that were stable in aqueous solution with small sizes (7.4-12 nm) by GPC. 
Their narrow size distributions by GPC (Figure 2-12b) indicate homogeneity of the monomeric product, 
comprising 95-100% of the total distribution. These hydrodynamic sizes were just 4-6 nm larger than their 
hard-core TEM sizes. Based on the expectation of a ~5 nm increase in hydrodynamic size by measuring the 
molecular length of the polymer from the imidazole group to the end of an adjacent OEG, this compact QD 
is consistent with a flat conformation of polymeric coating on the nanocrystal surface. TEM images showed 
these particles were well separated from each other (Figure 2-12c) and by staining these particles with 
tungstic acid, a crown-like structure observed around the QD confirmed the presence of a polymer coating.  
The QY of these QDs in water was about 30-50% which is lower than that of organic capped QDs. The QY 
of QDs is a function of surface traps, in which localized electrostatic charges arises from dangling bonds 
and provide non-radiative decay pathways which quench fluorescence emission. Although overgrowth of 
a wide bandgap shell such as ZnS can increase QY by serving as an electronic insulator to reduce exciton 
wavefunction overlap with surface traps, it is not sufficient alone unless thick shells are deposited, normally 





introduce new mid-gap electronic states and increased the rate of non-radiative relaxation which eventually 
caused a QY decrease. 
 
Scheme 2-1. Synthetic routes of polymeric ligands with negative or neutral charges. 
 
2.2.7 Minimizing Nonspecific Binding 
Surface coating does not only affect the size and stability of QDs, but also determines their nonspecific 
binding properties. For biomedical applications, nonspecific binding increases the background noise level, 
reduces the signal-to-noise ratio, and leads to false-positive staining for biomarkers in fluids, cells and 
tissue.[39, 40] Thus, minimizing nonspecific binding is critical to increasing the sensitivity of QD-based 
detection  of a target. A variety of other types of polymers with different negatively charged (carboxylic 
acid), zwitterionic (sulfobetaine), or neutral groups (oligoethylene glycol) were synthesized (Scheme 2-1) 
and characterized by 1H NMR (Figure 2-12a). QD coated by these polymers were homogeneous in size 
distribution was characterized by TEM, gel electrophoresis and DLS (Figure 12b-d).  The nonspecific 
interaction of these different polymer coated QDs with live Hela cells was evaluated as shown in Figure 2-
14. As expected, oligoethylene glycol-coated QDs or zwitterion (sulfobetaine) coated QDs can efficiently 
eliminate nonspecific interactions because of their nearly neutral surface and well-hydrated surface.[41] 





binding to live cells, presumably due to the electrostatic interactions between negative QDs and positive 
charged domain of cell membrane protein or extracellular matrix. To support this hypothesis, we further 
assessed the nonspecific binding of PIMAH coated QDs to fixed/permeabilized Hela cells that were pre-
treated with different blocking agents (Figure 2-15A) including surfactants (Tween-20, SDS, Triton-X, 
Igepal Co 520), proteins (BSA, FBS, milk powder, casein) and anionic polyelectrolytes (amphipol polymer, 
polyacrylic acid, dextran sulfate, polystyrene sulfonate (PSS), and DNA) (Figure 2-15B). Figure 2-15C 
and D shows the qualitative and quantitative nonspecific binding results under each treatment condition, 
respectively. Cells pre-treated with anionic polymers exhibited much lower nonselective binding than other 
samples. In the presence of PSS, the background level was close to that of blank control samples. It is likely 
that PSS was able to block the positively charged binding sites and thus minimize nonspecific binding of 
QDs to the cells. Based on the results, QDs with neutral surfaces such as PIM were chosen for our future 
bioimaging studies.  
 
Figure 2-13. Characterization of polymeric ligands and QDs coated by ligands with different charges. (a) 
1H NMR spectra of polymeric ligands in D2O. (b) TEM images of different polymeric ligand coated QDs. 
Scar bar: 20 nm. (c) Gel electrophoresis result confirmed the charge differences cross the five particles . 
Gel was  1% agarose in 50 mM sodium borate buffer. From left (L) to right (R) shows QD600 coated with: 
PIMCOOH, PIMA, PIMAH, PIM, and PSSB. (d) Size distribution of QDs coated with different ligands 







Figure 2-14. Fluorescence micrographs of live HeLa cells exposed to QD600 with different surface 
coatings. HeLa cells were treated for 0.5 h at 4 ℃ in Dulbecco's phosphate-buffered saline (DPBS) with 40 
nM of:  (a)PIMAH, (b)PIMCOOH, (c)PIMA, (d) PIM and (e) PSSB. Cells were imaged at 20× 






Figure 2-15. (A) Schematic illustration of different blocking agents to minimize the nonspecific binding of 
PIMAH coated QDs to fixed/permeabilized cells (not to scale). (B) Chemical structure of anionic 
polyelectrolytes used in this study. (C) Fluorescence images of cells using different blocking agents: (a) 
Untreated; (b) 0.1 % (v/v) Tween-20; (c) 0.1 wt % SDS; (d) 0.1 % (v/v) Triton-X 100; (e) 0.1 % (v/v) Igepal 
Co 520; (f) Control (PBS); (g) 1% BSA; (h) 1% FBS; (i) 1% Milk powder; (j) Casein; (k) 0.1 wt % AP; (l) 
0.1 wt% PAA; (m) 0.1 wt % DS; (n) 0.1 wt% PSS; (o) 0.01 wt% DNA. QD concentration is 100 nM. (C) 
Mean fluorescence intensity comparison between each sample. All data are represented as mean  standard 
error (SE) (n = 4~6) 
 
2.2.8 Engineering Reversible pH Responsive QDs Through Surface Chemistry 
In the past decade, QDs have been used as fluorescent probes to image and detect biological molecules 
such as proteins and DNA in biological fluids, living cells, and living organisms[42]. Compared to organic 
dyes or fluorescent proteins, an ongoing challenge is to control the fluorescence of QDs by external 
stimuli[43]. An environmentally responsive QD holds great promise in in vitro single molecule tracking 
and  in vivo imaging[44]. A variety of mechanisms have been proposed to modulate the fluorescence of 
QDs through either Förster resonance energy transfer (FRET)[45] or charge transfer[44], in which a pH-
sensitive responsive fluorophore or electron quencher group is attached in close proximity to QDs. However, 
such additional decoration usually impairs the integrity of the QDs surface and induces undesirable side 
effects including altered surface charge or hydrophobicity and increased nonspecific binding to nontarget 





responsiveness of QD-dye assemblies exhibit limited reversibility due to low photostability of the organic 
dyes[39]. Thus, there is an urgent unmet need for developing a novel mechanism to reversely control the 
optical properties of QDs based on change in the external environment. However, up to date, there are no 
reports on making core/shell QDs that can reversibly respond to pH between 4.0 and 7.4, a  range core to a 
diverse range of which is an attractive pH window related to a series of biological phenomena[46].   
Reversible pH-sensitive QDs require that QDs are stable across the entire working pH range of interest. 
Any loss of ligands during pH change may lead to a permanent damage of the optical properties of QDs.  
However, currently available binding groups are prone to detach from QDs due to reduced binding affinity 
towards to surface metal atom at lower pH[15, 30]. For example, at acidic pH values, thiolates can be 
readily protonated to thiols ,which have much lower affinity to metal surface atoms. Likewise, imidazole 
or pyridine groups are protonated at acidic Ph,  which significantly decreases interaction with metal surface 
atoms. In this context, the nitrogen-rich 1,2,3-triazole group is an ideal candidate for stabilizing QDs in an 
acidic environment owing to its strong metal complexation capability and low pKa (for azolium group, pKa 
= 1.3[47]) which enables the triazole group to maintain deprotonated even below pH 4.0. Although 1,2,3-
triazole has already been utilized as building blocks in a wide range of supramolecular and coordination 
chemistry, its potential in QD coating has not been explored. In this section, we present that QDs capped 
with a poly(1H-1,2,3-triazole) ligand is colloidally stable across a broad range of pH and its fluorescent 
intensity can be reversely switched off and on between pH 4.0 and 7.4.  
 
 
Figure 2-16. Photographs of QDs dispersed by triazole under room light (a) or UV lamp (b). Photographs 
of QDs stabilized by different concentration of triazole under room light (c) or ultraviolet light (d). A to F: 
1H-1,2,3-triazole with different concentrations in DMF (0, 0.1, 1, 10, 100 and 1000 mM). G: imidazole 
with 1000 mM concentration in DMF. Photographs of triazole-stabilized QD diluted by DI water under 
ultraviolet light. (e) before and (f) after centrifugation. W1 to W5: the dilution ratio is (W1) 2(W2) 5，(W3) 
10(W4) 50 and (W5) 100, respectively. Photographs of triazole-stabilized QD diluted by PBS buffer under 
ultraviolet light. (g) before and (h) after centrifugation. P1 to P5: the dilution ratio is  (P1) 2(P2) 5，(P3) 





To verify 1H-1,2,3-triazole can bind to QDs, CdSe/CdxZn1-xS QDs coated in aliphatic ligands in CHCl3 
were dried into a film and mixed with pure 1H-1,2,3-triazole. As shown in Figure 2-16a and b, QDs were 
successfully dispersed in 1H-1,2,3-triazole indicating the binding of 1H-1,2,3-triazole to QDs is strong 
enough to compete with the original hydrophobic ligands. In a large excess of ligands, QDs capped with 
1H-1,2,3-triazole were also stable in high dielectric solvent such as DMF. Under the same condition, QDs 
capped with imidazole were not stable (Figure 2-16c and d) implying 1H-1,2,3-triazole has stronger 
affinity to QDs in comparison with imidazole. However, the binding is not strong enough to stabilize QDs 
in aqueous solution as indicated by the precipitation in water/PBS after centrifugation (Figure 16e-h).  
 
Figure 2-17. (a)  Synthetic route of multidentate polymeric ligands that have different pKa of binding groups. 
(b) Schematic illustration of phase transfer and ligand exchange process for dispersing QDs in aqueous 
solution using multidentate polymeric ligands. (c) Comparison of 1H NMR spectra of these polymeric 
ligands in DMSO-d6. 
 
Recently, multidentate polymeric ligands have emerged as a promising surface coating to overcome 
the limited aqueous solubility of QDs coated with weakly bound ligands[17, 18, 48, 49]. The resulting 
colloids are stable for months to years and compatible with harsh purification processes that typically 
destabilize more weakly bound coatings. Using the synthetic strategy we developed above, we were able to 
attach the 1H-1,2,3-triazole to a linear polymer through via a two-step reaction including one amidation 
reaction and one Cu-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. CuI is used to catalyze the 
reaction between TMSN3 and the appended alkynyl group. After reaction, excess EDTA was added into the 
solution and the polymer solution was purified against ethylenediaminetetraacetic acid (EDTA) solution to 
remove any free copper ions which degrade QD fluorescence.[50]  For comparison, another three analogous 
multidentate polymers with thiols, pyridine and imidazole group were prepared (Figure 2-17a). The 





Figure 2-17b, the broad peaks ranged from 6.5 to 9.0 ppm refer to the appended groups reflect the 
successful synthesis of these multidentate polymeric ligands.  
 
Figure 2-18. Properties of multidentate polymer coated QDs (a) Digital photographs under room light (up), 
ultraviolet light (middle), and Gel permeation chromatogram (bottom), the well position is indicated by the 
arrow, and electrode polarities are indicated as (−) and (+); (b)DLS curves; (c) Digital photographs under 
ultraviolet light for coated QDs dispersed in buffer with different pH value after 3 weeks; (d) pH stability 
testing in buffers spanning pH 3-13. 
 
QDs were coated with these four polymers by the optimized two-step phase transfer and ligand 
exchange procedure to yield compact and stable dispersion in aqueous solution. All QDs can be dispersed 
readily in sodium borate buffer (pH=8.5) to obtain a clear solution as shown in Figure 2-18a. These 
solutions were stable for at least three months without significant precipitations. After centrifugation at 
7,000 g for 10 min, there was no aggregation except P-PM-coated QDs. Figure 2-18a shows that all the 
samples can emit bright orange fluorescence under ultraviolet light. The hydrodynamic diameters of coated 
QDs are determined by DLS. As shown in Figure 2-18b, PTM coated QDs has the size near 7.6 nm, while 





and broad distribution of PPy coated QDs implied presence of a small fraction of aggregations presumably 
due to weakly bound pyridine groups. 
The stability of QDs is a crucial property for single particle tracking, therefore, a serial of experiments 
was carried out to investigate the dependence of fluorescence on pH in buffers spanning pH 3.0-13. As 
shown in Figure 2-18c, the fluorescence intensity increased with increasing pH, and all QDs showed 
excellent particle stability above pH=6.0. However, the fluorescence intensity of PTM coated QDs 
decreased dramatically in acidic buffers, and it reduced to 30% when it was diluted in pH =4.0 buffer and 
up to 90% after 30 min as shown in Figure 2-18d.  
 
Figure 2-19. (a) Proposed mechanism of protonation and deprotonation of 1H-1,2,3-triazole between pH 
7.4 and 4.0. Fluorescence pH reversibility of PTM coated QDs; (b) pH fluorescence reversibility of single 
PTM-coated QDs adsorbed on glass. 
 
pH-reversibility is a very important feature of many kinds of nanoparticles applied for imaging and 
optical chemo/biosensing. Since the fluorescence of these QDs can be tuned by changing pH, a set of 
experiments was carried out to study the fluorescence reversibility. As shown in Figure 2-19b, the 
fluorescence intensity of PTM QDs can be reversely switched on-off-on at least over 4 rounds of pH change 
if time permits. However, PPy QDs and PIM QDs lost their stability and formed some aggregations after 2 
rounds of pH change. This result indicates that PTM QDs have the better stability and fluorescence pH-
reversibility. This feature can be useful to reveal the change of pH value in the environment by giving a 
significant fluctuation of fluorescence intensity. The fluorescence reversibility of PTM QDs was further 





from 7.4 to 4.0, the fluorescence intensity dropped rapidly, and the number of detectable QDs decreased. 
After 10 min, almost no QD can be observed in the image. Replacing the incubating buffer with pH 7.4 
solution, some QDs reappear and the fluorescence becomes brighter and brighter with time. The pH 
reversibility of PTM QDs may be attributed to the unique coordination interaction of 1H-1,2,3-triazole with 
surface zinc atoms. As shown in Figure 2-19a, its basic nitrogen atoms at N2 and N3 position can 
coordinate with zinc atoms. This interaction does not change between pH 4.0 to 7.4 due to its the low pKa 
of the azolium group. However, addition of hydroxide ions can remove the proton at the N1 position if the 
resulting anionic charge is suitably redistributed to the surface metal atom. This deprotonation process may 
thus increase the electrostatic interaction between the triazolate and the metal surface. Such increased 
binding strength of surface ligand and zinc atoms may be the reason for stability enhancement compared 
with the other polymer coatings.  
 
2.3 Conclusions 
In summary, I optimized a two-step multidentate ligand-coating strategy for preparing monodisperse 
and compact QDs. These new QDs are some of the smallest reported to date and exhibit long-term stability 
and low nonspecific binding on cells due to short-chain OEG tethers to the surface. Most importantly, I 
validated that the products are homogeneous using gel permeation chromatography and single-molecule 
imaging, and demonstrated how gel electrophoresis and light scattering measurements are insufficient alone 
to assess the presence of clusters or aggregates in a heterogeneous mixture. I further demonstrated that this 
strategy is robust and applicable for many other types of ligands including small molecular ligands, silica 
and polymeric ligands with different binding groups. By finely tuning the pKa of binding groups of surface 
ligands, I achieved a novel pH responsive QDs using polytriazole ligands. I anticipate that the approach 
presented here will greatly broaden the use of QD with thin polymeric coatings in a wide variety of 
biological applications and open up the potential use of stimuli responsive QDs in myriads of biological 
applications. 
 
2.4 Experimental Section 
Materials. Triethylene glycol (TEG, 99%), p-toluenesulfonyl chloride (TsCl, 99%), sodium azide 
(NaN3, >99.5%), triphenyl phosphine (PPh3, >98.5%), sodium bicarbonate (NaHCO3, >99.7%), 2,2’-
azobis(2-methylpropionitrile) (AIBN, 98%) , histamine (97%), N-hydroxysuccinimide (NHS, 98%), 
Acryloyl chloride (97%), 4-(dimethylamino)pyridine (DMAP, >99%) and 2-Cyanoprop-2-yl-





Silicycle Inc, Canada. Behenic acid (BAc, 99%) was obtained from MP Biomedicals. 
Tetradecylphosphonic acid (TDPA, >99%) was purchased from PCI Synthesis. Poly(maleic anhydride) 
(MW = 5 kDa) was purchased from PolySciences, Inc, USA. Solvents including tetrahydrofluran (THF), 
chloroform (CHCl3), hexane, toluene, methanol (MeOH), and acetone were purchased from various 
suppliers including Acros Organics, Fisher Scientific, Macron Fine Chemicals. Milli-Q water was used 
throughout. 1-octadecene (ODE, 90% tech.), oleylamine (OLA, 80–90% C18-content) and oleic acid (Oac, 
90% tech.) were obtained from Acros Organic. Trioctylphosphine oxide (TOPO, 99%) and 
trioctylphosphine (TOP, 97%) were purchased from Strem Chemicals (Newburyport, MA, USA). 
Anhydrous cadmium chloride (CdCl2, 99.99%), and zinc acetate (Zn(Ac)2, 99.98%) were obtained from 
Alfa Aesar. Cadmium acetate hydrate (Cd(Ac)2·H2O, 99.99+%), selenium dioxide (SeO2, 99.9%), selenium 
powder (Se, ~100 mesh, 99.99%), sulfur powder (S, 99.98%), diphenylphosphine (DPP, 98%), 1,2-
hexadecanediol (HDD, 97%) were purchased from Sigma-Aldrich. Thioglycerol (97%), triethylamine 
(TEA, >99%), ammonium sulfide solution ((NH4)2S, 40-48 wt.% in water), acylamide/N,N’-
methylenebisacrylamide (19:1, 40% mix solution in water), tetramethylammonium hydroxide solution 
(TMAH, 25 wt.% in methanol), N-methylformamide (NMF, >99%), fluorescein (fluorescence grade) were 
purchased from Sigma-Aldrich. Agarose was purchased from Fisher Scientific. N,N,N’,N’-
tetramethylethylenediamine (TMEDA) was obtained from Bio-Rad laboratories Inc. mPEG-SH (MW 356.5 
Da) was purchased from POLYPURE (Catalog No. 11156-0695, Norway). Unless specified, all the other 
chemicals and solvents were purchased from Sigma-Aldrich and used without further purification.  
Quantum dots purification and quantum yield calculation. A stock suspension of QDs (2 mL) was 
diluted with chloroform (2 mL) in a 15 mL tube. Acetone (8 mL) was added dropwise while mixing on a 
vortex. The QDs were isolated by centrifugation at 7000xg for 5 min and then dispersed in hexane (7 mL). 
Methanol (2 mL) was added to extract the hexane solution and the biphasic mixture was vigorously mixed. 
The methanol phase was discarded. The QD dispersion was diluted with hexane (5 mL) and extracted with 
methanol (2 mL). The biphasic mixture was centrifuged (7000 x g, 10 min) and the hexane phase was 
transferred to a 15 mL glass vial. The UV absorbance (A) was measured and used to calculate the molar 





Here ε represents absorption extinction coefficient, l is the path length of a quartz cuvette.  





Gel electrophoresis of QDs. In a 50 mL tube, an aqueous acrylamide/N,N’-methylenebisacrylamide 
solution (2 mL) was mixed with DI water (18 mL) and sodium borate buffer (10 X, 5 mL), and the mixture 
was heated to 55°C for 5 min in a warm water bath. In another 50 mL conical flask, agarose (0.25 g) was 
suspended in DI water (25 mL) and dissolved by heating in a microwave oven for 1 min, then mixed for 1 
min and allowed to cool for 2 min.  The first solution was then added and the solution was mixed for 1 min. 
An aqueous solution of ammonium persulfate (251 µL, 0.1g/mL) and TMEDA (20 µL) was added to this 
solution and mixed by gently shaking. The solution was added to a gel casting tray and was allowed to gel 
for 1 h. Electrophoresis was performed at 120 V for 30 min.  
Optical spectroscopy and fluorescence QY measurements. Fluorescent spectra were measured using a 
NanoLog Horiba Jobin Yvon (HORIBA Scientific, New Jersey, NJ, USA) and data were collected with 
Fluo Essence V3.5 software. UV-Vis spectra were obtained using a Cary series UV-Vis-NIR 
spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) and data were collected with Cary 
WinUV Scan Application Version 6.00 1551 software.  For fluorescence QY measurements, the solution 
was diluted to give NPL absorption of ~0.1 at 490 nm. QY was calculated relative to a reference dye 
(fluorescein in 1mM NaOH, QY=92%). 
Transmission electron microscopy (TEM). TEM images were obtained using a JEOL 2010 LaB6 high-
resolution microscope in the Frederick Seitz Materials Research Laboratory Central Research Facilities at 
University of Illinois. For QDs in organic solvents, samples were prepared by placing a drop of dilute NPL 
solution in hexane on an ultrathin carbon film TEM grid (Ted Pella; Product # 01824) and then wick the 
solution off with a tissue.  
1H and 13C NMR. 1H and 13C NMR spectra were recorded on a Varian U400 MHz, a UI500NB MHz or a 
VXR-500 MHz spectrometer.  
Dynamic light scattering. Light-scattering analysis was performed on a Malvern Zetasizer (Herrenberg, 
Germany). The QDs samples were about 300 nM and filtered through a 0.2 µm filter (Catalog No. 28143-
300, VWR). Each trace for autocorrelation was acquired for 15s, and averaged over 11 runs per 
measurement. The autocorrelation function was analyzed using Zetasizer software (ver. 7.02, Malvern 
Instruments Ltd.). Each DLS measurement resulted in an average QD diameter with a standard error of the 
mean.  Hydrodynamic diameters were obtained from a number-based distribution and reported as the mean 





Zeta potential Measurement. Zeta-potential of QDs were evaluated by a Malvern Zetasizer (Herrenberg, 
Germany). Zeta-potentials were measured in 10 mM phosphate buffer (pH 7.4) in a disposable capillary 
cell (DTS1070). Values were reported as the mean  SEM of triplicate measurements consisting of 20 scans.  
Gel permeation chromatography (GPC) for QD size determination. GPC was performed on an 
ӒKTApurifier UPC10 (GE Healthcare, Umeå, Sweden) with a Superose™ 6 10/300GL column or 
Superose™ 6 increase 10/300GL column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and data 
were processed with UNICORN 5.31 Workstation software.   
Gel electrophoresis. Gel electrophoresis was performed using an EPS-300X system (C.B.S. Scientific 
Company, Inc., Del Mar, CA, USA) and gel images were acquired with a Gel Doc™ XR+ System (Hercules, 
CA, USA).  
Gel permeation chromatography (GPC) for polymer analysis. GPC experiments for polymers were 
performed on a system equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, 
CA, USA). The molecular weights of polymers were processed by the ASTRA V5.1.7.3. 
Fluorescence microscopy. Samples were imaged on a Zeiss Axio Observer Z1 inverted microscope. 
Hoechst signal was imaged using a 365 nm excitation filter and 445/50 nm emission filter; QD565 signal 
was imaged using a 488 nm laser excitation and a 562/40 bandpass emission filter; QD600 signal was 
imaged using a 488 nm laser excitation and a 600/37 bandpass emission filter. Images from the control and 
QD samples were collected using the same imaging condition.  
Synthesis of Core/Shell CdSe/CdxZn1-xS QDs. CdSe cores with diameter of 2.3 nm (for QD525 and 
QD565) or 3.0 nm (for QD600 and QD605) were synthesized using conventional high-temperature arrested 
precipitation methods as previously described in the literature. After purification, CdxZn1-xS shells were 
grown layer-by-layer. In a typical shell growth reaction, a purified core stock in hexane (~1 micromole) 
was injected into a mixed solvent of ODE (12 mL) and OLA (6 mL) in a 250 mL round bottom flask and 
hexane was evaporated under vacuum at 40–50°C. Then, the solution was heated under nitrogen to a 
temperature used for the first 0.8 ML shell growth (typically 120–130°C). The first S precursor 0.8 
monolayer (ML) was added dropwise within 5–10 min and allowed to react for ~20 min. Equal amounts of 
Cd/Zn precursor was added in the same manner and allowed to react for another ~20 min to complete the 
0.8 ML shell growth. This cycle was repeated while gradually increasing both the Zn ratio (typically from 
0.5 to 1) and the reaction temperature (typically from 130oC to 200°C). An aliquot (200 µL) was withdrawn 
using a glass microsyringe after every 0.8 ML shell growth to monitor the reaction and to measure the 
extinction coefficient. When the desired emission wavelength was reached, an additional injection of Zn 





rich. Specific quantities used for each batch are provided in Supplementary Information. Mixtures were 
cooled and stored as a crude reaction mixture at -20°C freezer until use. 
Synthesis of monoazide triethylene glycol (TEG-N3, 2). PEG-N3 was synthesized according to literature 
protocols that were slightly modified. In a 300 mL round-bottom flask, 2-[2-(2-
Chloroethoxy)ethoxy]ethanol (compound 1, 6.7 g, 40 mmol) and NaN3 (5.2 g, 80 mmol) were dissolved in 
20.0 mL DI water, then the mixture was stirred for 27 h at 75 °C. After removal of the solvent by reduced 
pressure distillation at 60 °C, diethyl ether (100 mL x 2) was added, and the resulting suspension was 
filtered. The filtrate was washed with cold saturated brine (50 mL) and DI water (50 mL x 2). The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to obtain a colorless 
oil (6.7 g, 98% yield) as the product. 1H NMR (CDCl3, δ, ppm, 400 MHz): 3.71 (t, 2H, -OCH2CH2OH), 
3.66 (br, 6H, -OCH2CH2O-,-OCH2CH2N3), 3.59 (t, 2H, -OCH2CH2OH), 3.38 (t, 2H, -OCH2CH2N3); 13C 
NMR (CDCl3, δ, ppm, 500 MHz): 72.6, 70.8, 70.6, 70.2, 61.9. 
Synthesis of monoamine triethylene glycol (TEG-NH2, 3). In a 300 mL round-bottom flask, monoazide 
triethylene glycol 2 (6.0 g, 35.4 mmol) and triphenyl phosphine (10.2 g, 38.9 mmol, 1.1eq) were dissolved 
in 150 mL dry THF. The mixture was stirred at room temperature for 19 h. DI water (1.86 mL, 103.3 mmol) 
was added to the mixture, and stirring was continued for another 10 h. The solvent was removed under 
reduced pressure, and DI water (100 mL × 2) was added to the residue. The supernatant was collected and 
centrifuged at 7,000 × g for 10 min. The precipitate was removed and toluene (50 mL x 2) was employed 
to wash the solution. The down layer emulsion was collected using a separatory funnel and evaporated 
under reduced pressure at 70 °C. Some crystals were observed and removed by precipitating in chloroform 
and centrifuged at 7,000xg for 10 min. Then the supernatant was rotary evaporated at 60 °C to obtain pale 
yellow oil (4.0 g, yield 94%). 1H NMR (CDCl3, δ, ppm, 400 MHz): 4.89 (s, 1H, -OH), 3.52-3.70 (m, 10H, 
-OCH2-); 13C NMR (CDCl3, δ, ppm, 400 MHz): 73.2, 72.9, 70.6, 70.4, 61.9, 41.7. 
Synthesis of N-acryloxysuccinimide (NAS, 4). N-acryloxysuccinimide 4 was synthesized according to 
literature protocols that were slightly modified. In a 300 mL flask, N-hydroxysuccinimide (5.87 g, 50 mmol) 
and dry triethylamine (7 mL, 50 mmol) were dissolved in 100 mL dry DCM. Acryloyl chloride (4.6 mL, 
55 mmol) was slowly injected into the solution in an ice bath and the reaction was allowed to proceed for 
5 h. The suspension was filtered and washed twice with cold DI water (30 mL × 2) and cold saturated brine 
(30 mL). The organic layer was dried over anhydrous Na2SO4 and the filtrate was condensed to 20 mL by 
rotary evaporation under vacuum. A white solid was obtained by adding ethyl acetate (50 mL). The product 
was further purified by silica gel chromatography with DCM/ethyl acetate (3:1) as an eluent (6.6 g, 78% 





(br, 4H, -CH2CH2-); 13C NMR (CDCl3, δ, ppm, 400 MHz): 169.5 (CHC=OO), 161.5 (CH2C=ON), 136.9 
(CH2=CH-), 123.7 (CH2=CH-), 25.8 (-CH2-). 
Synthesis of polymer (PNAS, 5). Polymerization of monomer 4 was performed according to literature 
protocols. In a 20 mL Schlenk tube, NAS 4 (1.01 g, 6.0 mmol), 2-cyanoprop-2-yl-dithiobenzoate (44 mg, 
0.2 mmol) and AIBN (3.2 mg, 0.02 mmol) were dissolved in anhydrous DMF (1 mL). The [M]/[CTA]/ 
[Initiator] ratio was kept at 30:1:0.1. The Schleck tube was filled with argon and then evacuated (with an 
oil pump) in a dewar filled with liquid nitrogen. The argon/vacuum process was repeated three times.  The 
solution was then charged with argon and allowed to react at 70°C. After 2 h, the reaction was stopped by 
immersing the tube in liquid nitrogen. DMF (5 mL) was added to dissolve the product, which was 
precipitated with acetone (40 mL) and recovered by centrifugation. The polymer was further washed several 
times with anhydrous acetone and dried under vacuum (0.81 g, yield 80%). 1H NMR (d6-DMSO, δ, ppm, 
500 MHz): 7.36-7.91 (Ph, m), 3.10 (CH, br), 2.76 (CHCH2, br), 2.04 (CH2CH2, br), 1.28 (CH3, br).  
Synthesis of poly(histamine-b-TEG)amide (PIM, 6). In a 7 mL vial equipped a magnetic stir bar, PNAS 
(84 mg) was dissolved in dry DMF (1.0 mL). TEG-NH2 (325 µL, 1.0 mM in dry DMF) and histamine (175 
µL, 1.0 mM in dry DMF) were added and the solution was purged with N2 for 5 min. The solution was 
stirred for 24 h at room temperature. The solution was diluted 5-fold with deionized water and loaded into 
a dialysis bag (MWCO = 2 kDa). The polymer was purified by dialysis in deionized water for 6 h and 
repeated 3 times. A yellow solid product (49 mg) was collected after lyophilization (yield 51%). 1H NMR 
(d6-DMSO, δ, ppm, 500 MHz): 7.50-7.93 (Ph, IM, br), 4.58 (CH2, br), 3.18-3.47 (CH2, br), 2.81 (CHCH2,br), 
1.47-2.07 (CHCH2,m), 1.31 (CH3,br). 
Synthesis of poly(cysteamine-b-TEG)amide (PSH). In a 7 mL vial equipped a magnetic stir bar, PNAS 
(synthesized as described in the literature) (84 mg) was dissolved in dry DMF (1 mL). Monoamine 
triethylene glycol (HO-TEG-NH2, 325 µL, 1.0 mM in dry DMF) was added and the mixture was stirred for 
2 h. Cysteamine (350 µL, 0.5 mM in dry DMF) was then added and the solution was purged with N2 for 5 
min. The reaction was allowed to continue for 24 h at room temperature. DL-dithiothreitol (8 mg) was then 
added and the solution was stirred for 1 h. The solution was diluted 5-fold with an HCl aqueous solution 
(0.1 mM) and loaded into a dialysis bag (molecular weight cut-off, MWCO = 2 kDa). The polymer was 
purified by dialysis in HCl solution (1L, 0.1 mM) for 6 h and repeated 3 times. The yellow powder (51 mg) 
was collected using a lyophilizer (yield 68%).  1H NMR (d6-DMSO, δ, ppm, 500 MHz): 7.52-7.82 (Ph, br), 
4.57 (CH2, br), 3.14-3.52 (CH2, br), 2.85 (CHCH2, br), 1.54-2.31 (CHCH2, m), 1.22(CH3, br). 
Synthesis of poly(pyridine-b-TEG)amide (PPy). In a 7 mL vial equipped with a magnetic stir bar, PNAS 





(aminomethyl)pyridine (18.9 mg) in 0.75 mL dry DMF) were added, and the solution was purged with N2 
for 5 min. The solution was stirred for 24 h at room temperature. The solution was precipitated in 14-fold 
diethyl ether and centrifuged at 7,000xg for 10 min The precipitate was dissolved in 10 mL deionized water 
and loaded into a dialysis bag (MWCO = 2 kDa). The polymer was purified by dialysis in deionized water 
for 6 h and repeated 3 times. A white solid product (54 mg) was collected after lyophilization (yield 51%). 
1H NMR (d6-DMSO, δ, ppm, 500 MHz): 7.50−7.93 (pyridine, br), 4.58 (CH2, br), 3.18−3.47 (CH2, br), 2.81 
(CHCH2,br), 1.47−2.07 (CHCH2,m), 1.31 (CH3, br). 
Synthesis of poly(triazole-b-TEG)amide (PTM). In a 7 mL vial equipped with a magnetic stir bar, PNAS 
4 (168 mg, 1.0mmol) was dissolved in 0.5 mL dry DMF, TEG-NH2 2 (104.0 mg, 0.65 mmol) and 
propargylamine (19.3 mg, 0.35 mmol) were dissolved in 0.4 mL dry DMF, and the solution was purged 
with N2 for 5 min. The solution was stirred for 24 h at room temperature. The solution was precipitated in 
14-fold diethyl ether and centrifuged at 7,000 g for 10 min, the alkyne modified polymer was collected and 
dried in vacuum. 1H NMR (d6-DMSO, δ, ppm, 500 MHz): 7.36-7.91 (Ph, m), 3.10 (CH, br), 2.76 (CHCH2, 
br), 2.04 (CH2CH2, br), 1.28 (CH3, br). Trimethylsilyl azide (86.4 mg, 0.75 mmol) and alkyne modified 
polymer (92.6 mg, 0.5 mmol) were added to a DMF and MeOH solution (2 mL, 9:1) of CuI (4.8 mg, 0.025 
mmol). The mixture was purged with N2 for 5 min in a 7 mL vial. The reaction mixture was stirred at 100 °C 
for 12 h. Then the mixture was cooled to room temperature and precipitated in diethyl ether (40 mL). After 
centrifugation at 7000 g for 10 min, the residue was dissolved in 10 mL DI water. The aqueous solution is 
purified by dialysis against saturated EDTA solution for 24 h and DI water for another 12 h. The white 
polymer (30 mg) was obtained by lyophilization (yield 30%). 1H NMR (d6-DMSO, δ, ppm, 500 MHz): 
7.36-7.91 (Ph, m), 3.10 (CH, br), 2.76 (CHCH2, br), 2.04 (CH2CH2, br), 1.28 (CH3, br). 
Synthesis of poly(histamine-b-carboxyl acid)amide (PIMCOOH), poly(histamine-b-carboxyl acid-b-
oligoethylene glycol)amide (PIMAH), poly(histamine-b-carboxylic acid-b-alkene)amide (PIMA).  
Poly-maleic- anhydride (PMA, 100 mg) and 4- dimethylaminopyridine (DMAP, 2 mg) were dissolved in 
DMSO (0.5 mL) and purged with N2 for 5 min. Histamine (66.65 mg, 0.7 mmol) and 0.3 mmol of another 
amino monomer (allylamine or NH2-OE3-OH) were dissolved in 0.1 mL of DMSO and purged with N2. The 
solution was then mixed with the PMA and DMAP solution and stirred overnight at room temperature. The 
resulting solution was then diluted with water and purified by dialysis against 10 mm NaOH, followed by 
4-5 times buffer exchange with DI water. Solid products were obtained after lyophilization.  
Characterization of PIMA: 1H NMR (D2O, δ, ppm, 500 MHz): 7.50-8.5 (Ph, IM, br), 6.8-7.2 (Ph, IM, br), 





Characterization of PIMAH: 1H NMR (D2O, δ, ppm, 500 MHz): 7.50-8.5 (Ph, IM, br), 6.8-7.2 (Ph, IM, br), 
6.8-7.2 (NHCO, br), 3.3-3.7 (OEG, br),  2.0-3.7 (-CH2CH2, >CH-C=O, br). 
Characterization of PIMCOOH: 1H NMR (D2O, δ, ppm, 500 MHz): 7.50-8.5 (Ph, IM, br), 6.8-7.2 (Ph, IM, 
br), 6.8-7.2 (NHCO, br), 2.0-3.7 (-CH2CH2, >CH-C=O, br). 
Synthesis of Polymer 7.  116.67 mg PAA(MW 1800 g/mol, 1.62 mmol COOH), 910.17 mg HBTU (2.4 
mmol), 356.98 mg HOBt (2.31 mmol) was dissolved in 5 mL DMF for 5 minutes. Then 846 µL DIPEA 
(4.8 mmol, 620.35 mg) was added to activate the acid for 10 minutes followed by addition of S-trityl-
protected cysteamine  (181.8 mg, 0.57 mmol) and 120 µL Dimethylethylenediamine (97 mg, 1.1 mmol). 
The mixture was stirred for overnight at room temperature. Then the mixture was precipitated in 250 mL 
10 mM NaOH solution to remove any excess HBTU, HOBt, DIPEA and DMDA. The precipitate was then 
collected by centrifugation and re-dissolved in acetone. The acetone was then dried by anhydrous Na2SO4, 
filtered and dried under vacuum. The viscous oil was then washed with ether to remove any possible 
residual solvent to get yellow plastic powder product polymer 1. (Yield: 40%) 1H NMR (d6-DMSO, δ, ppm, 
500 MHz): 7.1-7.4 (Ar-H, br), 3.25-3.6 (br), 2.84 (-S-CH2, br), 2.75 and 2.4 (-CH2-N<, m),   2.0-2.4 (CH3, 
br). 
Synthesis of Polymer 8. 100 mg (0.7 mmol) of polymer 1 was treated with 129 mg (1.05 mmol) of 1,3-
propanesultone in dry propylene carbonate (1.5 mL) at room temperature under continuous stirring for 24 
h and then another 24  h at 80 oC. The reaction mixture was then precipitated in 40 mL ether to obtain white 
powder. The powder product polymer 2 was then rinsed with ether and dried under vacuum. (Yield: 70%).  
1H NMR (D2O, δ, ppm, 500 MHz): 6.5-7.51 (Ar-H, br), 3.25-3.75 (br), 3.0-3.2 (br), 2.4-3.0 (br), 1.8-2.3 
(br). 
Synthesis of poly(thiol-b-sulfobetaine)amide (PSSB). 10 mg polymer 2 (11 µmol SH) and 3.2 mg TCEP 
(11 µmol) was treated with 1 mL TFA/Phenol/TIPS (38:2:1, v/v/v) under N2 for 5 h. The reaction mixture 
was then precipitated in 10 mL ether. The solid product PSSB was collected by centrifugation at 7, 000 g/5 
min and directly used for coating without purification. 
Preparation of PSSB coated QDs. Purified QDs in hexane was first phase transferred into N-
methylformamide (NMF) with addition of tetramethylammonium hydroxide (100 equivalents of surface 
atoms of QDs). PTSB dissolved in 0.5 mL NMF was mixed with 0.4 mL OH- QDs (Emission at 600 nm) 
(1 µM) (Molar ratio of thiol to surface atom of QDs is 5: 1) and purged with N2 for 2 min. The reaction was 
allowed to stir at 110 oC for 4 h and then diluted with 4 mL 50 mM sodium borate buffer (pH 8.5). To 





borate buffer ( pH 8.5) and then purified by ultrafiltration for five times against 50 mM sodium borate 
buffer (pH 8.5) with Amicon Ultra 50 kDa MWCO. 
Polymer Coating Methods: CdSe/CdxZn1-xS QDs in the crude reaction mixture were purified and the 
solution was centrifuged to remove possible aggregates. The general procedures for six different phase 
transfer methods used in this work are described as follows.  
Method 1 (hydrophobic ligand surface): Hexane was removed from a dispersion of QD605 by evaporation 
and the nanocrystals were redispersed in CHCl3. Multidentate ligands PIM or PSH (5 equiv of binding 
group per QD surface atom) dissolved in CHCl3 were added under N2 atmosphere. The reaction was allowed 
to proceed for 10 min at room temperature. Methanol was then added and the reaction was continued for 
20 min under N2 atmosphere. QDs were collected by precipitation with hexane. The nanocrystals were 
purified by dialysis (MWCO = 50 kDa) to remove residual organic solvent and excess polymers, 
concentrated by centrifugal filtration (MWCO = 50 kDa), and stored in sodium borate buffer (50 mM, pH 
8.5) at room temperature. 
Method 2 (S2- surface): An aqueous solution of (NH4)2S (40%) was added to a biphasic mixture of NMF 
and hexane containing QD605. The mixture was stirred vigorously until complete phase transfer to the 
NMR phase. Hexane was removed and the NMF layer containing the QDs was washed with hexane twice, 
followed by precipitation with ethyl acetate and centrifuged to collect the QDs. The QDs were resuspended 
in NMF. A solution of PIM or PSH in NMF was added dropwise into the solution under stirring and N2 
atmosphere. The reaction was allowed to proceed at room temperature for 24 h. The nanocrystals were 
purified and stored in the same way as Method 1. 
Method 3 (Zn2+ surface): QDs with a S2- surface in NMF from Method 2 were mixed with a solution of 
Zn(Ac)2 in formamide and stirred for 5 min. The QDs were collected by precipitation from toluene and 
redispersed in NMF. A solution of PIM or PSH in NMF was added dropwise into the QD-NMF solution 
while stirring. The solution was bubbled with N2 for 5 min and the reaction was allowed to proceed at room 
temperature for 24 h. The nanocrystals were purified and stored in the same way as Method 1.  
Method 4 (thioglycerol surface): Hexane was removed from a dispersion of QD605 by evaporation. 
Pyridine was added in a N2 atmosphere and the solution was stirred at 80oC for 2 h. Then thioglycerol was 
added and stirred at 80oC for an additional 2 h. Triethylamine was added after the solution was cooled to 
room temperature and stirred for 30 min. The QDs were precipitated by slow addition into a acetone/hexane 
mixture and collected by centrifugation. The obtained QDs were homogeneously dispersed in DMSO. A 





reaction was then heated to 80oC under N2 for 1.5 h. The nanocrystals were purified and stored in the same 
way as Method 1. 
Method 5 (mPEG-SH surface): A hexane dispersion of QDs was diluted with CHCl3, and a solution of 
mPEG-SH in CHCl3 (5000 per QD) was added and stirred for 3 h at room temperature. The solvent was 
evaporated and the QDs were dispersed in methanol and bubbled with N2 for 3 min. A methanol solution 
of tetramethylammonium hydroxide (TMAH, 25 wt%) was added with mPEG-SH in the same molar 
quantity. The reaction was allowed to proceed for 2 h at 60oC under N2 atmosphere. The QDs were collected 
by precipitation and redispersed in DMF. PIM or PSH was added dropwise into the QDs solution with 
stirring and in a N2 atmosphere. The reaction was allowed to proceed at room temperature for 24 h. The 
nanocrystals were purified and stored in the same way as Method 1. 
Method 6 (OH- surface): A methanol solution of TMAH (25%) was added to biphasic mixture of NMF and 
a hexane suspension of QD605. The suspension was stirred vigorously for 1 h until the QDs were 
completely transferred to the NMF phase. Hexane was removed and the NMF solution was washed with 
hexane twice. Residual hexane and methanol were evaporated under vacuum. A solution of PIM or PSH in 
NMF was added dropwise into the solution under stirring and N2 atmosphere. The reaction was allowed to 
proceed at room temperature for 24 h. The nanocrystals were purified and stored in the same way as Method 
1. 
Optimization of Method 6 
Solvent: The QD605 NMF solution obtained in Method 6 (0.2 mL, 10 µM) was diluted with DMSO (0.4 
mL), NMF (0.4 mL) or methanol (0.4 mL). Then PIM (3.8 mg, 5 equiv of surface atoms of QDs) dissolved 
in corresponding solvent (0.2 mL) was added while stirring in a N2 atmosphere. The reaction was stirred at 
70oC for 5 h. The nanocrystals were purified and stored in the same way as Method 1. 
Time:  The QD605 NMF solution obtained in Method 6 (0.2 mL, 10 µM) was diluted with DMSO (0.4 mL). 
Then a DMSO solution of PIM (5 equiv of surface atoms of QDs, 19 mg/mL, 0.2 mL) was added while 
stirring in a N2 atmosphere. The reaction was stirred at 70oC for 1 h, 2 h, or 4 h. The nanocrystals were 
purified and stored in the same way as Method 1. 
Molar Capping Ratio: The QD605 NMF solution obtained in Method 6 (0.2 mL, 10 µM) was diluted with 
DMSO (0.4 mL). Then a DMSO solution of PIM (1equiv, 2 equiv and 5 equiv of surface atoms of QDs) 
was added while stirring in a N2 atmosphere. The reactions were carried at 70oC for 2 h. The nanocrystals 





Temperature: The QD605 NMF solution obtained in Method 6 (0.2 mL, 10 µM) was diluted with DMSO 
(0.4 mL). Then a DMSO solution of PIM (5 equiv of surface atoms of QDs, 19 mg/mL, 0.2 mL) was added 
while stirring in a N2 atmosphere. The solution was stirred at room temperature, 70oC or 110oC 2 h. The 
nanocrystals were purified and stored in the same way as Method 1. 
Synthesis of (QD525)PIM, (QD565)PIM and (QD605)PIM. The synthesis procedures for (QD525)PIM, 
(QD565)PIM and (QD605)PIM were identical except that the number of surface atoms was different 
between the different QDs due to different diameters. NMF solutions (0.2 mL) of hydroxide-coated QDs 
obtained through Method 6 (QD605, 2.0 nmol; QD565, 5.1 nmol; QD525, 8.7 nmol) were diluted with 
DMSO (0.4 mL). Then PIM DMSO solution (5 equiv of surface atoms of QDs, 19 mg/mL, 0.2 mL) was 
added while stirring in a N2 atmosphere. The solution was stirred at 110 oC for 2 h. The QDs were further 
purified by dialysis to remove organic solvents and unreacted polymer and concentrated by centrifugal 
filtration. For QD605 and QD565, the MWCO of dialysis bag and centrifugal filter was 50 kDa. For QD525 
the MWCO was 30 kDa. The obtained QDs were stored in sodium borate buffer (50 mM) for use and 
characterization. The procedures were identical when using the PIM-N3, PSH, PTM polymer. 
Synthesis of (QD600)PIMAH, (QD600)PIMCOOH, (QD600)PIMA. The synthesis procedures for 
(QD600)PIMAH, (QD600)PIMCOOH, (QD600)PIMA were similar as (QD605)PIM except that the 
diluting solvent was NMF as these polymers did not have a good solubility in DMSO.  
Synthesis of Monodisperse and Polydisperse QDs. QD cores with 720-nm emission were chosen for this 
sample so that we could achieve the highest signal-to-noise ratio in single-molecule imaging experiments 
for hydrodynamic size analysis with maximum accuracy, and were synthesized according to our previous 
publication.7b The monodisperse and polydisperse samples were prepared using identical cores and identical 
procedures except using different molar capping ratios and coating temperatures during polymer attachment. 
For both, NMF dispersions (0.255 mL) of hydroxide-capped QDs (1 nmol) obtained through Method 6 
were diluted with DMSO (0.75 mL). For monodisperse samples, a DMSO solution of PIM (12 mg/mL, 33 
µL) was added at a molar capping ratio of 1.5 while stirring under a nitrogen atmosphere. The solution was 
stirred at 110°C for 2 h. For polydisperse samples, the molar capping ratio was 0.5 and the temperature was 
70°C. All other conditions were identical and the QDs were purified and concentrated using the same 
procedure described in Method 1 above.  
Evaluation of Nonspecific Binding to Live Cells. HeLa cells (ATCC #CCL2) were cultured in Eagles’ 
Minimum Essential Medium (EMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(P/S) at 37°C with 5% CO2. Cells were seeded at a 5 × 104 cell/well density on 8 well-labtek chamber and 





5 min to minimize endocytosis, and then incubated with 40 nM QDs in DPBS for 30 min at 4 oc. The cells 
were washed four times with DPBS to remove unbound QDs and the nuclei were stained with Hoechst 
33258 dye (5 µg/mL, Thermo Scientific). Cells then were rinsed by DPBS for three times and imaged in 
HBSS with 2% FBS using a Zeiss Axio Observer Z1 inverted microscope (Zeiss) with an EC Plan-Neofluar 
20 × 0.50 N.A. air microscope objective. Hoechst signal was imaged using 100 W halogen lamp excitation 
with a 365 nm excitation filter and 445/50 nm emission filter; QDs were imaged using a 488 nm laser 
excitation and 600/37 nm bandpass emission filter. Images from the control and QD samples were collected 
using the same imaging conditions.  
Evaluation of Nonspecific Binding to Fixed Cells. HeLa cells (ATCC #CCL2) were cultured in Eagles’ 
Minimum Essential Medium (EMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(P/S) at 37°C with 5% CO2. Cells were seeded at a 5 × 104 cell/well density on 12-mm circular coverglass 
(Catalog No. 633029, Carolina) in 24 well plates and cultured for 24 h. The cells were washed three times 
with PBS before fixation with freshly prepared 4% paraformaldehyde (PFA, catalog no. RT 15714, Electron 
Microscopy Sciences, Hatfield, PA) for 20 min at room temperature. The cells were washed with PBS three 
times and permeabilized with 0.1 % Triton X-100 (catalog no. T8787, Sigma-Aldrich, St. Louis, MO) in 
PBS for 20 min. The cells were washed with PBS three times and blocked with 1 wt % bovine serum 
albumin (BSA) for 1 h. The cells were washed with PBS three times, and 40 nM dispersions of (QD)PIM 
or (QD)PIM-COOH in 1 wt % BSA solution were added to the wells and incubated for 1 h at room 
temperature. Control experiments were carried out by incubating cells without QDs. The cells were washed 
three times with PBS to remove unbound QDs and the nuclei were stained with Hoechst 33258 dye (2 
µg/mL). The coverglass with cells was then mounted with 90% glycerol in PBS on a glass slide and sealed 
with nail polish. The cells were imaged immediately on a Zeiss Axio Observer. Z1 inverted microscope 
(Zeiss,) with an EC Plan-Neofluar 20×/0.50 NA air microscope objective and 100 W halogen lamp 
excitation. Hoechst signal was imaged using a 365 nm excitation filter and 445/50 nm emission filter; QDs 
were imaged using a 488 nm laser excitation and 600/37 bandpass emission filter. Images from the control 
and QD samples were collected using the same imaging conditions.  
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CHAPTER 3: EFFICIENT BIOCONJUGATION OF MULTIDENTATE 
POLYMER-COATED QUANTUM DOTS THROUGH CLICK 
CHEMISTRY AND HIS-TAG SELF-ASSEMBLY 
 
3.1 Background and Motivation 
In Chapter 3, we prepared a series of monodisperse, compact and stable multidentate polymer coated 
QDs. However, for use as molecular and cellular imaging agents, QDs must be linked with functional 
biomolecules such nucleic acids, peptides, aptamers, and antibodies that allow binding to specific targets. 
Ideally, conjugation methods should be efficient, minimally alter QD optical properties, yield stable 
products, and retain the activity or binding affinity of the conjugated targeting agent. A wide variety of 
chemical reactions have been used to achieve this goal including amide-generating reactions, maleimide-
thiol reactions, “click” chemistry,, and noncovalent self-assembly. However, efficient bioconjugation 
methods with controllable reactions and minimal purification steps still remain an urgent unmet need. 
In this chapter, we demonstrate that these nanocrystals can be functionalized with biological molecules 
using copper-free azide-alkyne click chemistry and self-assembly with molecules containing a His-tag. 
Unlike frequently use amide-generating bioconjugation reactions (e.g., EDC/NHS chemistry), the reaction 
yields for these methods are very high, prevent protein cross-linking, and do not require extensive 
purification[1-6]. We demonstrate that the QDs can be used for a broad range of biomolecular detection 
and imaging applications, as DNA conjugates retain their molecular affinity toward hybridization with 
complementary DNA sequences, antibody conjugates specifically stain cellular antigens, and conjugates to 
small antibody fragments specifically bind to tagged motor proteins to allow precise measurements of 
single-molecule motion. We expect that these results will enable the broad adoption of multidentate 
polymer ligands for quantum dot coating and enhance the utility of QDs for applications requiring highly 






Scheme 3-1. (a) Schematic illustration of phase transfer and ligand exchange processes through different 
tested methods. Schematic illustration of optimized bioconjugation methods using His-tag based self-
assembly (b) and copper-free click chemistry (c). (d) Table of click chemistry with different reaction rates.  
 
3.2 Results and Discussion 
3.2.1 Synthesis and Characterization of Azide Functionalized QDs and Methyltetrazine 
Functionalized QDs 
In contrast to traditional conjugation chemistry such as EDC/NHS, copper-free click chemistry has 
many advantages in bioconjugation such as high reaction yield, mild reaction conditions, controllable 
reaction rate, and high reaction specificity to the functional groups. By incorporating clickable groups such 
as azide or methyltetrazine (MeTz) groups in ligands, I was able to functionalize QDs with different 
biomolecules such as nucleic acids and antibodies through copper free click chemistry. In Chapter 3, we 
showed that high temperature (110 ℃) is critical for achieving homogeneous multidentate polymer coated 
QDs. Unlike azide group, MeTz group is not thermally stable at 110 ℃[7]. As a result, instead of 
functionalizing QDs with MeTz directly using the MeTz modified polymer coating, I prepared amino-QDs 






Scheme 3-2. Preparation of functional multidentate polymer ligands and polymer coated QDs. (a) Synthetic 
routes for PIM-N3 and PIM-NH2; (b) Ligand exchange with PIM-NH2 and PIM-N3. Modification of PIM-
N3 coated QDs with Tris through strain-promoted alkyne-azide cycloaddition. Preparation of MeTz 
functionalized QDs by reacting MeTz-sulfo-NHS ester with amino QDs.  
 
3.2.2 Post-Modification of PNAS to Afford Azido Polymers and Amino Polymers 
PIM-N3 and PIM-NH2 were synthesized through post-modification of PNAS as shown in Scheme 3-
2a. PNAS with narrow size distribution (Mn=13.1 kDa, PDI=1.03) was synthesized as described in Chapter 
3. PIM-N3 was obtained by reacting compounds 1, 2, 3 together with PNAS. The mole fraction of compound 
1 is designed to be 35%. By varying the ratio of compound 2 to 3, reactive azido percentage in PIM-N3 was 





intensity of azide peak at 2100 cm-1 in FT-IR spectra as shown in Figure 3-2a.  For preparation of PIM-
NH2, azido compound 3 was replaced by compound 4 in the synthesis. PIM containing 10% mole fraction 
of compound 4 was synthesized in a similar manner as PIM-N3. After deprotection of Boc groups by TFA 
in water, PIM-NH2 was successfully synthesized as demonstrated by the disappearance of the Boc proton 
peak at 1.37 ppm (Figure 3-1).   
 
Figure 3-1. 1H NMR spectra of compound 4, PNAS, PIM-NH-Boc and PIM-NH2 in DMSO-d6. 
. 
3.2.3 Preparation and Characterization of Azide Functionalized QDs and Methyltetrazine 
Functionalized QDs 
In Chapter 3, I optimized the coating condition for PIM polymer on QDs. With the optimal coating 





able to prepare functionalized QDs with azide groups or primary amines upon water solubilization using 
PIM-N3 or PIM-NH2 polymers. GPC results in Figure 3-2 demonstrated that coating QD565 with these 
polymers still resulted in small and monodisperse particles. Although PIM-N3-3 coated QDs were stable in 
water, unlike PIM-N3-1 or PIM-N3-2, d PIM-N3-3 coated QDs cannot elute from the column during GPC 
measurement. This is probably because agarose beads in the column can interact with PIM-N3-3 coated 
QDs due to its relative high hydrophobicity. To avoid this issue, he azide groups on QDs were modified to 
more hydrophilic moieties using a large excess of DBCO-TEG5-TRIS. As shown in Figure 3-2b, this new 
PIM-N3-3-TRIS coated QDs has a monodisperse size distribution with hydrodynamic diameter about 15.9 
nm. The increased coating thickness is about 2.3 nm is close to the molecular length of DBCO-TEG5-TRIS, 
indicating the azide percentage did not affect the final size of azido polymer coated QDs.  
To functionalize QDs surfaces with MeTz groups, different molar ratios of MeTz-sulfo-NHS ester to 
QDs (0, 50, 100 , 200) was added to react with amines on PIM-NH2 coated QDs. The successful conjugation 
was confirmed by both GPC and gel electrophoresis. As shown in the gel electrophoresis results in Figure 
3-2c, QDs migrated further in the gel implying the amines were depleted. GPC results revealed that when 
the ratio of MeTz-sulfo-NHS ester to QDs is higher than 50, a shoulder peak gradually appeared indicating 
that the particles began to aggregate. The reason for this might because MeTz is a bulky and hydrophobic 
group, high percentage of MeTz may decrease the solubility of QDs in water and as a result, particles 
became aggregated. Therefore, the ratio 50 of MeTz-sulfo-NHS ester to QDs was selected to prepare 
homogeneous MeTz functionalized QDs for the next bioconjugation steps.  
QDs with different sizes/composition were prepared in this work to tune their emission color for 
different biological applications. As shown in Figure 3-2d, PIM-N3 coated QDs with emission from red to 
near-infrared color have a relatively homogeneous size distribution by GPC. Near-infrared (NIR) emission 
has significant benefits in bioimaging due to the greater tissue penetration and lower autofluorescence 
background.  
 
3.2.4 Bioorthogonal Click Chemistry and His-Tag-Based Self-assembly for Efficient 
Bioconjugation  
With the robust and compact nature of click functional QDs established in section 2.1, I turned my 
attention to conjugate QDs to different biomolecules for targeting and sensing applications. Compact QDs 
are similar in hydrodynamic size to many of the biological molecules to which they are conjugated, such 
as globular proteins. Because simple purification methodologies are usually based on size, it is critical that 





not be efficient. I developed two high-efficiency methodologies for our optimized compact particles, using 
click chemistry and His-tag-based self-assembly.  
 
Figure 3-2. Characterization of PIM-N3 polymers and multidentate polymers coated QD565. (a) FT-IR 
spectra of PIM, PIM-NH2, PIM-N3-1, PIM-N3-2 and PIM-N3-3. (b) GPC curves of PIM-N3-1 coated QD565, 
PIM-N3-2 coated QD565, and PIM-N3-3-TRIS coated QD565. (c) GPC curves of PIM-NH2 coated QD565 
at different molar ratio of MeTz-sulfo-NHS ester to QD. Inset image: gel electrophoresis validation for 
different MeTz-sulfo-NHS ester: QD reaction ratios (0, 50, 100, 200). Black arrow indicates the well 
position. (d) GPC curves of PIM-N3 coated QDs with different emission and core sizes.  
  
3.2.4.1 Click Conjugation to Nucleic Acids and Functionality Assays 
A highly promising translational application is the use of QD conjugates of DNA for visualization and 
quantification of nucleic acid sequences in pathological tissue specimens through fluorescence in situ 
hybridization (FISH). However, FISH with QD-DNA probes has been limited due to the relative large size, 
multivalency, and nonspecific binding of commercially available QDs. Here we demonstrated that 
attachment of DNA to these compact QDs still maintain the hybridization capability of DNA with targeted 





Gel electrophoresis is separation technique based on size and charge. It has been widely used for 
characterization and isolation of QD-DNA conjugates since binding of DNA to QDs typically increases the 
charge density per nanocrystal; as a result, a significant shift in electrophoretic mobility is observed as 
shown in Figure 3-3a. By reducing the agarose percentage in a gel, I was able to obtain a higher separation 
resolution between monovalent QD-DNA and divalent QD-DNA, presumably due to the minimized size 
sieving effect. However, the downside of low- percentage agarose is that the gel becomes either too fragile 
to handle or it does not form a gel. In this study, I found that 0.33% agarose was optimal.  
 
Figure 3-3. Conjugation of QDs to DNA through click chemistry with different reaction rates. (a) Gel 
electrophoresis results of QD reacted with different DNA: QD ratio (0, 1, 4, 9). The same samples were run 
in gels with different agarose percentage (0.33%, 0.5%, 1%). Gel electrophoresis results of QD mixed with 
different DNA:QD ratios (0, 0.24, 0.4, 0.6, 1.0, 1.6, 2.5, 4.0, 6.6). (b) Tetrazine-norbornene cycloaddition. 
DNA length is 90 bases. (c) Strain-promoted alkyene-azide cycloaddition. DNA length is 60 bases. (d) 
Tetrazine-trans cyclooctene cycloaddition. DNA length is 90 bases. The reaction was conducted at room 
temperature for 24 or 48 h.  
 
Bioorthogonal reactions with a variety of reaction rates from 0.091 M-1 s-1 to 3 × 106 M-1 s-1 were 
employed to graft DNA to QDs. As shown in Figure 3-3a, DNA oligomers terminated with norbornene 
mixed with QDs increased the migration distance of QDs, consistent with an increase in charge. After 48 h 
reaction under ambient conditions, a 1: 1 DNA : QD mixture was 15% complete, measured by depletion of 
the unconjugated QD band. With increasing reaction rate, depletion of the unconjugated QDs increased to 





functionalized DNA to QD-MeTz, discrete bands were observed indicative of varying stoichiometric 
valencies. As shown in Figure 3-3d, monovalent bioconjugates can be distinguished from divalent ones in 
gel electrophoretic analysis.  
Monofunctional QD-DNA conjugates provide more accurate and precise analytical results in 
quantitative molecular imaging compared with multivalent conjugates which bind with unknown number 
of target molecules. Due to the presence of multiple chemically reactive groups on the QDs surface, the 
population of resulting QD-DNA conjugates is typically inhomogeneous. In theory, reducing the number 
of functional groups may be beneficial to minimize the formation of multivalent conjugates. Therefore, we 
were curious if the yield of monofunctional QD-DNA over polyvalent conjugates can be tailored by varying 
the functional groups numbers. As shown in Figure 3-4, QDs coated with different azide numbers were 
mixed with same amount of oligonucleotides terminated with DBCO. With the increase number of 
functional groups, the unconjugated QDs depletion increased from 66.7% to 80.5%. At same time, the 
monoconjugates decreased for QDs with highest number of aizde groups. However, no significant 
difference between gel results of QD-DNA conjugates for PIM-N3-1 and PIM-N3-2 coatings. To maximize 
the yield of monoconjugates, it may be necessary to further decrease the functional groups numbers in the 
future. 
 
Figure 3-4. Gel electrophoresis results for QD-DNA conjugations with a 6 : 1 molar ration ratio of DNA 
to QD after 24 h incubation time using QDs coated by PIM-N3 with varying azide numbers. DNA length is 
90 bases.  
 
To verify the biofunctionality of the attached DNA, QD-DNA conjugates prepared through reaction b 
were mixed with a complementary DNA sequence, which bound to the DNA-conjugated QD but not the 





had nonspecific adsorption onto QDs validated by absence of gel shift when QDs were mixed with either 
of them. However, when complementary DNA was added to QD-DNA conjugates, QDs migrated further 
in the gel. In the meantime, no mobility shift of QD-DNA band was observed in the presence of scrambled 
DNA. Taken together, it is concluded that the conjugated DNA can selectively hybridize with 
complementary targeted oligonucleotides.  
  
Figure 3-5. DNA sequences and gel electrophoresis validation of DNA hybridization. (a) Sequences of the 
DNA backbone with a 5’ DBCO functionalization, the complementary DNA sequences and the scrambled 
DNA sequences. The schematics show the hybridization of complementary DNA with DNA on QDs. (b) 
Gel electrophoresis results for QD-DNA (conjugations with a 1: 1 or 6: 1 molar ratio) hybridized with 






3.2.4.2 Click Conjugation to Proteins for Specific Labeling 
We also conjugated azide-functional QDs to proteins such as streptavidin (SAv) or antibodies modified 
with DBCO using DBCO-NHS ester. As shown in Figure 3-6a, DBCO-SAv specifically conjugated to the 
QDs based on gel electrophoresis shifts and a 24 h reaction. 
 
Figure 3-6. Conjugation of QDs to proteins through click chemistry is efficient and yields bio-functional 
conjugates. (a) Schematic illustration of QD-streptavidin (SAv) conjugation reactions through copper-free 
click chemistry and reactions with biotin-DNA. (b) Gel electrophoresis result for SAv-QD reactions using 
different molar reaction ratios between DBCO-SAv and QD-azide, including a control using SAv without 
DBCO modification. The reaction was conducted at 4°C for 24 h. (c) Gel electrophoresis results for QD-
SAv-Biotin-DNA conjugations using different molar reaction ratios of biotin-DNA to SAv-QDs, including 
controls using QDs without SAv conjugation. The reaction was conducted at 4°C for 2 h. Black arrows 
indicates the well positions. (d) Schematic illustration of QD-EGFR Ab conjugation and gel electrophoresis 
validation for different DBCO-Ab:QD reaction ratios (0 0.63, and 2.5). Black arrow indicates the well 
position. Specific labeling of EGFR on A431 cells by QD-EGFR Ab conjugates is shown by 100× 
fluorescence images of fixed and permeabilized A431 cells treated with (e) QD conjugated to a control IgG 
or (f) QDs conjugated to an antibody against EGFR. Scale bar: 10 µm. Blue color is Hoechst nuclear stain 






With an equimolar or slight excess of SAv, the reaction was efficient based on the disappearance of the 
unconjugated QD gel band (Figure 3-6b). SAv-QD conjugates retained functional binding to biotin, as 
assessed by mixing with biotin-terminated DNA which yielded a gel shift relative to SAv-QDs (Figure 3-
6c). The two gel bands that appear at higher biotin-DNA : QD ratios (>1.6) may derive from QDs bound to 
1 or 2 SAv proteins within the distribution, however additional analysis is needed to validate this. 
Nevertheless, it can be deduced that biotin conjugation to SAv-QDs is efficient based on depletion of the 
SAv-QD band and the absence of additional gel shifts for biotin-DNA reactions with a DNA : QD ratio 
higher than 4:1 (SAv is a tetramer capable of binding up to 4 biotins but likely cannot be fully saturated in 
this experiment due to steric and/or electrostatic repulsion). These findings of high reaction efficiencies are 
important for the wide use of compact QDs, as separation of QD-protein conjugates from unreacted proteins 
is highly inefficient and low-throughput using processes involving chromatography, electrophoresis, and 
centrifugation.  
QD-antibody conjugates hold great potential in multiplexed profiling of molecular biomarkers to 
facilitate clinical diagnosis of tumor samples. Epidermal growth factor receptor (EGFR), as an example, is 
overexpressed in cancer cells. Detection of EGFR can be used in clinic for diagnosis of breast cancer or 
other cancer types that are associated with elevated EGFR. Using click chemistry, we conjugated (QD)PIM-
N3 to DBCO modified EGFR. The conjugate was characterized by gel electrophoresis. As shown in Figure 
3-6d, adding more antibodies to the QDs causes the QDs to migrate less in the gel, suggesting successful 
conjugation. The QDs were added to A431 cells expressing human EGFR, and bound selectively to the 
membrane region, unlike QDs conjugated to an isotype control antibody (see Figure 3-6e, f).  
 
3.2.4.3 Click Conjugation to Dextran for Imaging Macrophages  
Macrophages are a type of leukocyte belonging to the mononuclear phagocytic system. Macrophages are 
recruited to inflamed tissue sites and differentiate into specific phenotypes which enhance or attenuate 
inflammation or immune response. Chronic inflammation can cause a constant infiltration of macrophages. 
In the long term, low levels of inflammatory mediators such as chemokines and cytokines released by these 
cells are detrimental to the host leading to a series of non-infectious chronic inflammatory diseases such as 
atherosclerosis, obesity induced insulin resistance, cancer, asthma, and rheumatoid arthritis[8, 9]. As a 
result, the ability to image macrophage cells could be potentially valuable for diagnosis and prognosis  in 
many human diseases[9, 10]. 
Nanoparticles have become a favorite strategy to labeling macrophages in view of their naturally high 





efficiently and selectively by macrophage cells due to their expression of a series of dextran-binding 
receptors such as C -type lectins and scavenger receptors [11-15]. Thus, dextran functionalized QDs are 
desirable candidates to image macrophages and study how macrophages interact with their 
microenvironment using fluorescence microscopy. 
 
Figure 3-7. Click conjugation to dextran for imaging macrophages. (a) Schematic illustraton of grafting 
dextran to PIM-N3 coated QDs. (b) Gel electrophoresis result of QD-N3 with addition of DBCO-dextran at 
different molar ratios (0, 1, 10, 100) or dextran alone (100). Black arrows indicate the well positions. (c) 
GPC curves of QD-N3 before and after dextran conjuation. (d) Fluorescence microscopy image of pro-
inflammatory macrophages after treated with QD-dextran for 4 hours at 37℃. Blue color is Hoechst nuclear 
stain and red color is QD emission.  
 
To decorate QDs with dextran, we first synthesized amino-dextran (see Chapter 6 for more details on 
synthesis) and then convert the amines to DBCO groups by reacting with an excess of DBCO-TEG5-NHS 
ester. To avoid cross-linking of DBCO-dextran to multivalent QDs, the amino number per dextran was 
designed to be about 1, which was assessed by a fluorescamine assay. Figure 3-7a depicts the synthesis of 
QD-Dextran conjugate through copper free click chemistry and the successful conjugation was 
characterized by gel electrophoresis and GPC (Figure 3-7c and 3-7d). As shown in Figure 3-7c, after 
conjugation, dextran modified QDs still retain size homogeneity without aggregates by GPC. A cellular 





confirmed by fluorescence microscopy (Figure 3-7d).  Future studies will be focused on engineering 
dextran-QDs with a series of sizes to study size effect on the uptake efficacy of macrophages with different 
phenotypes. 
3.2.4.4 His-tag Self-Assemble for Efficient Protein Conjugation 
Pre-modification of proteins is a prerequisite for click conjugation to QDs. This covalent conjugation may 
potentially alter the integrity of antibody function. Another approach to attach proteins to QDs is through 
His-tag self-assembly. Taking advantage of the thin polymer coating, QDs capped with PIM can efficiently 
self-assemble with proteins expressed as fusions to a His-tag, similarly to previous reports using QDs coated 
with small ligands[16]. I conjugated QDs to proteins (Protein A) using this mechanism as shown in Figure 
3-8a. Protein binding decreased the gel mobility of QDs with multiple protein conjugate bands observed, 
and the unconjugated QDs were largely depleted at a protein : QD ratio of 4:1. Specificity for attachment 
through the His-tag was verified by control experiments in which Protein A was not labelled with a His-
tag, showing no change in gel mobility of the QDs. To verify that they retained their function such that they 
could be used for imaging applications, I conjugated PIM-coated QDs to a His-tagged protein called a 
nanobody, which is a small variant of an antibody (Figure 3-8b). The nanobody was specific for green 
fluorescent protein (GFP)[17]. The QD-nanobody was mixed with a GFP-kinesin fusion protein, and we 
applied a well-established single-molecule kinesin motility assay to evaluate whether these QD tags are 
effective probes for enzymatic single-molecule analysis. As shown in Figure 3-8c, individual conjugates 
were readily seen through fluorescence imaging. Kinesin mobility analysis showed about 15 mobile QDs 
per movie for QD-nanobody conjugates compared to zero mobile QDs for samples not conjugated to 
nanobodies (Figure 3-8d). We compared these results for self-assembled QD-nanobody conjugates with 
an assay that was identical, except we used QDs-nanobody conjugates prepared through covalent linkage 
through a PEG spacer, and the results were statistically indistinguishable (Figure 3-8d). These results 
demonstrate that PIM QD probes allow nanobodies bound through His-tags to retain their affinity and do 
not damage the enzymatic function of kinesin, despite possibly being slightly buried in the OEG shell due 
to the very short linker between the nanobody and QD. Due to the very high photostability and brightness 
of these probes under high-power laser excitation, we were able to analyze the step size of the kinesin motor 
protein with nanometer-accuracy and 100 ms time resolution (Figure 3-8e). Statistical analysis showed an 
average step size of 8.9 nm, which is in excellent agreement with the predicted 8.3 nm per step for kinesin 
labelled at its center of mass position[18]. These very compact and functional conjugates (~12 nm diameter) 








Figure 3-8. PIM-coated QDs conjugate through His-tag linkers, retain protein function, and can be used 
for single-molecule imaging of motor proteins. (a) Left: schematic illustration of self-assembly between 
PIM-coated QDs and His-tagged Protein A. Right: gel electrophoresis analysis of QDs mixed with His-
tagged Protein A or Protein A without a His-tag at different Protein:QD ratios (0, 0.5, 1, 2, 4). (b) Schematic 
illustration of self-assembly between PIM-coated QDs and His-tagged nanobodies that can be used to label 
GFP-kinesin proteins. Inset image shows gel shift for the indicated nanobody:QD ratios (0, 1, 4). Black 
arrow indicates the well position. (c) Single-molecule fluorescence image from a movie of QD-nanobody-
labeled kinesin. Kinesin (K560-GFP) was labeled with the QD-nanobody and imaged while walking in the 
presence of 800 nM ATP. Dim fluorescent lines are Hilyte488-labeled microtubules (scale bar: 8 µm). The 
inset figure is a time lapsed projection of fluorescent spots over 300 frames (scale bar: 0.5 µm). (d) 
Quantitative analysis of mobile spots per movie using different samples. Error bar indicates standard error 
(N = 5 for QD-nanobody conjugate; N = 3 for control QD) (e) Example data of a single QD-nanobody-
labeled kinesin position analysis with nanometer accuracy. QD position was measured with 100 ms time 
resolution and individual traces were fit by a step-finding algorithm. The numbers below the curve are step 
sizes that the step finding algorithm detected based the position over time trace. A histogram of step sizes 
was compiled from 474 steps and 19 traces and fit to a double Gaussian function (center and 2 × center), 
showing a fundamental step size of 8.9 nm, which is in excellent agreement with the predicted 8.3 nm per 
step for a kinesin labeled at its center of mass position. The 2 × center derives from kinesin taking two steps 






3.2.5 Suppression of His-Tag Binding to QDs through Surface Hydroxylation 
Since His-tag is usually engineered in proteins to facilitate the protein purification, the presence of 
His-tags in target molecules can be a problem for QDs labelling as His-tag binding to metal ions of QDs 
can cause a false positive signal. Therefore, it is extremely important to suppress the self-assembly of His-
tag with QDs in these scenarios. Here, we demonstrate that by simply storing hydroxide ions capped QDs 
at -20 ℃ for an extended duration period of time, the interaction between His-tag and resulting polymer 
coated QDs can be significantly suppressed.  
As shown in Figure 3-9a, for PIM-coated QD565 that were prepared freshly using the method 6 
developed in Chapter 3, new discrete gel electrophoresis bands gradually appear with increase of His-tagged 
Protein A (PA). This result is consistent with our study using His-tagged PA to conjugate with QD605. 
However, after 8 months of aging, PIM-coated QD565 that were prepared with these aged hydroxide ions 
capped QDs did not exhibit strong binding to His-tagged PA, inferred from the negligible gel band shift 
observed in gel electrophoresis. The difference between these two QDs in terms of His-tagged self-
assembly was also confirmed by GPC. These two particles had same size distribution and showed no 
specific binding to protein A alone. However, at a ratio 5:1 of His-tagged PA to QD, conjugated QD 
percentage dramatically reduced from 88.2% to 30.4% (Figure 3-9b and c) in the final conjugate products.   
It is not clear how this aging process affected the His-tag binding to QDs. The L-type imidazole ligand 
as an electron donor that preferentially binds to metal ions on the QD surface. All the QDs used in this 
study were passivated by Zn ions using zinc acetate at the last step of nanocrystal synthesis. Thus, the 
outmost layer of the QDs is Zn-rich surface. It is highly possible that the presence of large molar excess of 
hydroxide ions has altered the surface properties of QDs during the storage. Figure 3-9d showed that there 
was no significant changes in both the absorption and fluorescent spectra. Thus, it is unlikely that QDs were 
degraded during the aging process. Given the hard base character of hydroxide ions, zinc ions on the QD 
surface might form a more stable ionic bond with hydroxides over time as proposed in Figure 3-9e. Such 
surface hydroxylation may lead to a decreased number of available zinc ions on the QD surface. As a result, 
the binding strength of a His-tag will be significantly reduced. In the case of freshly prepared hydroxide 
ion capped QDs, this hydroxylation process may not happen quickly and thus, zinc ions are still available 
for His-tag binding. Nevertheless, the exact mechanism for the reduction of binding affinity may be due to 
other reasons such as surface oxidation, which may lead to the formation of a oxide layer on the surface. 
Future XPS characterization of these aged QDs is needed to confirm the presence of hydroxyl groups on 
the surface. To fully understand the mechanism, it is also necessary to study how storage temperature and 






Figure 3-9. Suppression of His-tag binding to QDs through surface hydroxylation. (a) Gel electrophoretic 
analysis of His-tagged PA mixed with PIM coated QDs using freshly prepared OH- capped QDs or eight 
months old OH- capped QDs at different protein to QD ratios (0, 1, 2, 5). Black arrow indicates the well 
position. (b) GPC curves of PIM coated QDs prepared by freshly OH- capped QDs. QDs were mixed with 
pure Protein A alone or His-tagged Protein A at ratio 5 of Proteins to QD. (c) GPC curves of PIM coated 
QDs prepared by eight months old OH- capped QDs. QDs were mixed with pure Protein A alone or His-
tagged Protein A at ratio of 5 proteins per QD. (d) Absorption and fluorescent (FL) spectra of PIM coated 
QDs in sodium borate buffer (pH 8.5). (e) Proposed reactions of QDs with hydroxide ions during storage 
and possible mechanism for reduced His-tag binding to QDs.   
 
3.3 Conclusions 
I demonstrated the utility of copper-free click chemistry and His-tag based self-assembly for efficient 
bioconjugation to DNA and proteins, without the need for inefficient purification, and without altering the 
function of the conjugated biomolecules. Unlike products from amide-generating reactions, the reactions 
are highly controllable and proceed effectively to completion. The products were demonstrated to be 
excellent probes for DNA hybridization, immunofluorescence staining, and single-molecule enzyme 
imaging, which are some of the most important studies being pursued at present with QDs. I anticipate that 
the approach presented here will greatly broaden the use of QD with thin polymeric coatings in a wide 





3.4 Experimental Section 
Synthesis of Tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate. Di-tert-butyl decarbonate (0.98 
g, 4.5 mmol) in 1,4-dioxane (12 ml) was added dropwise over 30 min to 2,2’-(ethylenedioxy)bis(ethylamine) 
(5.0 g, 34 mmol) in 1,4- dioxane (12 ml) at 0 ℃. The reaction mixture was stirred overnight at room 
temperature. Then it was concentrated in vacuo and then was re-dissolved in water (20 ml). The aqueous 
layer was extracted with DCM (20 ml) for three times. The organic layer was combined and washed with 
water (20 ml), then dried with Na2SO4, filtered and concentrated under vacuum. The residue was purified 
by flash column chromatography (DCM : MeOH, 1: 0 to 1:1, v/v) to give the product as a colorless viscous 
oil. 1H NMR (CDCl3, 500 MHz): δ 5.31 – 5.13 (m, 1H), 3.61 (d, J = 1.3 Hz, 4H), 3.57 – 3.47 (m, 4H), 3.31 
(q, J = 5.3 Hz, 2H), 2.88 (td, J = 5.3, 1.3 Hz, 2H), 1.65 (s, 2H), 1.43 (d, J = 1.3 Hz, 9H). 13C NMR (CDCl3, 
500 MHz): δ 156.2, 112.7, 79.4, 73.6, 70.4). 
Synthesis of Poly(histamine-b-TEG-b-azide TEG)amide (PIM-N3) with Different Azido Percentage 
(10%, 20%, 65%).  A typical procedure for preparing PIM-N3 with 20% azido groups is shown as follows. 
In a 7 mL vial equipped a magnetic stir bar, PNAS (84 mg) was dissolved in dry DMF (1.0 mL). Then 2-
[2-(2-azido-ethoxy)-ethoxyl]-ethylamine (Boc-NH-TEG-NH2, 100 µL, 1.0 mM in dry DMF), TEG-NH2 
(225 µL, 1 mM in dry DMF) and histamine (175 µL, 1.0 mM in dry DMF) were added and the solution 
was purged with N2 for 5 min. The solution was stirred for 24 h at room temperature and then diluted 5-
fold with deionized water and loaded into a dialysis bag (MWCO = 2 kDa). The polymer was purified by 
dialysis in deionized water for 6 h and repeated 3 times. A yellow solid product was collected after 
lyophilization. Yield: 62 mg (56%).1H NMR (d6-DMSO, δ, ppm, 500 MHz): 7.45-7.93 (Ph, br), 3.21-3.47 
(CH2, br), 2.80 (CHCH2, br), 1.51-1.93 (CHCH2, m), 1.20(CH3, br). By varying the feeding ratio of Boc-
NH-TEG-NH2 and TEG-NH2, PIM-N3 with 10% and 65% can be obtained in the same procedure.  
Synthesis of poly(histamine-b-TEG-b-Amine TEG)amide (PIM-NH2). In a 7-mL vial equipped a 
magnetic stir bar, PNAS (200 mg) was dissolved in dry DMF (1.0 mL). Then tert-butyl (2-(2-(2-
aminoethoxy)ethoxy)ethyl)carbamate (Boc-NH-TEG-NH2, 32.3 mg, 0.13 mmol), TEG-NH2 (106.7 mg, 
0.72 mmol) and histamine (50.6 mg, 0.45 mmol) in DMF (0.5 ml) were added and the solution was purged 
with N2 for 5 min. The solution was stirred for 24 h at room temperature and then precipitated in diethyl 
ether (45 mL) to obtain PIM-NH-Boc. PIM-NH-Boc was deprotected with TFA (0.5 mL) in DI water (3 
mL) overnight under N2. After neutralization with 4.0 M NaOH to pH = 7.0, the mixture was purified by 
dialysis in DI water and a solid sample was obtained after lyophilization. Yield: 80 mg (45%).1H NMR (d6-





3.82 (-C-CH2-CH2-NH-, br), 2.63 (-C-CH2-CH2-NH-, br), 1.64-2.2 (CHCH2, br), 1.02-1.64 (CHCH2,br), 
1.20(CH3,br). 
Synthesis of Azido or Amino Functionalized Coated QDs. Purified QDs (λem= 565 or 605 nm) in hexane 
were phase transferred into NMF by dropwise addition of TMAH (100 equivalents of QD surface atoms). 
PIM-N3 or PIM-NH2 dissolved in DMSO (11.3 mg/ml, 150 µL) was mixed with hydroxide ion capped QDs 
in NMF (8.41 µM, 237.8 µL) (5: 1 imidazole to QD surface atom) and purged with nitrogen gas for 2 min. 
The mixture was stirred at 110 ℃for 2 hours before precipitation with ether/CHCl3 mixture. A QD pellet 
was collected and dried after centrifugation of the mixture at 7,000 g for 5 min. Excess polymer was then 
removed using centrifugal filtration (Amicon Ultra 50 kDa MWCO) against 50 mM sodium borate buffer 
(pH 8.5) or 10 mM phosphate buffer (pH 7.4). This dilution-filtration cycle was performed four times.  
Synthesis of Methyltetrazine Functionalized Coated QDs. Methyltetrazine-sulfo-NHS ester (Click 
Chemistry Tools, Scottsdale, AZ) in anhydrous DMSO (27.9 mM) was added into a solution of purified 
amino functionalized QDs in 10 mM phosphate buffer (pH 7.4)   with different ratio of NHS ester to QDs 
(0, 50, 100, 200, 400). The solution was incubated for 12 hours at room temperature before dialysis against 
50 mm borate buffer for 24 hours. The methyltetrazine functionalized QDs were characterized by GPC.  
Conjugation of DNA to QDs via Click Chemistry. Dibenzocyclooctyl (DBCO), trans-cycloctene (TCO), 
norbornene terminated oligonucleotide probe (length 90bp) was purchased from a commercial vendor 
(Integrated DNA technology, Coralville, Iowa) with HPLC purified. The sequences were /5’-DBCO-
triethyleneglycol (TEG)/ (T)68 TAG CCA GTG TAT CGC AAT GAC G-3’, 5’-/5TCO-PEGN/(T)68 TAG 
CCA GTG TAT CGC AAT GAC G-3’, 5’-/5NorborN/(T)68 TAG CCA GTG TAT CGC AAT GAC G-3’, 
respectively. Azide functionalized QD565 in 10 mM phosphate buffer (pH 7.4) was reacted with DBCO-
DNA for overnight at room temperature. Methyltetrazine functionalized QD565 in 10 mM phosphate buffer 
(pH 7.4) was reacted with TCO or Norbornene functionalized DNA for overnight at room temperature. 
Conjugation was measured using electrophoresis in 0.33% agarose gel. 
Hybridization of Complementary DNA with QD-DNA. Complementary oligonucleotides (Integrated 
DNA technology, Coralville, Iowa) were used to confirm that DBCO DNA-conjugated QDs retained their 
capacity for hybridization. The sequence used was 5’-CGT CAT TGC GAT ACA CTG GCT AA TTT TTT 
TTT TTT TTT TTT TTT TTT CGT CAT TGC GAT ACA CTG GCT AA-3’. Scramble oligonucleotides 
(Integrated DNA technology, Coralville, Iowa) was used as a negative control. The sequence of scramble 
oligonucleotides was 5’-GGT ATT CAC TGA CTA AGC CGC TA TTT TTT TTT TTT TTT TTT TTT 
TTT GGT ATT CAC TGA CTA AGC CGC TA-3’. Briefly, different ratio of DNA was added to QD-DNA 





8.0, 1 mM EDTA, 100 mM NaCl, 10 mM MgCl2). The reaction was performed at 45 ℃for 1h followed by 
room temperature 1h and 4 ℃ for 3 hours. Conjugation was measured using electrophoresis in 0.33% 
agarose gel.  
Conjugation of Streptavidin to PIM-N3-coated QDs. Streptavidin (Catalog No. 43-4302, Life 
Technologies, Grand Island, NY) was conjugated to azide functionalized QD565 using DBCO-sulfo-NHS 
ester (Catalog No. A124, Click Chemistry Tools, Scottsdale, AZ). Briefly, Streptavidin was reacted with a 
5-fold molar excess of DBCO-sulfo-NHS ester on ice for 2 h. This DBCO-SAv was purified using a 
centrifugal filter (MWCO = 30 kDa) at 4 ℃. To conjugate azide-functionalized QD565 with DBCO-SAv, 
azide functionalized QD565 in 50 mM sodium borate was transferred to PBS using a centrifugal filter 
(MWCO = 50 kDa) and mixed with different ratios of DBCO-SAv at 4 ℃ for 24 h. The reaction was 
quenched by adding a 50-fold molar excess of 2-azidoacetic acid (Catalog No.763470, Sigma-Aldrich, St. 
Louis, MO) on ice for 15 minutes. The conjugation was confirmed using electrophoresis in hybrid 
polyacrylamide-agarose gels (2% polyacrylamide and 0.5% agarose) at 4 ℃. 
Conjugation of Biotin-DNA to SAv-QDs. Biotin-labelled DNA (Integrated DNA technology, Coralville, 
Iowa) was used to confirm streptavidin conjugation to QDs. The sequence used was /5’-Biotin/ (T)68 TAG 
CCA GTG TAT CGC AAT GAC G-3’. Briefly, SAv-QD (1:1 molar ratio of DBCO-Sav: QD) was 
incubated with different ratios of biotin-DNA at 4 ℃ for 2 h. Conjugation was measured using 
electrophoresis in hybrid polyacrylamide-agarose gels (2% polyacrylamide and 0.5% agarose) at 4 ℃. 
Conjugation of Antibodies to PIM-N3-coated QDs. Mouse anti-human EGFR antibody (Catalog No. 
555996, BD Biosciences, San Diego, CA) and mouse IgG Isotype Control (Catalog No. 02-6502, 
ThermoFisher Scientific, Waltham, CA) were conjugated to PIM-N3-coated QDs. Briefly, sodium azide 
was removed from the stock Ab using a 50 kDa MWCO centrifugal filter and then reacted with a 50-fold 
molar excess of DBCO-sulfo-NHS ester on ice for 2 h. Unreacted reagents were removed using a centrifugal 
filter. PIM-N3-coated QD565 in 50 mM sodium borate were transferred to PBS using a centrifugal filter 
and then incubated with different ratios of DBCO-activated antibody at 4 ℃ for 7 h. The reaction was 
quenched by adding a 50-fold molar excess of 2-azidoacetic acid on ice for 15 minutes. Conjugation was 
confirmed using electrophoresis in hybrid polyacrylamide-agarose gels (2% polyacrylamide and 0.5% 
agarose). 
Conjugation of DBCO-Dextran to PIM-N3 coated QDs. Detailed synthesis of amino dextran (10 kDa) is 
described in Chapter 6. DBCO-EG5-NHS ester (2 mg, 2. 88 µmol, Click Chemistry Tools, Scottsdale, AZ) 
in 200 µL was mixed with amino dextran (26.1 mg, 2.61 µmol amines) DMSO solution (300 µL) containing 





with Tris-HCl buffer (1.5 mL, 100 mM). The solution was dialyzed against DI water (MWCO 1 kDa). 
White solid DBCO modified dextran was obtained after lyophilization. DBCO-dextran in water (0.75 mM) 
was then mixed with PIM-N3 coated QDs (100 µL, 0.8 µM) at room temperature for 12 hours. Excess 
dextran polymers were removed by ultrafiltration with Amicon filter (MWCO 50 kDa). Conjugation was 
confirmed using GPC and electrophoresis in hybrid polyacrylamide-agarose gels (2% polyacrylamide and 
0.5% agarose). 
Pro-inflammatory Macrophages Uptake of Dextran Functionalized QDs. RAW 264.7 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS and 1% P/S at 
37 °C with 5% CO2. To induce M1 polarization, cells seeded in 8 well-labtek chamber (5×104 cells/well) 
were grown in the presence of 100 ng/mL LPS (Sigma Aldrich, Product No. L2880) for 24 hr. Then dextran-
QD conjugates (100 nm) in serum free DMEM containing 100 ng/ml LPS was added to the wells and the 
cells were incubated for an additional 4 h. After removal the QDs solution, the cells were washed three 
times with pre-warmed 1XPBS and then stained by Hoechst 33258 (80 µg/ml) for 20 min at 37 oC. Cells 
then were rinsed by 1XPBS for three times and imaged in reduced serum DMEM with 10 mM HEPES 
buffer containing 100 ng/ml LPS using a Zeiss Axio Observer Z1 inverted microscope (Zeiss, Oberkochen, 
Germany) with an EC Plan-Neofluar 20 × 0.50 NA air microscope objective. Hoechst signal was imaged 
using 100 W halogen lamp excitation with a 365 nm excitation filter and 445/50 nm emission filter; QDs 
were imaged using a 488 nm laser excitation and 600/37 nm bandpass emission filter. 
Immunofluorescence Staining using QD-Ab Conjugates. A431 cells (ATCC # CRL-1555) were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% P/S. were seeded 
at a density of 50,000 cells/well in a labtek glass-bottom 8 well chamber (Thermo Scientific, Waltham, MA) 
and incubated at 37°C with 5% CO2 for 20 h.  The cells were then fixed with 4% PFA for 20 minutes, 
permeabilized with 0.1% (v/v) Triton X-100 for 20 minutes, and blocked with 1% BSA for 1 h. The cells 
were then incubated with 10 nM QD565-EGFR antibody conjugate in 1% BSA at temperature for 30 
minutes, and stained with 2 µg/mL of Hoechst for 10 minutes. All treatments were carried out at room 
temperature. The samples were imaged immediately using a 100x 1.45 NA alpha Plab-Fluar oil immersion 
objective on a Zeiss Axio Observer Z1 inverted microscope. Hoechst signal collected as described above; 
QD565 signal was imaged using a 488-nm laser excitation and a 562/40 bandpass emission filter. Images 
from the QD565-IgG control conjugate and QD565-EGFR antibody conjugate samples were collected 
using the same imaging conditions.  
Conjugation of His-Tagged Protein A to QD. To conjugate His-tagged protein to PIM-coated QDs, the 





Inc., Milpitas, CA) or Protein A without a His-tag (Catalog No. 21181, Thermo Scientific, Waltham, MA) 
at room temperature in 10 mM phosphate buffer (pH 7.4) for 2 hours. Conjugation was assessed by gel 
electrophoresis in a hybrid polyacrylamide-agarose gel (2% polyacrylamide and 0.5% agarose) at 4 °C. For 
aging experiments, QD565 was first phase transferred into NMF using tetramethylammonium hydroxide. 
The hydroxide ions capped QDs was then stored at -20 ℃for eight months before use.  
Conjugation of Nanobody to QD. The His-tagged GFP-binding nanobody was a gift provided by Paul 
Selvin’s group. To conjugate His-tag nanobody to PIM-coated QDs, the QDs in borate buffer were 
transferred to PBS, and incubated with different ratios of His-tag nanobody at 4 ℃for 4 h. Conjugation was 
measured using electrophoresis in hybrid polyacrylamide-agarose gels (2% polyacrylamide and 0.5% 
agarose). 
Labeling of Kinesin and Single-Molecule Imaging of Labeled Kinesin. Truncated Kinesin-1 with a 
green fluorescent protein at the c-terminus (K560-GFP) was incubated with QD-nanobodies or 
unconjugated QDs at a 3-fold molar excess of QDs for 20 minutes on ice. An imaging chamber was 
assembled by creating micro-channels roughly 2 mm in width using double sided tapes on cleaned 
microscope slides. A coverslip coated with 5% PEG-Biotin / 95% PEG was firmly mounted to the other 
side of the double-sided tape. 10 μL of 0.5 mg/mL Streptavidin was added to the micro-channels and 
incubated for 5 minutes. Excess streptavidin was rinsed out of the micro-channel. 10 μL of biotinylated 
Hilyte488-labeled microtubule consists of roughly 25 nM tubulins in solution of BRB80-BSA (80 mM 1,4-
piperazinediethanesulfonic acid (PIPES), 1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM MgCl2, and 
8 mg/mL BSA, pH 6.8) containing 20 μM paclitaxel was added to the flow channel and allowed to bind for 
5 minutes. Excess microtubules were rinsed out with BRB80-BSA containing 20 µM paclitaxel. Kinesin-
QD mixture was diluted to nanomolar concentration and added to Imaging Buffer (BRB80-BSA, 1 mM 
tris(3-hydroxypropyl)phosphine (THP), 20 μM paclitaxel, 1U/mL creatine kinase, 2 mM creatine phosphate, 
50nM protocatechuate-3,4-dioxygenas, 1 mg/mL protocatechuic acid) and subsequently flowed into the 
micro-channels containing microtubules, and allowed to incubate without any adenosine triphosphate (ATP) 
for 5 minutes to allow labeled kinesin to bind to the microtubules. Then 800 nM ATP in Imaging Buffer 
was added to the chamber to wash out the unbound kinesin and unlabeled QDs. For experiment involving 
measurement of step sizes, 300 nM of ATP was used instead. The sample was imaged using a custom-built 
objective-type total internal reflection fluorescence (TIRF) microscope. QDs were excited using a 532 nm 
laser. For experiments that involved measuring step sizes, a 605/15 emission filter was added to the setup. 
For motility experiments, movies were collected using an Andor iXon EM-CCD camera with 150 ms 
exposure time and EM gain of 200 for 300 frames. To discern individual step sizes, laser power was 





Data Analysis of Motile Kinesin and Step Size Determination. The number of processive moving bright 
spots in each movie obtained at 800 nM ATP were counted and averaged to yield the number of motile 
kinesin per movie. For step size determination, motile spots in movies recorded at 300 nM ATP were 
cropped, and single-molecule fluorescence images of QDs in each frame of the movie were fit to a 2D 
Gaussian function to determine its center. Since kinesin travels on a single protofilament in one direction, 
the set of x-y coordinate obtained from Gaussian fitting was linearized to reduce its dimensionality. The 
tracked position as function of time is then fit using the SICstepfinder algorithm to determine the step size 
from the recorded traces. The step sizes were collected from all traces, and Gaussian functions were used 
to fit the distribution of the step sizes. 
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CHAPTER 4: COMPACT AND STABLE QUANTUM DOTS COATED BY 
MULTIDENTATE POLYMER FOR IMMUNOFLUORESCENCE 
 
4.1 Background and Motivation 
Quantum dots (QDs) are tiny light-emitting nanocrystals with great potential for use in 
immunofluorescence applications due to significant advantages over conventional molecular fluorophores, 
including size and composition tunable light emission, improved brightness, excellent photo-stability, and 
spectral multiplexing capabilities[1, 2].  An ongoing problem of using QDs for biomedical imaging is the 
relatively large size. Extensive efforts have been made to engineer the surface coating to minimize the QDs 
size. Among of those methods, multidentate and polymeric ligands have been used to prepare nanocrystals 
that are both highly stable and compact[3-9]. In Chapter 2, I introduced a two-step phase transfer and ligand 
exchange process to prepare compact and homogeneous QDs with efficient bioconjugation[10].  
For immunostaining applications, QDs must be linked with antibodies that allow binding to specific 
targets[11]. To date, a plethora of coupling chemistries have been employed to link antibodies with QDs. 
Compared to conventional coupling reactions using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-
hydroxysulfosuccinimide (EDC/NHS) and thiol-maleimide, click chemistries, such as strain promoted 
alkyne-azide cycloaddition and inverse-electron-demand Diels-Alder cycloaddition, have emerged as 
attractive alternatives for efficiently attaching biomacromolecules to QDs. Major advantages are high 
reaction specificity to the functional groups, and the high product yield. However, the multivalency of QDs 
may lead to aggregation of antibodies (Abs) with QDs due to the possible cross-linking reactions.  
In contrast, QDs with molecular adaptors, such as streptavidin and Protein A or G, are amenable to 
conjugation with antibodies through strong affinity through self-assembly. Compared with covalent 
conjugation, molecular adaptors have unique advantages in controlling the Ab orientation with Fab regions 
face outward without the necessity to modify the Ab. Moreover, since Protein A can bind to Fc antibody 
domains from numerous species, QDs modified with Protein A are a nearly universe platform for fast 
preparation of a library of QD-Ab conjugates through self-assembly.  
Another efficient noncovalent self-assembly process is the binding of poly-histidine (His) tags with 
metal ions (zinc ions or cadmium ions) on QDs surfaces, which has shown to have a dissociation constant 
on the order of 1 nM[11-13] The benefits of using direct His-tag self-assembly include fast reaction kinetics, 
high product yield, no need for further purification steps and aggregate-free conjugate products[12]. 
Compared with indirect Ni2+ mediated His-tag assembly binding to chelating groups on surface coating, 





direct His-tag conjugation strategy has not been applied to prepare primary QD-antibody conjugates for 
primary labeling of cellular and tissue antigens [14-16].  
Depending on which coupling method is used, QD-antibody conjugates will have different structures 
and can be classified into four categories: (a) QDs covalently linked to an antibody; (b) His-tagged antibody 
self-assembled to QDs directly; (c) QDs linked to His-tagged molecular adaptor proteins such as Protein 
A/G or Fc Receptor, which can further bind to an antibody to leave the target-specific (F(ab’)2) domains 
facing outward; (d) QDs covalently conjugated to molecular adaptor proteins which bind to the Ab without 
the need for additional Ab modification. Each conjugation method and its corresponding QD-Ab conjugate 
has its own advantages and limitations in terms of protein function and orientation, which in turn determine 
the specific labeling efficiency of QD-Ab conjugates. However, a head-to-head comparison between these 
four different QD-Ab conjugates on their staining performances has not been reported. For 
immunohistochemistry application, standardization of QD-Ab conjugates would be greatly beneficial for 
comparing data across different labs and essential for translation of this powerful imaging tool into clinical 
studies.  
In this study, I compare the tubulin staining performance of four primary QD-anti-tubulin conjugates 
that are prepared via above four conjugation approaches. The combination of His-tag-driven binding with 
Protein A-mediated orientated antibody attachment is highly effective for use with QDs with compact 
surface coatings of multidentate yielding the best tubulin labeling performance. These results demonstrate 
recombinant Protein A can be an efficient linker to rapidly prepare functional primary QD-antibody 
conjugates.  
      
4.2 Results and Discussion 
4.2.1 Synthesis of Multidentate Polymeric Ligands Coated Near-Infrared QDs  
Highly monodispersed near-infrared (NIR) HgxCd1-xSeyS1-y/CdS/ZnS (Figure 4-1a) QD was 
synthesized through Hg cation exchange on CdSeS alloy core followed by a gradient shell growth of 4.7 
monolayers of CdZnS according to our published protocol with a few modifications[17]. The resulting QDs 
were phase transferred to water with multidentate polymeric ligands (PIM and PIM-N3) to generate compact 
and stable water-soluble NIR QDs. Transmission electron microscopy (TEM) in Figure 4-1b showed the 
average core diameter of QDs is about 4.5 nm. The QDs coated with the multidentate polymer have a 
monodisperse size distribution by size exclusion chromatography, revealing a hydrodynamic dimeter of 
~11 nm indicating the polymers are compactly attached on the surface. The fluorescence emission peak of 





final QDs in buffer is about 30% based on fluorescein as a relative standard. These QDs are ultra-stable in 
neutral phosphate buffer at 4 ℃ and no detectable aggregates were observed by size exclusion 
chromatography after one year as shown in Figure 4-2.  
 
4.2.2 Minimizing Nonspecific Binding Through Protein Conjugation 
Previously, we have demonstrated that compared with negative charged QDs that bind to 
fixed/permeabilized cells nonspecifically, neutralizing QDs surface charge using PIM or PIMN3 can 
significantly avoid the undesired nonspecific binding due to the presence of a high graft density of neutral 
oligo ethylene glycol[18]. However, further examination of these QDs showed that these particles are 
prone to binding to the nuclei of fixed/permeabilized cells as shown in Figure 4-3a. Colocalization of QDs 
with the cell nucleus was further confirmed by confocal laser scanning microscopy as shown in Figure 4-
3d-f. This nuclear nonspecific binding of nonfunctional QDs can be attributed to small sizes and the 
porosity of the polymer surface coating. Nonionic detergents like Triton-X can create pores on the nuclear 
membrane by dissolving the membrane lipids. Small particles less than 50 nm can easily diffuse into the 
nucleus through the pores to interact with DNA binding proteins. These proteins include a variety of metal 
binding proteins such as histones, leucine zipper and zinc finger that are rich in arginines, lysines and 
histidines. QD surface facets are heterogeneous crystalline surfaces with a range of binding affinity to 
polymer ligands. Thus, it is possible that the polymer coating the QDs creates a porous shell that is not 
densely enough to cover the whole surface. The porosity of the surface coating exposes the surface metal 
to DNA binding proteins eventually leading to an accumulation of QDs in the nuclei. This hypothesis is 
supported by the reduction of nonspecific binding when cells are pre-blocked by either metal ions such as 
Zn2+ or Ni2+, or anionic polymers such as dextran sulfate or polyacrylic acid (Figure 4-4). However, these 
blocking reagents not only reduce the nonspecific binding, but also block the specific labeling of QD 
antibody conjugates (Figure 4-5). Therefore, pre-blocking with a single blocking reagent to avoid the 






Figure 4-1. Characterization of QDs, modified antibodies and azido-Histag. QD-(a) Optical absorption and 
fluorescence of QD720 coated with PIM; (b) TEM image of QD720; (c) Size exclusion chromatograms of 
QD720 coated with PIM or PIMN3.  (d) Ultraviolet absorption spectra of Ab, DBCO-EG5-Ab and histag-
EG5-Ab. (e) Numbers of DBCO per anti-tubulin Ab, Protein A, and IgG2b control. (f) HPLC curve of 
purified azido His-tag (g) Fluorescence micrographs of HeLa cells immunolabeled with the indicated 
antibodies using secondary antibody conjugates with Alexa 647. Cells were imaged at 20×; scale bar: 50 
µm. Blue color is Hoechst nuclear stain and red color is Alexa 647. 




























 After One Year
 
Figure 4-2. Stability of QD720 coated with PIM assessed by size exclusion chromatography. GPC result 





     Surface modification of these small QDs with proteins can significantly reduce nonspecific binding to 
the cells. As shown in Figure 4-3g, the fluorescent intensity of HeLa cells dropped from 7.37 × 104 a.u./cell 
to 2.44 × 104 a.u./cell after conjugation of Protein A through a covalent linkage at a ratio or 4: 1 protein to 
QD (Figure 4-3b). A similar reduction of nonspecific binding was also observed when Protein A was 
attached to QDs via His-tag self-assembly (Figure 4-3c). Increasing the ratio of Protein A to QDs from 4 
to 10 can further minimize the nonspecific binding of QDs (2.08 ×104 a.u./cell) to the level of blank samples 
(1.54 × 104 a.u./cell). The reduction of nonspecific binding may be attributed to the additional protein 
intermediate layer that keeps the QDs surface away from the DNA binding proteins as shown in Figure 4-
3i. Thus, for engineering the QD antibody conjugates for specific labeling, it will be necessary to eliminate 
the percentage of free QDs to avoid any nonspecific binding. 
 
Figure 4-3. Minimizing nonspecific binding of polymer coated QD720 through protein modification. 
Fluorescent images of fixed/permeabilized Hela cells treated with (a) PIM coated QDs; (b) QD-c-PA (PA : 
QD = 4: 1); (c) QD-sa-PA (PA : QD = 4: 1); (d-f) Confocal laser scanning microscopy images of 
fixed/permeabilized Hela cells treated with PIM coated QDs show Hoechst channel (d), QD720 channel 
(e), and overlay (f); (g) Quantitative analysis of QD fluorescence intensity per cell in different samples. The 
value in the figure is the signal-to-noise ratio calculated by dividing the intensity per cell from QD-Ab 






Figure 4-4. Fluorescence images of fixed/permeabilized Hela cells pre-blocked using indicated conditions 
and treated with (QD720)PIM (25 nM). Cells were imaged at 20× and the red color is from QD720 emission. 
 
 
Figure 4-5. Fluorescence images of fixed/permeabilized Hela cells pre-blocked using indicated conditions 
and then stained with QD-sa-PA-sa-Anti tubulin antibody (25 nM). Cells were imaged at 20X and the red 
color is from QD720 emission. 
 
 
4.2.3 Preparation and Characterization of QD-Antibody Conjugates 
The conceptual design of four QD-Ab conjugates is illustrated in Scheme 1. The anti-alpha tubulin 
antibody was selected as a model antibody because of the abundance of alpha-tubulin in HeLa cells and the 
distinctive pattern of specific staining. Protein A was chosen as a model molecular adaptor due to its high 
specificity and affinity to the Fc region of most antibodies.  
     Chapter 3 showed copper free click chemistry is an efficient bio-conjugation approach to covalently 
attach proteins such as antibodies or PA to QDs without the need for any purification. Therefore, this 
reaction was chosen here to prepare covalently linked QD-protein conjugates. As depicted in Scheme 4-1a 





reacting with water-soluble DBCO-OEG4-NHS ester. The incorporation of DBCO groups was determined 
by UV-vis absorption spectroscopy (Figure 4-1d) and the number of DBCO per Ab, control IgG and PA 
was estimated to be 6.6, 6.2, and 4.1, respectively (Figure 4-1e). 
 
 
Scheme 4-1. Schematic illustration of the preparation of different QD-antibody (Ab) conjugates. (a) DBCO-Ab is 
directly conjugated to QDs through click chemistry to prepare QD-c-Ab. (b) Ab is modified with DBCO-EG5-NHS 
ester to obtain DBCO-Ab, which can react with azide-Histag to obtain a His-tagged antibody. The Ab is then attached 
to QDs through His-tag linker self-assembly to form QD-sa-Ab. (c) PA is first modified with DBCO-EG5-NHS ester 
and then conjugated to azide-QDs through click chemistry to form a covalently bound QD-c-PA conjugate. The Ab is 
then bound to QDs through interaction between PA and the Fc region of antibody to generate QD-c-PA-sa-Ab;. (d) 
His-tagged PA is attached to QDs through self-assembly with the His-tagg linker and then the Ab is bound through 
interaction between PA and the Fc domain of the Ab. 






Figure 4-6. Characterization of QD-Ab conjugates by gel electrophoresis. (a)  Gel electrophoresis result 
for QD-Ab reactions using different molar reaction ratios between DBCO- Ab and QD-azide, including a 
control using Ab without DBCO modification. The reaction was conducted at room temperature for 12 h. 
(b) gel electrophoresis analysis of QDs mixed with His-tagged Ab at different Protein : QD ratios (0, 0.5, 
1, 2, 4), including a control using Ab without a His-tag. The reaction was conducted at room temperature 
for 12 h. (c) Left: gel electrophoresis result for preparing QD-c-PA conjugate using different molar reaction 
ratios between His-tagged-PA and QD-azide, including a control using PA without a His-tag. The reaction 
was conducted at room temperature for 12 h. Right: Gel electrophoresis result for preparing QD-c-PA-sa-
Ab conjugate using different molar reaction ratios between QD-c-PA and Ab, including a control using 
antibody with Fc domain cleaved. The reaction was conducted at room temperature for 2 h. (d) Left: gel 
electrophoresis analysis of QDs mixed with His-tagged PA at different PA to QD ratios (0, 0.5, 1, 2, 4), 
including a control using PA without a His-tag. The reaction was conducted at room temperature for 12 h. 
Right: Gel electrophoresis result for preparing QD-sa-PA-sa-Ab conjugate using different molar reaction 
ratios between QD-sa-PA and Ab, including a control using Ab without Fc fragment. The reactions were 
conducted at room temperature for 2 h. The top part of each figure is the schematic illustration for 
constructing each QD-Ab. 
 
For conjugation through self-assembly, both His-tag proteins (anti-tubulin antibody and PA) and 
molecular adaptor (PA) self-assembly were evaluated in this work. As shown in Scheme 4-1d, recombinant 
protein A with His-tag can be simply attached to QDs surface to form QD-sa-PA conjugate. We also 
designed and synthesized a clickable His-tag by standard solid phase synthesis as shown in Scheme 4-1. 
The successful synthesis of azido His-tag was confirmed by mass spectrometry and its purity was confirmed 





azido His-tags were reacted with DBCO modified antibody to afford a His-tagged anti-tubulin antibody. 
The conjugation was confirmed by the disappearance of the DBCO absorbance at 309 nm, indicating 
complete reaction of the DBCO group with azido His-tags (Figure 4-1e). The average number of His-tag 
per antibody was about 6.  
One limitation of using covalent conjugation is the need for pre-modification of the antibody with 
functional groups like DBCO used in this study. Depending on the position of lysine groups in the protein, 
such treatment may result in a loss of antibody binding affinity. Thus, the labeling specificity of DBCO or 
His-tag modified anti-tubulin antibodies were investigated using a standard two-step immunofluorescence 
staining. As shown in Figure 4-1g, compared with the unmodified anti-tubulin antibody, no significant 
change on staining intensity was observed for modified antibodies, suggesting that these modifications did 
not alter the binding sites on the anti-tubulin antibody. The QD-Ab conjugates prepared using these 
antibodies are expected to function with high labeling specificity and sensitivity. 
As shown in Figure 4-6a, DBCO-Ab was conjugated to PIMN3 coated QD720 through covalent 
conjugation. Thanks to the compact and thin surface coatings of these particles, His-tagged Ab can be 
effectively attached to PIM coated QDs as shown in Figure 4-6b. The synthesis was validated by the 
retardation of the gel shift with the increased ratio of protein to QDs but no difference was observed in the 
gel electrophoresis result of QD reacting with antibodies without DBCO groups. At a protein to QD ratio 
of 4, nearly all of the unconjugated QDs were depleted for these two QD-Ab conjugates indicated by the 
disappearance of original QD band in the gel electrophoresis results. It is noteworthy that Xia et al showed 
that the tetra-His-tags can increase the association rates up to 50-fold compared with single His-tag 
counterpart[19-21]. Thus, this multi-Hi-tags binding approach would have some unique benefits in the rapid 
preparation of stable QD-protein conjugates.  
Similarly, QD-c-PA and QD-sa-PA were synthesized at the protein to QD ratio of 4 as shown in Figure 
4-6c and d. Mattoussi et al demonstrated that for protein with a single His-tag protein, the number of protein 
on QD-protein conjugate follow Poisson distributions at ratios below saturation of the QDs surface[22]. To 
verify if QD-PA conjugates (QD-c-PA and QD-sa-PA) can still be used as modular adaptors for IgG 
conjugation, PA and QDs were reacted with 4 to 1 and mixed with various amounts of Ab. The right gel 
images in Figure 4-6c and d show the gel electrophoresis results of these conjugates. It can be seen that the 
migration distance of QDs steadily decreased with increasing amount of Ab but no obvious change was 
found on the QD-PA band with the addition of Ab with Fc domain cleaved, confirming the specific binding 
of Protein A to the Fc region of Ab. Each PA has four binding sites for IgG, so it is possible that more than 
one IgG molecules can bind to one QD-PA conjugate, which may explain why original QDs band still 






4.2.4 Immunostaining of Anti-tubulin QDs Conjugates on Cells and Tissue  
As demonstrated in Section 2.1, it is critical to minimize the free QDs percentage to suppress the 
nuclear nonspecific binding. Therefore, based on the gel electrophoresis result from Section 2.3, the 
protein/QD ratio of 4 was selected to prepare the four QD-Ab conjugates because at this ratio, the original 
QD band has almost disappeared in all gel results. To determine if the QD-Ab conjugates maintain antigen 
recognition and binding of its Fab domain, the four freshly prepared QD-Ab conjugates and QD-control IgG 
conjugates were evaluated for alpha-tubulin binding on fixed/permeabilized HeLa cells using a standard 
single step immunofluorescence protocol.  
 
Figure 4-7. Comparion of staining performance of four different QD-Ab probes. Left: (Top row images) 
alpha-tubulin are labeled with QD-Ab in a single step staining process. (Bottom row images) Staining 
results using QD-IgG control. Right: Quantitative analysis of QD fluorescence intensity percell in different 
samples. The value in the figure is the signal-to-noise ratio calculated by dividing the intensity per cell from 
QD-Ab sample by that from its corresponding control sample. Cells were imaged at 20×; scale bar: 50 µm. 
Blue color is Hoechst nuclear stain and red color is QDs.    
 
 
The staining results are presented on the left in Figure 4-7 and the quantitative intensity results are 
summarized on the right in Figure 4-7. As shown in the bar graph, the four QD-Ab conjugates showed 
different levels of nonspecific binding to fixed cells. In general a decrease in nonspecific binding was 
observed for the covalent conjugation. Although the QD-sa-PA-sa-Ab conjugate showed the highest 
specific labeling, its negative control conjugate also exhibited the highest nonspecific binding. By close 
inspection of the gel electrophoresis results, there is a small tail in the gel band of QD-sa-Protein A 





4-6d). This tiny amount of unbound QDs may be responsible for the increased nonspecific labeling. 
Although increasing the Protein A ratio to 10 in the reaction mixture can reduce the nonspecific binding 
(section 2.2), this can significantly lower the staining intensity (data not shown). This may be because this 
ratio (10) has exceeded the saturation ratio (4) of His-tag protein A to QDs, and as a result, the amount of 
Ab on the QD is lower than QD-sa-PA-sa-Ab that is prepared using ratio of 4.  
 
Figure 4-8. Top row: schematic illustration of each QD-Ab conjugate; Middle row: 100X images of 
fixed/permeabilized Hela cells stained by QD-Ab conjugate; Bottom row: morphological analysis of the 
images in middle row.  
 
Specific labeling results were then compared between the QD-Ab conjugates. Among of them, QD-
sa-PA-sa-Ab and QD-c-PA-sa-Ab exhibited a high degree of binding to alpha-tubulin with average signal 
intensity of 2.0×105 and 1.7×105 a.u./cells, respectively. In contrast, cells stained by QD-c-Ab and QD-sa-
Ab showed three times lower intensity (7.0×104 a.u./cell and 5.1×104 a.u./cell respectively). This result is 
significantly different from what was seen in the immunostaining study using the organic dye labeled 
secondary antibody (Figure 4-1g). In contrast to the Protein A based oriented attachment strategy which 
generates functional QD-Ab conjugates (QD-c-PA-sa-Ab and QD-sa-PA-sa-Ab), direct conjugation of 
antibodies to QDs can damage Ab function via either improper orientation, denaturation or steric hindrance 





demonstrated that commercial conjugation kits from Invitrogen yielded less than 0.1 functional Ab per QD 
through thiol-maleimide reactions. Also, Pons et al recently validated that QD-Ab made through Protein A 
self-assembly has about three times the functional Ab number than that of QD-Ab prepared by thiol-
maleimide reaction (QD : Ab = 1: 4).[23] Thus, it is not surprising that QD-PA-Ab showed much higher 
labeling than QD-Ab. The slightly lower fluorescence intensity associated with QD-c-PA-sa-Ab may be 
ascribed to free, unreacted DBCO-Protein A in the mixture which can capture a few portion of Ab, 
decreasing the effective concentration of QD-c-PA-sa-Ab in the final conjugate. Interestingly, we found 
that QD-sa-Ab is able to stain the tubulin although the staining level is quite low compared with other 
conjugates. This approach can potentially expand the application of using His-tag self-assembly to construct 
stable QD-protein conjugates when His-tagged proteins are not available.  
To further evaluate the staining performance of these QD-Ab conjugates, microtubule connectivity 
was measured through morphological image analysis[24]. As shown in Figure 4-8, QD-sa-PA-sa-Ab 
staining enables best continuity and connectivity preservation as demonstrated by the longer continuously 
connected pixels and fewer isolated spots. Previously, it was shown that QD-His-tag nanobody is stable for 
single molecule analysis of kinesin motor proteins. For the first time, we demonstrated herein that stains 
based on QD-His-tagged Protein A-Antibody complexes can withstand long period of time and multiple 
rounds of washing. The staining performance with QD-sa-PA-sa-Ab is comparable with QD-c-PA-sa-Ab, 
a structure that has been widely used in many previous QD imaging studies[24-26]. This study reveals that 
the direct binding of His-tagged protein with QDs may be not a concern for immunohistochemistry 
application. Further evaluation on the stability on QD-sa-PA-sa-Ab may be needed to strengthen this notion. 
Among of these four conjugates, it is easiest and least time consuming to prepare QD-sa-PA-sa-Ab because 
both two steps are based on simple and efficient self-assembly reactions without the need to modify either 
QD, His-tagged Protein A or Ab. Moreover, His-tag self-assembly approach can reduce the hydrodynamic 
diameter of QD-PA-Ab conjugates through direct attaching Protein A to QD surface rather than to the 






Figure 4-9. Tissue staining with QD-sa-PA-sa-Ab. (a) Schematic illustration of primary immunostaining; 
Staining of frozen breast tumor tissue section (b-d) and FFPE brain tissue section (e-g). Cells were imaged 
at 20×. Blue color is Hoechst nuclear stain and red color is QDs.    
 
The use of NIR light (650 – 1000 nm) is beneficial for immunostaining, especially for fixed tissue, due 
to the reduced autofluorescence background signal within this spectral range. The self-assembled QD-sa-
PA-sa-Ab with NIR emission were used for staining paraformaldehyde-fixed tumor and formalin-fixed 
paraffin-embedded (FFPE) brain tissues. Tissues were cut into 5-6 µm sections, and then stained by QD-
sa-PA-sa anti-tubulin Ab to visualize the tubulin structures using a NIR emission filter (732/68 nm). As 
shown in Figure 4-9, successful labeling of targets was validated by the strong fluorescent signals on cells 
stained by QDs while blank and negative controls (QD-sa-PA-sa-cIgG) showed similar fluorescence 
intensity as autoflourescence levels. This result suggests that the self-assembled QD-sa-PA-sa-Ab is 
suitable for tissue staining.  
 
4.3 Conclusions  
In this work, four different primary QD-Ab conjugates were engineered using different approaches and 
their staining performance in Hela cells was directly compared. The results showed that chemical 
modification of anti-tubulin antibodies with different functional groups such as His-tag and DBCO did not 
change the function of antibodies. However, the attachment of these functional antibodies to QDs via 
different attachment strategies led to varied immunostaining results. When QDs were conjugated to an 
antibody through a His-tagged Protein A, the resulting QD-sa-PA-sa-Ab exhibited a best staining 





polyhistidine-driven metal-affinity for metal ions on QDs and oriented conjugation between Protein A and 
antibodies. Unlike in the random attachment strategies (QD-c-Ab and QD-sa-Ab) which can hinder protein 
function, such strategy can maximize the number of antibodies in the primary QD-Ab conjugates. 
Compared with QD-c-PA-sa-Ab conjugates, QD-sa-PA-sa-Ab may have some benefits in cellular imaging 
when large size is a limiting factor as the Protein A is directly attached to QD surface rather than the attached 
ligand for the case of QD-c-PA-sa-Ab conjugate. Moreover, its fast binding kinetics and high reaction yield 
make this approach ideal for reproducible and quick preparation of functional primary QD-Ab conjugates 
without the need for knowledge in conjugation chemistry which typically involves complicated purification 
processes. It should be noted here other recombinant molecular adaptor (Protein G, Protein A/G, 
streptavidin, and Fc receptor) can be applied in the same way to prepare QD-Ab conjugates. Recently, 
molecular adaptor-mediated QD-Ab conjugates have emerged as a popular strategy to engineer primary 
QD-Ab conjugates for multiplexed imaging[26, 27]. It is anticipated that this work will provide new insights 
due to the direct and robust comparisons with well controlled experimental design. During this study, it was 
clear that QD-sa-PA-sa-Ab showed higher nonspecific binding, which most likely drives from the 
remaining unconjugated QDs that nonspecifically bound to the nuclei. The mechanism for this nonspecific 
nuclear binding is still under investigation. This problem may be solved by selecting proper blocking 
reagents or using a more densely packed polymer coating. Another limitation of this study is that the 
conjugate was not purified prior to staining. The antibody conjugation efficiency may also have effect on 
the staining results. In view of high efficiency of the reactions used in this study, the influence of this factor 
on the result may be limiting.  
 
4.4 Experimental Section 
Quantum Dot Synthesis 
Core/shell HgxCd1-xSeyS1-y/CdS/ZnS nanocrystals with emission at 725 nm were synthesized and purified 
according to published protocols[17] with a few modifications. First, CdSeS alloy core QDs (d = 2.8 nm; 
λabs= 506 nm) were synthesized by heating-up a vacuum-dried mixture (~100°C, 1h) of Cd behenate (0.2 
mmol), selenium dioxide (0.13 mmol), sulfur powder (0.07 mmol), and 1,2-hexadecanediol (0.2 mmol) in 
1-octadecene (4 mL) to 230°C under nitrogen and react at the temperature for 15 min. As-synthesized 
CdSeS QDs were purified according to the standard protocol[17], and dispersed in CHCl3. Next, HgCdSeS 
QDs (λabs= 640 nm) were obtained through Hg cation exchange on CdSeS QDs by injecting Hg acetate-
oleylamine stock solution (Hg(Ac)2(OLA)2 in CHCl3, 0.2M; 2x excess of total Cd) into CdSeS QD solution 





by injecting octanethiol (~100 µL) and precipitating QDs with a methanol/acetone mixture (1:1 v/v; ~20 
mL). HgCdSeS QDs were further purified by three cycles of ‘dispersion in hexane (~10 mL) with 
oleylamine (~100 µL) and oleic acid (~100 µL) and precipitation with methanol/acetone mixture (~20 mL)’, 
then stored as stock solution in fresh hexane for shell growth. Finally, HgCdSeS/CdZnS core/shell QDs 
(λabs= 680 nm; λem= 720 nm) were synthesized by growing graded CdZnS shell over HgCdSeS core through 
standard layer-by-layer shell growth protocol with 0.8-monolayer (ML) increment described in the 
literature.7 Cadmium acetate dissolved in oleylamine (0.1 M), zinc acetate in oleylamine (0.1 M), and 
elemental S dissolved in 1-octadecene were respectively used as Cd, Zn, and S precursors for the shell 
growth. The exact shell composition for QD720 was CdS 2.4ML/Cd0.75Zn0.25S 0.8ML/ZnS 1.5ML. The 
resulting QDs were purified by precipitating into acetone. QDs were re-dispersed in hexane and stored at -
20 ℃ until use.   
Synthesis of Polymer-Coated QDs 
Purified near infrared-emitting QDs (λem= 720 nm) in hexane were phase transferred to N-methylformamide 
(NMF) by dropwise addition of tetramethylammonium hydroxide (TMAH, 100 equivalents of QD surface 
atoms). PIM or PIM-N3 dissolved in DMSO (11.3 mg/ml, 150 µL) was mixed with hydroxide ion-capped 
QDs in NMF (8.41 µM, 237.8 µL) (5: 1 imidazole to QD surface atom) and purged with nitrogen gas for 2 
min. The mixture was stirred at 110 ℃ for 2 h before precipitation with ether/CHCl3 mixture. A QD pellet 
was collected and dried after centrifugation of the mixture at 7,000 g for 5 min. Excess polymer was then 
removed using centrifugal filtration (Amicon Ultra 50 kDa MWCO) against 50 mM sodium borate buffer 
(pH 8.5). This dilution-filtration cycle was performed four times.  
Synthesis of Azido Hexahistidine (Azido-histag) 
The azido hexahistidine peptide was synthesized by standard Fmoc solid-phase synthesis as previously 
published[28]. Typically, 20% piperidine in the N′, N′-dimethyl formamide (DMF) was mixed with N-
terminal fluorenylmethyloxycarbonyl (Fmoc)-protected rink amide resin for 15 min to remove Fmoc 
protecting groups. After filtration, the resin was collected and rinsed with DMF 4 times. A DMF mixture 
of amino acid (three equiv.), N-methylmorpholine and benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) was added and incubated with the resin for 2 h at room temperature under 
rigorous stirring. The reaction was halted by filtration to collect the resin followed by 4 washes with DMF. 
After deprotection of the next Fmoc group, coupling and deprotection was assessed by a standard ninhydrin 
test. At the final step, the peptides were capped with 2-azidoacetic acid in DMF overnight. Then the resin 
was incubated with a mixture containing 95% trifluoroacetic acid (TFA), 2.5% H2O, and 2.5% 





filtration. The peptides were further purified by precipitation in ice-cold diethyl ether and was further 
purified by three additional dissolution/precipitation circles using TFA/ether. Finally, the peptides were 
dissolved in water and dried by lyophilization. The purity of the azido histag was > 90% as analyzed by 
semipreparative reversed-phase high-performance liquid chromatography (RP-HPLC) (PerkinElmer 
Flexar). ESI-MS (low resolution, positive mode): calculated for C38H46N22O7, m/z 462.5 [M+2H]+/2; found 
462.5 [M+2H]+/2.  
Modification of Anti-Tubulin Antibody or Control IgG2b with DBCO-PEG5-NHS ester 
Anti-alpha tubulin antibody (mouse monoclonal IgG2b isotype, catalog No. 66031-1-Ig) was purchased 
from Proteintech (Rosemont, IL). After removal of sodium azide in the antibody stock, 2.5 mM of DBCO-
PEG5-NHS ester (10 times molar equivalent of antibody) in anhydrous DMSO was added and incubated at 
room temperature for 30 min as recommended in the product instructions. The reaction was quenched by 
addition of 1M Tris-HCl (pH 8.5, 5 µl) and incubation for 5 min at room temperature before purification of 
the mixture through ultrafiltration with an Amicon filter (MWCO 50 kDa) against 1×PBS five times. 
Absorption spectra of the antibody solution were acquired to determine the number of DBCO per antibody 
using the absorption at 280 nm and 309 nm according to the product manual from Click Chemistry Tools. 
DBCO modified control IgG2b (Invitrogen, catalog no. 02-65300) was prepared using a similar protocol.  
Modification of Protein A with DBCO-PEG4-NHS ester 
Protein A purchased from Fisher-Pierce (catalog No.: 21181-5 mg) in 1×PBS was mixed with 5 mM 
DBCO-PEG5-NHS ester (10 equiv. of Protein A) in anhydrous DMSO. The mixture was incubated at room 
temperature for 30 min before the reaction was quenched by addition of 1M Tris-HCl (pH 8.5, 5 µl), 
followed by a 5 min incubation at room temperature. The resulting DBCO-modified Protein A was purified 
by using ultrafiltration with an Amicon filter (MWCO 3 kDa) against 1×PBS five times. The final 
concentration of protein A was measured using a Pierce BCA protein assay kit (catalog no. 23225). The 
number of DBCO incorporated in the protein A conjugates was determined by the ultraviolet 
spectrophotometric method described above.   
Conjugation of DBCO-Modified IgG with Azido-Histag 
To engineer the His-tagged anti-tubulin antibody, the fresh prepared DBCO-modified IgG (anti-tubulin 
antibody or control IgG2b) was mixed with azido histag (10 equiv. of DBCO amount) at room temperature 
overnight with gentle shaking. After reaction, any unbound azido His-tag was removed by ultrafiltration 





antibody was confirmed by the disappearance of characteristic DBCO absorption peak at 309 nm by 
Nanodrop.  
Conjugation of DBCO-Modified IgG or DBCO-Modified Protein A to QDs Through Copper Free 
Click Chemistry 
PIM-N3 coated QD720 in 10 mM phosphate buffer (pH 7.4) was mixed at different ratios with freshly 
prepared DBCO-activated IgG (anti-tubulin antibody or control IgG2b) or DBCO-activated Protein A at 
room temperature overnight. Then a 50-fold molar excess of 2-azidoacetic acid was added to the solution 
to react at room temperature ad allowed for react for 15 min to quench the remain DBCO. Conjugation was 
confirmed by gel electrophoresis in a hybrid polyacrylamide-agarose gel.  
Conjugation of His-Tagged IgG or His-Tagged Protein A to QDs Through Self-assembly 
PIM coated QD were mixed with different ratios of His-tagged IgG (anti-tubulin antibody or control IgG2b) 
or His-Tagged Protein A at room temperature in 10 mM phosphate buffer (pH 7.4) for 4 h. Conjugation 
was confirmed by gel electrophoresis in a hybrid polyacrylamide-agarose gel.  
Conjugation of IgG to Protein A-Modified QD 
Protein A modified QD (either covalent or noncovalent bound) was mixed with IgG (anti-tubulin antibody 
or control IgG2b) at room temperature for 4 h. Conjugation was confirmed by gel electrophoresis in a 
hybrid polyacrylamide-agarose gel.  
Evaluation of Nonspecific Binding to Cells 
HeLa cells (ATCC #CCL2) were cultured in Eagles’ Minimum Essential Medium (EMEM) with 10% fetal 
bovine serum (FBS) and 1% penicillin/ streptomycin (P/S) at 37 °C with 5% CO2. Cells were seeded at a 5 
×104 cell/well density on 12 mm circular coverglass in 24 well plates and cultured for 24 h. The cells were 
washed three times with PBS before fixation with freshly prepared 4% paraformaldehyde (PFA) for 20 min 
at room temperature. The cells were washed (PBS three times), permeabilized (0.1% Triton X-100 in PBS 
for 20 min), washed again (PBS three times), and blocked with 1 wt % bovine serum albumin (BSA) for 1 
h. The cells were then washed (PBS three times) and 40 nM dispersions of PIM-QD720, PIMN3-QD720, 
IgG modified QD720, or His-Tagged Protein A modified QD720 in 1 wt % BSA solution were added to 
the wells and incubated for 1 h at room temperature. Control experiments were carried out by incubating 
cells without QDs. The cells were washed three times with PBS to remove unbound QDs, and nuclei were 
stained with Hoechst 33258 (2 μg/mL). The coverglass with cells was then mounted with 90% glycerol in 





Observer Z1 inverted microscope (Zeiss, Oberkochen, Germany) with an EC Plan-Neofluar 20 × 0.50 NA 
air microscope objective. Hoechst signal was imaged with 100 W halogen lamp excitation with a 365 nm 
excitation filter and 445/50 nm emission filter; QDs were imaged using 100 W halogen lamp excitation 
using a 488 nm excitation filter and 732/68 bandpass emission filter. Images from the control and QD 
samples were collected using the same imaging conditions. 
Immunofluorescence Staining on Hela Cells Using Alexa 647 Secondary Antibody 
HeLa cells (ATCC #CCL2) were cultured in Eagles’ Minimum Essential Medium (EMEM) supplemented 
with 10% FBS and 1% P/S, seeded at a density of 5 × 104 cells/well in a Labtek glass-bottom 8 well chamber, 
and incubated at 37 °C with 5% CO2 for 20 h. The cells were then fixed with 4% PFA for 20 min, 
permeabilized with 0.1% (v/v) Triton X-100 for 20 min, and blocked with 1% BSA for 1 h. The cells were 
then incubated with primary anti-tubulin antibody in 1% BSA for overnight at 4 ℃. After washing the cells, 
the cells were incubated with the secondary antibody conjugated to Alexa 647, and stained with 2 μg/mL 
of Hoechst for 10 min. All treatments were carried out at room temperature. The cells were imaged 
immediately on a Zeiss Axio Observer Z1 inverted microscope (Zeiss, Oberkochen, Germany) with an EC 
Plan-Neofluar 20 × 0.50 NA air microscope objective. Hoechst signal was imaged using 100 W halogen 
lamp excitation with a 365 nm excitation filter and 445/50 nm emission filter; tubulin were visualized using 
using100 W halogen lamp excitation with a 594 nm excitation filter and 732/68 bandpass emission filter. 
Images from the control and stained samples were collected using the same imaging conditions. 
Immunofluorescence Staining on Hela Cells Using QD-Ab Conjugates 
HeLa cells (ATCC #CCL2) were cultured in Eagles’ Minimum Essential Medium (EMEM) supplemented 
with 10% FBS and 1% P/S, seeded at a density of 5 × 104 cells/well in a Labtek glass-bottom 8 well chamber, 
and incubated at 37 °C with 5% CO2 for 20 h. The cells were then fixed with 4% PFA for 20 min, 
permeabilized with 0.1% (v/v) Triton X-100 for 20 min, and blocked with 1% BSA for 1 h. The cells were 
then incubated with 25 nM QD720-Anti tubulin antibody conjugate in 1% BSA at a temperature for 2h and 
stained with 2 μg/mL of Hoechst for 10 min. All treatments were carried out at room temperature. The cells 
were imaged immediately on a Zeiss Axio Observer Z1 inverted microscope (Zeiss, Oberkochen, Germany). 
Hoechst signal was imaged using 100 W halogen lamp excitation with a 365 nm excitation filter and 445/50 
nm emission filter. For 20 X images, QDs were imaged using 100 W halogen lamp excitation with a 488 
nm excitation filter and 732/68 bandpass emission filter. For 100 X images, QDs were imaged using a 488 
nm laser excitation and 732/68 bandpass emission filter. Images from the control and QD samples were 





Immunofluorescence Staining on Frozen Mouse Breast Cancer Tissue Section using QD-Ab 
Conjugates 
Mouse breast tumor was provided by the Erik Nelson from Department of Molecular & Integrative 
Physiology. The tumor was first fixed with 4% PFA for 24 h and embedded in optimum cutting temperature 
(O.C.T.) compound. Tissues were sectioned using a cryostat at a thickness of 6 µm and air-dried. Slides 
were stored at -80 ℃ before used for immunostaining. Tissue sections were permeabilized (0.1% Triton X-
100 in PBS) for 20 min, washed (1×PBS three times) and blocked (2 wt% BSA solution) for 30 min. Then 
the tissue was stained with QD primary antibody conjugate (40 nM) for 2 h at room temperature. After 
washing with 1×PBS for three times, cell nuclei were counterstained using Hoechst (5 µg/ml) for 5 min. 
The slides were mounted with 90% glycerol and sealed with nail-polish. Hoechst signal was imaged using 
100 W halogen lamp excitation with a 365 nm excitation filter and 445/50 nm emission filter; QDs were 
imaged using a 488 nm laser excitation and 732/68 bandpass emission filter. Images from the control and 
QD samples were collected using the same imaging conditions. 
Immunofluorescence Staining on Brain PEFF Section Using QD-Ab Conjugates 
Paraffin embedded formalin fixed brain tissue section slides were provided by the Catherine Best from 
Department of Bioengineering. After deparaffinization in xylene for 5 min and rehydration with a gradient 
ethanol solution (from 100% to 75%), antigens were retrieved by heating the tissue slides in a microwave 
oven in citrate buffer (10 mM, pH 6.1). After cooled to room temperature, the slides were washed (0.2% 
Triton X-100 in PBS) for 25 min and incubated with BSA solution (2 wt%) for 30 min to reduce nonspecific 
binding. The slides were then incubated with QD primary antibody in BSA (1 wt%) for 2 h at room 
temperature. After washing with 1XPBS for three times, cell nuclei were counterstained using Hoechst (5 
µg/ml) for 5 min. The slides were mounted with 90% glycerol and sealed with nail-polish. Hoechst signal 
was imaged using 100 W halogen lamp excitation with a 365 nm excitation filter and 445/50 nm emission 
filter; QDs were imaged 100 W halogen lamp excitation with a 488 nm excitation filter and 732/68 bandpass 
emission filter. Images from the control and QD samples were collected using the same imaging conditions. 
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CHAPTER 5: EFFICIENT TARGETING OF ADIPOSE TISSUE 
MACROPHAGES IN OBESITY 
 
5.1 Background and Motivation 
The worldwide prevalence of obesity has risen tremendously over the past four decades, and 36% of 
Americans are now classified as obese (body mass index≥ 30)[1, 2]. This epidemic is a major societal and 
economic burden due to the damaging impact of obesity on health that stems from an increased risk for a 
variety of diseases, including type 2 diabetes, heart disease, stroke, and cancer[3, 4]. Diabetic disorders and 
cardiovascular diseases in particular are the leading comorbidities associated with a shortened lifespan. 
Diabetes and its associated disorders are mediated through an inability of tissues to respond to blood glucose 
(glucose intolerance) and insulin (insulin resistance). Cardiovascular dysfunction occurs through 
chronically elevated blood pressure, impaired angiogenesis, and increased plaque deposition, leading to 
ischemic heart disease, stroke, and impaired wound healing. 
Recently, chronic low-grade systemic inflammation has been identified as the causal link between 
obesity and its comorbidities[5]. The emerging mechanism implicates macrophage cells as central 
mediators[6]. Macrophages are resident immune cells in most tissues, comprising 10-15% of the cell 
population in normal adipose tissue where they predominantly exhibit an anti-inflammatory phenotype, 
classically dubbed M2[7]. However in obese humans and rodents, macrophages infiltrate adipose tissue in 
large numbers in response to local release of chemoattractants such as monocyte chemoattractant protein-
1 (MCP-1). In the obese state, macrophages make up 40-50% of the interstitial cell population and switch 
phenotype to a pro-inflammatory state, dubbed M1, releasing cytokines such as tumor necrosis factor alpha 
(TNFα) and interleukin-6 (IL-6)[8, 9]. These cytokines induce a slew of pathological effects both locally 
and systemically, resulting in glucose intolerance, insulin resistance, and vascular dysfunction. In fact, 
TNFα administration is widely used to induce insulin resistance in mice, and insulin sensitivity can be 
restored both by pharmacological inhibition of TNFα and reversal of the M2  M1 switch[7], supporting 
the damaging role of macrophages and distinguishing them as a target for clinical intervention[10-12]. 
Importantly, visceral adipose tissue (VAT, surrounding the organs) is thought to be the primary site of these 
pathological effects, as opposed to subcutaneous adipose tissue (beneaththe skin)[13]. 
Most clinical treatments for obesity comorbidities, such as insulin or statins, act downstream of 
inflammatory processes rather than resolving the underlying causes[10, 12, 14]. Anti-inflammatory (AI) 
drugs such as glucocorticoids (e.g. dexamethasone) and non-steroidal anti-inflammatory drugs (NSAIDs) 





high doses and chronic use have serious side effects (e.g. gastrointestinal irritation and bleeding) and 
clinical studies have not demonstrated an improvement in insulin resistance. Evidence suggests that side 
effects result from impact of these small-molecule drugs in off-target tissue, particularly in the liver[16, 17].  
Nanomedicine offers a potential solution by enabling tissue-specific drug delivery through molecular 
and cellular targeting for reducing off-target side effects[18-26]. Conventional nanomedicines are 
nanometer-scale particles composed of lipids, polymers, and/or biomolecules linked to targeting agents (e.g. 
antibodies) that selectively bind to specific tissues, allowing the particles to locally release a drug payload. 
Nanomedicine is expected to have a transformative impact on pharmaceutical medicine, which has 
traditionally been based on small molecule drugs that access all tissues and elicit major side effects. 
Limitations to date have been low targeting efficiency of diseased tissue after systemic administration (>90% 
of dose is usually retained in liver), especially when targeting solid tumors, and frequent reliance on 
chemical agents that are not clinically approved, which slows clinical translation[27-32].  
In this chapter, a new nanomedicine strategy is developed for targeting adipose tissue macrophages in 
obesity to therapeutically modulate inflammation. The central finding is that a drug delivery platform based 
on polysaccharide nanoparticles can specifically target macrophage cells in the VAT of obese animals. The 
targeting efficiency is exceptionally high (35-60% of the injected dose), orders of magnitude greater than 
that observed for conventional small-molecule drugs and conventional nanomedicine agents, and stems 
from a unique combination of macrophage-selectivity and regional peritoneal administration. The resulting 
concentration is more than two times higher in the VAT compared to the liver, and anti-inflammatory 
prodrugs delivered with this strategy induce a local reduction in pro-inflammatory markers in the adipose 
tissue of obese mice, using chemical building blocks that are all approved for use in the clinic. These 
findings demonstrate that there is a unique opportunity to treat obese patients using a nanomedicine strategy 
with a very high degree of specificity that may attenuate unwanted side effects in non-targeted tissues. 
 
5.2 Results 
5.2.1 Macrophage-targeted Polysaccharide Conjugates 
Certain polysaccharides of glucose such as dextran are known to be internalized efficiently and 
selectively by macrophage cells due to their expression of different classes of dextran-binding receptors 
such as C–type lectins and scavenger receptors[33-35]. As depicted in Figure 5-1a, I designed a series of 
imaging agents and drug conjugates of dextran with the expectation that these nanomaterials would enable 
macrophage targeting in inflamed adipose tissue. The detailed synthetic routes of these conjugates are 
shown in Scheme 5-1. The size of dextran was tuned using molecular weights of 10 kDa (D-10), 70 kDa 





distribution using gel filtration chromatography. I also synthesized a variant of the 70 kDa dextran for which 
polyethylene glycol (PEG) was conjugated to sugar hydroxyl groups through a carbamate bond to block 
receptor-mediated uptake. This PEGylated dextran (D-PEG) was designed to have a size distribution 
between that of D-70 and D-500 as shown in Figure 5-1b. Three functional derivatives of these polymers 
were prepared to either contain NOTA-64Cu (D-rad) for biodistribution studies using positron emission 
tomography (PET), tetramethylrhodamine or Texas Red (D-fluor) for flow cytometric analyses and 
fluorescence imaging, or dexamethasone (D-drug) for anti-inflammatory effects. The D-rad and D-fluor 
conjugates were linked through stable thiourea bonds whereas D-drug conjugates were linked through 
hydrolysis-labile ester bonds. All of these conjugates were characterized by 1H NMR as shown in Figure 
5-2 and 5-3.  To tune the dexamethasone content, different feeding ratios of dexamethasone succinic acid 
(DSA) and dextran were used (Figure 5-4). The conjugate with 4.57 wt% dexamethasone was used in the 
reported therapeutic studies. As shown in Table 5-1, to minimize the impact of side chain modification on 
the targeting ability of dextran, the total modification of dextran side chain was synthesized to be less than 
5% for D-NOTA conjugates.  
 
Figure 5-1. Dextran conjugate used in this work. (a) Structures and (b) gel filtration chromatograms of 






 Scheme 5-1. Synthetic routes for D-70-drug, D-10-NH2 , D-70-PEG-NH2 and dextran TR or NOTA 
conjugates.  
 
5.2.2 Biodistribution of Dextran Conjugates in Lean and Obese mice 
To determine how dextran vehicles distribute in lean and obese mice, radiolabeled conjugates were 






Figure 5-2. 1H NMR of NOTA-dextran conjugates in D2O. 
 
Figure 5-3. 1H NMR spectra of D-70-drug conjugates, dextran and DSA (from top to bottom) in DMSO-
d6. 











Figure 5-4. Weight percentage of dexamethasone in D-70-drug with different feeding ratios of 
dexamethasone succinic acid (DSA) and dextran (D-70) determined by UV-Vis spectroscopy. 
 
Table 5-1. Dextran-NOTA conjugate properties. 
*determined by ICP-MS 
 
kcal from fat) diet (obese). The biodistribution of D-rad and D-PEG-rad conjugates was measured following 
intravenous (i.v.) or intraperitoneal (i.p.) administration using a combination of whole animal PET imaging 
with overlay of X-ray computed tomography (CT) images (Figure 5-5a and 5-5b, respectively) and 
quantitative gamma well counting of excised tissues (Figure 5-5c and 5-5d). Figure 5-5a shows PET/CT 
images demonstrated that D-70 administered through jugular vein injection predominantly resulted in liver 
uptake after 24 hr for both lean and obese mice, which is consistent with previous dextran biodistribution 
studies[36]. However, as shown in Figure 5-5b, a remarkably different trend was observed after i.p. 
administration, yielding a large fraction of D-70 and D-500 located in VAT of obese mice. This effect was 
not observed in lean animals for which the liver remained the dominant site of uptake. This effect was 
eliminated in obese mice when the molecular weight was low (D-10) or when receptor targeting was 






















D-10-NOTA 10 62 1.36 0.02
D-70-NOTA 70 432 21.8 0.05
D-500-NOTA 500 3086 113 0.04





attenuated through PEGylation (D-PEG). Time-course PET/CT results show that this distribution reached 
steady state within 4 hours after injection (Figure 5-6).  
 
Figure 5-5. Biodistribution of dextran nano-carriers in lean and obese mice. (a) Reconstructed PET/CT 
images of lean mice (top row) and obese mice (bottom row) 24 hr after jugular vein injection of D-70-rad. 
Liver (L) and adipose tissue (AT) are denoted by white arrows. (b) PET/CT images of lean mice (top row) 
and obese mice (bottom row) 24 hr after intraperitoneal injection with D-rad conjugates (from left to right: 
D-10, D-70, D-500, D-PEG). (c,d) Quantitative gamma well counting results from lean (c) and obese (d) 
mice 24 hr after intraperitoneal injection with four different D-rad conjugates. Data depict liver, 





Figure 5-5c and 5-5d depict post-mortem gamma well counting analysis of tissues 24 hr after i.p. 
administration of D-rad conjugates, which quantitatively confirmed imaging results. In lean mice, i.p.-
administered D-70 and D-500 resulted in a liver concentration of >60% injected dose (I.D.) per gram tissue. 
This value was just ~20% for obese mice, suggesting a redistribution to other organs and tissues. In these 
obese mice, 35-60% I.D. per gram tissue was observed in the left perirenal adipose tissue, which exhibited 
much lower dextran accumulation in lean mice (12-20%). In obese mice, the other visceral and 
subcutaneous adipose tissues also exhibited significant but lower accumulation. When accounting for tissue 
weight, the amount of D-70 and D-500 that accumulated in adipose tissue was 35-60% of the total injected 
dose (Figure 5-6b), which is a remarkably high level of targeting. A second notable finding is that even in 
lean mice, a substantial amount of the injected dose was detected in adipose tissues for D-70 and D-500, 
which has not previously been reported.  
 
Figure 5-6. (a) Three-dimensional PET/CT images of obese C57BL/6J mice after intraperitoneal injected 
of D-70-rad conjugate, 1 hr, 4 hr, and 24 hr after injection. (b) Biodistribution of dextran conjugates in lean 
and obese mice. Lean and obese mice i.p. injected with 64Cu-labeled D-70 and D-500. 24 hours later, 
visceral adipose tissue (VAT) containing mesenteric AT, perirenal AT, and gonadal AT from both sides 
were isolated. (n=4~5) 
 
Efficient targeting to VAT in obese mice required high molecular weight dextran. As shown in Figure 
5-5c and 5-5d, the amount of D-10-rad was very low in all tissues, which is consistent with previous 
observations that low molecular weight dextran is efficiently cleared from the body through renal 
filtration[37] and exhibits low association with macrophages[38]. When using higher molecular weight 
dextran that was PEGylated to block receptor binding, we also observed a substantial reduction in uptake 
in the adipose tissue, liver and spleen. However in this case, the conjugate was observed to be in systemic 
circulation rather than cleared from the body. Interestingly, efficient uptake in VAT was mainly 





uptake from the peritoneal cavity is rapid and that there is little circulation in the cavity before absorption 
into the tissues. 
 
5.2.3 Dextran Uptake by Myeloid Cells in Obese Mice 
To characterize the cell types responsible for VAT uptake of dextran in obese mice, we performed 
flow cytometric analysis of digested tissue 24 hr after i.p. injection of D-70-fluor into obese mice. Isolated 
cells were stained with a fluorescently labeled antibody against CD11b, a standard marker of myeloid cells 
such as monocytes and macrophages[6, 39]. Figure 5-7a shows that more than 80% of cells associated with 
D-70-fluor were also CD11b-positive in three of the adipose depots (subcutaneous, gonadal, and perirenal). 
These findings are consistent with fluorescence microscopy images of adipose tissue sections shown in 
Figure 5-7b, in which fluorescence signal is localized to the interstitial spaces between adipocytes, as 
indicated by large fat globules. Interestingly, in the mesenteric fat pad, less than 50% of the cells associated 
with dextran were myeloid. These results demonstrate that D-70 injected through the peritoneal cavity is 
selectively associated with macrophage-like cells in the AT of obese mice.  
 
Figure 5-7. Dextran uptake by myeloid cells in adipose tissue of obese mice. (a) Obese mice i.p. injected 
with D-70-fluor. After 24 hours, subcutaneous, mesetenric, perirenal, and gonadal adipose tissue depots 
from both sides were isolated. The bar graph depicts the percentage of D-70-fluor cells that are also CD11b-
positive in each depot. (n=3) (b) Obese mice were i.p. injected with D-70-fluor. 24 hours later, left gonadal 
AT was isolated, sectioned, and stained with Hoechst dye. Confocal laser scanning microscopy images 
show Hoechst channel (top left), D-fluor channel (top right), brightfield microscopy (bottom left), and 
overlay (bottom right). D-70 was located within the interstitial space between adipocytes. (Scale bar: 200 
µm)  
 
5.2.4 Anti-inflammatory Effects of Dextran-drug Conjugates on Macrophages In Vitro 
Based on the capacity of high molecular weight dextran to selectively accumulate in macrophage cells 





conjugates of D-70 carriers linked through ester bonds, which slowly hydrolyze and can be selectively 
cleaved by intracellular esterases. For proof of concept, we chose the AI drug dexamethasone which has 
been shown to yield anti-inflammatory effects in M1 macrophages[40]. Controlled release of 
dexamethasone from D-70 in pH 7.4 phosphate buffered solution was measured to occur with a half-time 
of approximately 4 days (Figure 5-8). To assess the capacity of this conjugate to modulate macrophage cell 
phenotype, cultured mouse RAW 264.7 cells were polarized to the M1 pro-inflammatory state using 
lipopolysaccharide (LPS), which increased secretion of TNFα and IL-6[41]. The cells were then exposed 
to D-70-drug or free drug at equivalent drug concentrations and TNFα and IL-6 in the supernatant were 
measured over time using enzyme-linked immunosorbent assays (ELISAs). Figure 5-9 shows that D-70-
drug and the free drug resulted in comparable anti-inflammation effects, verifying that the prodrug can be 
efficiently dissociated from the dextran carrier backbone in cells.  
 
Figure 5-8. Time-course release of dexamethasone (and succinylated dexamethasone) from D-70-drug in 
PBS (pH 7.4) at 37°C. n=3. 
 
Figure 5-9. Relative IL-6 (a) and TNF (b) expression in M1 macrophages in presence of vehicle, free 
drug or D-70-drug. n=2. 





























5.2.5 Anti-inflammatory Effects of Dextran-drug Conjugates in Obese Mouse VAT 
To determine if dextran conjugates of clinical anti-inflammatory drugs induce therapeutic effects in 
inflamed VAT, we administered D-70-drug conjugates via i.p. injection to 26-wk old diet-induced obese, 
glucose intolerant C57BL/6J mice and measured adipose tissue gene expression profiles after 24 hr. We 
compared four experimental groups (n=8/group): lean mice injected with saline control (lean), obese mice 
injected with saline control (obese), obese mice injected with D-70 conjugates of the dextran-
dexamethasone conjugate (obese + D-70-drug), and obese mice treated with free dexamethasone (obese + 
free-drug) which was administered using an ethanol vehicle for solubilization at equivalent drug doses (5 
mg/kg BW)[42]. Gene expression of inflammatory markers was measured in mesenteric, perirenal, gonadal 
and subcutaneous AT depots using real time qRT-PCR of TNF, IL-6, monocyte chemoattractant protein 
1 (MCP-1), IL-10, peroxisome proliferator activated-receptor gamma (PPARγ), adiponectin and leptin. The 
obese + free-drug group yielded substantial abnormalities resulting from the vehicle and data. Results are 
depicted in Figure 5-10.  
Consistent with previous studies[43], in comparison with the lean mice, obese mice exhibited 
increased expression of pro-inflammatory markers (TNF, IL-6, and MCP-1), increased expression of the 
anti-inflammatory cytokine IL-10, reduced expression of regulators of adipogenesis, lipid metabolism, and 
glucose levels (PPARγ and adiponectin), and increased expression of a satiety hormone (leptin). The 
absolute differences between the two groups were dependent on the specific adipose depot, consistent with 
adipose inflammation heterogeneity previously described in the literature[44]. Remarkably, a single dose 
of D-70-drug yielded a trend of reduced expression of the three pro-inflammatory markers in all of the 
adipose tissues after just 24 hr, with several tissues restored to basal levels observed in the lean group. 
Compared to obese mice, statistically significant reductions (p < 0.05) were observed in the obese + D-70-
drug mice for TNF in all AT (Figure 5-10a), for IL-6 in gonadal and perirenal AT (Figure 5-10b), and 
for MCP-1 in mesenteric AT (Figure 5-10c). This drug treatment had little impact on the anti-inflammatory 
marker IL-10 (Figure 5-10d). PPARγ expression was found to be significantly increased in perirenal and 
subcutaneous AT of obese + D-70-drug compared to obese mice (Figure 5-10e) but no significant change 
was observed in adiponectin (Figure 5-10f). Strikingly, leptin expression levels were significantly 
increased in all adipose tissues of obese + D-70-drug when compared to obese mice (Figure 5-10g), which 
may be due to the high local concentration of dexamethasone in the adipose tissue that stimulates the leptin 
production of adipocyte at the mRNA level.  
Adipose tissues were also characterized using histopathological analysis. As shown in the images of 
gonadal tissue in Figure 5-10h, the lean group tissue was predominantly composed of adipocytes whereas 





proinflammatory immune cells that localize to and surround dead adipocytes within adipose tissue[45, 46], 
consistent with the well-known patterns of obese VAT. These patterns were significantly reduced in the 
obese + D-70-drug mouse tissue, suggesting a reduction in the number of infiltrating macrophages after 
just a single dose of drug. Taken together, these data demonstrate that dextran can be an effective carrier 
for anti-inflammatory prodrugs for modulating the local inflammatory state of VAT in obese mice. 
 
 
Figure 5-10. In vivo anti-inflammatory effects of D-70-drug in obese mouse VAT. (a-g). Relative mRNA-
level expression of genes in 4 adipose depots, comparing lean mice (relative expression = 1), with obese 
mice and obese mice treated with D-70-drug or free drug. Values of significance are indicated as (*) for 
lean vs. obese and obese vs. obese + D-70-drug for p < 0.05. (h) Representative haematoxylin-and-eosin-
stained images of paraffin-embedded gonadal adipose tissue isolated from each mouse group. n=4 or 5. 
Scale bar: 100 µm. 
 
5.2.6 Effects of Dextran-Drug Conjugates on Circulating Cytokines in Obese Mice 
       To determine if dextran-mediated delivery of AI drugs can modulate obesity-associated systemic 
inflammation, levels of circulating cytokines were measured using a multiplexed bead array assay for IL-





serum cytokine IL-6 tended to increase (p=0.059) with obesity, consistent with previous results from male 
mice49. The anti-inflammatory cytokine IL-10 also increased (p=0.032) with obesity in our study, which 
disagrees with most, but not all of the previous reports50. However, serum IL-10 have been shown to 
increase with LPS, an endotoxin that is elevated in obese patients and animals[47, 48]. Differences between 
the two groups in serum concentrations of TNF and IFN-γ were less substantial. The obese + D-70-drug 
group yielded a trend of restoring all of the cytokines in the obese group to their basal levels of the lean 
group, although with varying degrees of significance. Unlike a response to pathogens, obesity does not 
result in dramatic changes in circulating cytokine levels, so detecting statistically significant decreases with 
standard commercial kits is challenging[46, 47]. However, the low p-values are promising in that they 
demonstrate a restoration of systemic inflammation markers to levels observed in lean animals. 
 
Figure 5-11. Relative serum cytokines, comparing lean mice (relative expression = 1), with obese mice and 
obese mice treated with D-70-drug. Values for p are only indicated for those near to or less than 0.05 for 
lean vs. obese and obese vs. obese + D-70-drug. 
 
5.3 Discussion 
Macrophage targeting has become an important goal in pharmaceutical medicine due to the clear 
involvement of these cells in a multitude of pathologies including arteriosclerosis, cancer, and 
immunological disorders[49-51]. An assortment of targeted nanomedicine-based strategies has been 
contrived using antibodies against macrophage receptors[52-54], monosaccharide-based targeting[55], and 
polysaccharides-mediated delivery[50]. Polysaccharides have distinct advantages due to their low cost, ease 
of conjugation, biocompatibility and low toxicity, and clinical safety record of certain variants as blood 
volume expanders (dextran) and anticoagulants (e.g. heparin)[56]. Previously dextran has been used as a 
carrier for imaging agents and therapeutic compounds that have demonstrated specific uptake in liver 





following oral administration for gastrointestinal diseases[60]. However delivery through intravenous 
routes has not yielded efficient targeting for any tissue types beside the liver and spleen, where the majority 
of nanomedicines distribute[50]. 
 
 
Scheme 5-2. Schematic illustration of how dextran conjugate accumulates in obese VAT and interfere in 
cross-talk between M1 macrophages and adipocytes. (a) Dextran conjugate (green color) accumulation at 
left perirenal adipose tissue (AT) and left gonadal AT after intraperitoneal injection in obese mouse.  (b) 
View of mouse abdominal cross section at plane 5. Green color represents the location of dextran conjugate. 
(c) Rapid association of dextran conjugate with M1 macrophage in inflamed AT. (d) Intervention in 
paracrine loop between M1 macrophages and inflamed adipocyte by dextran-dexamethasone conjugate. In 
lean individuals, anti-inflammatory cytokines such as PPARγ, adiponectin and IL-10 are preferentially 
generated to maintain anti-inflammatory homeostasis in adipose tissue. In the obese state, hypertrophied 
adipocytes produce MCP-1 in response to oxidative stress, promoting adipose tissue inflammation, and 
causing monocyte recruitment followed by macrophage phenotype shift from M2 to M1. TH1 cell-derived 
IFNγ and IL-17 further help maintain the M1 macrophage phenotype and inflammation. Endogenous free 
fatty acids activate inflammatory signaling pathways involving NF-κB and NLRP3 inflammasomes in M1 
macrophages. These pathways lead to production of a broad range of pro-inflammatory cytokines and 
chemokines including MCP-1, TNF-, IL-1 and IL-6. These in turn enhance lipolysis and inflammation 
of adipocytes. This then initiates crosstalk between the M1 macrophages and adipocytes. The dextran AI 
prodrug is selectively uptake by M1 macrophage through receptor mediated endocytosis and free 
dexamethasone is released within the cells by esterase hydrolysis. The released dexamethasone then binds 
to the glucocorticoid receptor in the cytoplasm. The complex enters into nucleus and inhibits transcription 
of pro-inflammatory genes to disrupt the paracrine loop between macrophages and adipocytes. IFNGR: 








Figure 5-12. In vitro cell uptake of fluor-dextran (D-70) by M1, M2 and nonactivated RAW 264.7 cells 
was measured as mean fluorescence of treated cells via flow cytometry. (** = p<0.01) 
 
This work demonstrates a unique opportunity to efficiently target adipose macrophages involved in 
the pathogenesis of obesity comorbidities by using high molecular weight dextran as a targeting agent 
delivered through the peritoneum. Between 35-60% of the total injected dose was retained in adipose tissue 
of obese mice 24 hours after injection (Figure 5-6a) and >80% of the cells associated with dextran in three 
of the adipose tissues were myeloid in origin (Figure 5-7). This completely altered biodistribution in obese 
mice compared to what is observed through i.v. administration likely originates from the unique initial 
peritoneal injection pathway, which allows direct physical access of the administered dose to the perirenal, 
mesenteric, and gonadal fat pads. Based on the current understanding of i.p. delivery (see Scheme 5-2) 
from studies of peritoneal dialysis and ovarian cancer drug delivery[61], liquids delivered to this cavity 
generate a positive fluid pressure that drives convective flow of the injected solution directly into the 
peritoneal tissues and into the lymphatics through the lymphatic lacunae. Therefore some fraction of the 
injected dose of dextran can rapidly access the adipose interstitium where a large number of M1 
macrophages reside that can bind to and uptake dextran (Scheme 5-2c). This bypasses the conventional 
boundaries encountered with i.v. routes of administration that require inefficient extravasation across the 
vascular endothelium for access to interstitial macrophages. Indeed, the biodistribution of the injected 
conjugates was not substantially different after 4 hours following injection. The injected dose is likely to 
filter through the VAT in both lean and obese mice, however retention is higher by weight in the obese 
mice likely due to the higher macrophage population and their M1 polarization, which may be able to uptake 
dextran more efficiently than those in the M2 polarization. This is supported by in vitro macrophage culture 
























inconsistent in literature reports[62-64]. The higher total retention in the VAT in obese mice is also driven 
by the total greater amount of VAT compared with the lean mice. 
The origin of why certain adipose tissues, predominantly the left perirenal adipose tissue, retained 
more of the injected dose than others likely derives from the initial delivery location within the peritoneal 
cavity (Scheme 5-2a). Based on proximity to the injection site on the lower left dorsal region in the supine 
mouse, the perirenal and gonadal fat pads are expected to experience the most direct physical contact with 
the administered fluid (Scheme 5-2b). The dextran within this adipose tissue was almost homogeneously 
distributed by PET/CT (Figure 5-13), demonstrating that it has equal access to all of the tissue regions once 
it influxes into the tissue. Based on these observations, homogeneous delivery to all VAT may be possible 
through bilateral injections or through a catheter to ensure access to all of the peritoneal VAT depots, if that 
is desired. In addition, based on the trend in increasing total accumulation in VAT with increasing dextran 
molecular weight, it may be advantageous to further increase the molecular weight above 500 kDa to further 
decrease uptake in off-target tissues in the spleen and liver.  Increasing VAT uptake reflected decreasing 
uptake in the liver and spleen, such that a 2.2-fold higher concentration was observed in the perirenal VAT 
compared to the liver. This suggests the possibility of a wide therapeutic window in which drugs can elicit 
an efficacious effect in the VAT and avoid toxic or side effects in off-target organs. The capacity to do so 




Figure 5-13. C57BL/6J obese mice afterintraperitoneal injection with D-70-rad conjugate. After 24 hours, 
coronal section of PET/CT image showed even distribution of D-70-rad in adipose tissue. 
 
As a proof-of-concept of drug delivery using this new approach, we used dextran as a carrier to deliver 
dexamethasone, a glucocorticoid that inhibits the glucocorticoid receptor in a wide variety of cells in the 
body[65, 66]. In macrophages, glucocorticoids are known to induce strong anti-inflammatory effects and 





dexamethasone elicited similar effects toward inhibiting the production of TNFα and IL-6 by cultured 
macrophages compared with free dexamethasone (Figure 5-9). Moreover, this carrier substantially 
increased the solubility of this poorly soluble drug, mitigating the need for us of a toxic solvent adjuvant 
(e.g. ethanol or oils).  
Obese animals exhibited substantially increased expression of pro-inflammatory markers in VAT 
compared to lean animals, and the D-70-drug conjugate had a major effect toward reducing inflammatory 
phenotype. A single dose administration of D-70-drug to obese mice significantly reduced the TNF 
mRNA expression levels in all of studied AT along with inhibition of IL-6 and MCP-1 expression (Figure 
5-10a-c), suggesting efficient drug release, anti-inflammatory effects and decrease macrophages infiltration 
in adipose tissues. There was also a significant increase in PPARγ expression in both perirenal and 
subcutaneous AT after drug treatment. PPARγ agonists (thiazolidinediones, TZDs) such as rosiglitazone 
and pioglitazone have been used in the treatment of insulin resistance in clinical trials to upregulate the 
glucose uptake in adipose tissue[14, 67, 68]. Thus, this enhanced PPARγ mRNA expression may be 
beneficial for glucose uptake, regeneration of adipocytes, and insulin sensitivity. The lack of an effect on 
adiponectin may be due to the fact that its expression is regulated by PPARγ and 24 h may not be sufficient 
time to turn over multiple levels of this regulated pathway. The implications of a significant increase in 
production of leptin in AT with D-70-drug may be due to the high local concentration of free 
dexamethasone that were may have been released from neighboring macrophages over 24 hours. Numerous 
studies have confirmed that dexamethasone is a potent stimulator of leptin production at both mRNA and 
secreted protein levels. It should be mentioned that leptin promotes the secretion of pro-inflammatory 
cytokines and is also a satiety hormone that controls food intake[14, 69]. Several studies showed that leptin 
administration or glucocorticoid-induced leptin elevation could decrease caloric intake in obese human[70, 
71]. The additional leptin in the adipose tissue may be beneficial for weight loss by further reducing appetite. 
Collectively, these results showed that the inflammation microenvironment of adipose tissue has shifted 
to the normal state of lean control, which is correlated to histological observation of fewer “crown-like 
structures” in the obese + D-70-drug group compared with the obese group. The disappearance of immune 
cells here may indicate a quick dynamic response of immune cells to the change in inflammatory 
microenvironment[72]. It should be noted that this result was only after a single dose and short period of 
time (24 hours), so clearly, longer term studies are mandated to determine long-term effects on 
inflammation and associated pathologies as well as potential side effects. 
It is further important to note that different fat depots display functional differences. For instance, in 
humans the portal-drained visceral fat depots (mesenteric  and omental) are more lipolytically active 
compared to the subcutaneous fat pads, particularly in obese individuals[73]. Moreover, there are 





fat pad is only found in rodents. Importantly, perirenal fat depots, where the most uptake of dextran 
conjugates occurred in this study, are present in both mice and humans so we expect that these results are 
meaningful for clinical translation.  
Although i.p. administration is commonly used in the clinical care of pancreatic cancer, ovarian cancer, 
and kidney disease, it is more invasive than i.v. routes and carries a higher risk[74-76]. Therefore, for 
clinical translation, we envision that our targeted compounds will need to be delivered as slow-release 
formulations such that a patient can receive a single i.p. administration several times per year by a trained 
medical professional. Appropriate preparations could make use of the numerous biocompatible and 
biodegradable microsphere and emulsion technologies used as injectable “depots” with slow drug release 
over weeks, such as poly(lactic-co-glycolic acid)[76, 77]. Some of these are currently in clinical use for 




Visceral adipose tissue inflammation is thought to play a critical role in systemic inflammation and the 
development of insulin resistance associated with obesity[79]. Anti-inflammatory therapies represent a 
promising approach to potentially reverse pathological damage in adipose tissue inflammation[10, 12], but 
no clinically successful treatments have been found largely due to the off-target side effects of AI drugs. In 
addition, recent studies toward alleviating inflammation in obese rodents to enhance insulin sensitivity have 
not shown desirable results[44, 80]. One explanation for the frequently observed absence of effects of these 
drugs in obese subjects may be their inability to target adipose tissue in which endogenous cytokines act in 
a paracrine fashion and due to severe side effects of drugs to off-target organs, particularly the liver[80]. 
To our knowledge, this work represents the first example of active targeted drug delivery adipose tissue in 
obesity and one of the highest efficiency nanoparticle delivery results to date[81]. Acute prodrug 
administration after one day restored gene expression levels of key pro-inflammatory cytokines (TNF, IL-
6, MCP-1) and ameliorated many critical effects of obesity-induced inflammation. It is important to note 
that all components of these delivery agents are FDA approved agents that potentially enable rapid clinical 
translation. Future studies of this unique delivery strategy will be focused on drug dose and long-term 






5.5 Experimental Section 
Materials. Dextran (MW = 10 kDa and MW = 70 kDa), 4-(dimethylamino)pyridine (DMAP), 4-
Nitrophenyl chloroformate  (PNC),  lithium chloride (LiCl), trifluoroacetic acid (TFA), triethylamine 
(TEA), succinic anhydride, ethylenediaminetetraacetic acid (EDTA) and fluorescamine were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Anhydrous dimethyl sulfoxide (DMSO) was purchased from Macron 
Fine Chemicals (Center Valley, PA, USA). Anhydrous pyridine was purchased from EMD Chemicals. 
Anhydrous dimethylformamide (DMF) was purchased from Alfa Aesar (Ward Hill, MA, USA). CH3O-
PEG-NH2 (MW = 2 kDa) and H2N-PEG-NH-Boc (MW = 3 kDa) were purchased from Rapp Polymere 
(Tuebingen, Germany). Amino dextran (MW = 70 kDa and MW = 500 kDa) was purchased from Life 
Technologies (Grand Island, NY, USA). Dexamethasone was purchased from Cayman Chemical Company 
(Ann Arbor, Michigan, USA). Tetramethylrhodamine-5-isothiocyanate (5-TRITC) was obtained from 
Setareh Biotech (Eugene, OR, USA). p-SCN-Bn-NOTA was purchased from Macrocyclics (Dallas, TX, 
USA). Spectra/Por RC dialysis tubing with a molecular weight cut-off (MWCO) of 1 kDa and 2 kDa was 
purchased from Spectrum Laboratories (Rancho Dominguez, CA, USA). Dextran and LiCl were dried at 
80°C under vacuum for 4 hours before use. All other solvents were used as received. Monoboc protected 
diethylamine (BocEDA) was prepared according to the literature[82]. 
Instrumentation. NMR spectra were recorded using a Varian U500 or VXR500 500 MHz NMR 
spectrometer. UV-Vis absorption spectra were recorded using a Cary 5000 UV-Vis-NIR spectrophotometer 
from Agilent Technologies (Santa Clara, CA, USA). Size-exclusion chromatography (SEC) experiments 
were performed on a system equipped with an isocratic pump (Model 1100, Agilent Technology, Santa 
Clara, CA, USA), a DAWN HELEOS multi-angle laser light scattering (MALLS) detector, and an Optilab 
rEX refractive index detector (Wyatt Technology, Santa Barbara, CA, USA). The detection wavelength of 
HELEOS was set at 658 nm. Separations were performed using serially connected size exclusion columns 
(50 Å, 100 Å, 500 Å, and 103 Å Phenogel columns, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) 
at 60 °C using DMF containing 0.1 M LiBr as the mobile phase. The MALLS detector is calibrated using 
pure toluene with no need for calibration using polymer standards and can be used for the determination of 
the absolute molecular weights (MWs). The MW was determined from the dn/dc value calculated offline 
by means of the internal calibration system processed by the ASTRA V software (Version 5.1.7.3, Wyatt 
Technology). Gel filtration chromatography (GFC) was performed using a chromatography system from 
GE Healthcare (ÄKTApurifier  NPC 10, Pittsburgh, PA, USA) equipped with a HiPrep 16/60 Sephacryl S-
500 HR column was used as the mobile phase with a flow rate of 0.5 mL/min. The typical sample injection 
volume was 100 µL. Detection was by eluent absorption at 254 nm. For purification, a HiPrep 16/60 





column was used for amino dextran (MW 70 kDa). Elemental analysis was performed with a PerkinElmer 
Optima 2000DV ICP–optical emission spectrometer in the Microanalysis Laboratory at the University of 
Illinois. 
Cell Culture and Flow Cytometric Analysis of Macrophage Endocytosis. RAW 264.7 cells were cultured 
at 37 oC with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % FBS 
and 1 % P/S.  RAW 264.7 cells were seeded in 12-well plate at 3×105 cells/well in presence of 100 ng/mL 
LPS (Sigma Aldrich, Product No. L2880) or 20 ng/mL (IL-4) (PeproTech, Rocky Hill, NJ) and incubated 
24 h at 37 oC in 5% CO2. After activation, dextran Texas Red (MW = 70 kDa, Life technologies, Catalog 
No. D1830) (100 µL, 10 mg/mL) was added to the wells and incubated for another 4 h. Cells were then 
washed and lifted up by cell scraper gently. The harvested cells were transferred into microcentrifuge tubes 
and keep them on ice. After wash the cells with 500 µL cold wash buffer (PBS, 2% FBS, 0.1 % sodium 
azide), centrifuge down the cells and discard the supernatant. Repeat above washing step for three times 
and then resuspend the cells in 500 µL ice cold FACS buffer (PBS, 10% FBS, 0.1 sodium azide). At least 
10,000 cells/sample was analyzed by BD LSRFortessaTM cell analyzer (BD Biosciences).  
 
Animals and Diets. All animal procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Illinois, and housed under a temperature- and humidity-controlled 
environment, with a 12 hour light-12 hour dark cycle. All mice were purchased from Jackson Laboratory 
(Bar Harbor, ME) and fed either a high-fat diet (HFD, 60% ME from fat; D12492, Research diet, Inc.) or 
low-fat control diet (HFD, 10% ME from fat; D12450J, Research diet, Inc.) ad libitum in this work. 
 
Biodistribution in Rodents. Twenty18-wk-old diet induced-obese C57BL/6J mice and twenty 18-wk-old 
LFD fed lean C57BL/6J mice were purchased and fed either HFD or LFD ad libitum with free access to 
fresh water for 8 wk. At 26 wk of age, mice were randomly allotted to the following groups (n=4/group): 
1) HFD, administrated with 10KD radiolabelled dextran (obese, 64Cu-D-10); 2) HFD, administrated with 
70KD radiolabelled dextran (obese, 64Cu-D-70); 3) HFD, administrated with 500KD radiolabelled dextran 
(obese, 64Cu-D-500); 4) HFD, administrated with radiolabelled PEG-dextran (obese, 64Cu-D-70-PEG); 5) 
LFD, administrated with 10KD radiolabelled dextran (lean, 64Cu-D-10); 6) LFD, administrated with 70KD 
radiolabelled dextran (lean, 64Cu-D-70); 7) LFD fed, administrated with 500KD radiolabelled dextran (lean, 
64Cu-D-500); 8) LFD, administrated with radiolabelled PEG-dextran (lean, 64Cu-D-70-PEG). All the 
injections were administered intraperitoneally (i.p.) 24h before euthanasia, and each mouse received ~100 
µCi of radioactivity. One mouse from each group was randomly selected for PET/CT imaging at 1 h, 4 h, 





obtained via cardiac puncture, and various tissues were collected for radioactivity measurement including 
adipose tissues (mesenteric, perirenal, gonadal, and subcutaneous fat depots), liver, spleen, heart, kidneys, 
lungs and intestine.  
 
Dextran-drug Conjugates Administration in Obese Mice. Twenty-four 6-wk-old C57BL/6J mice were 
purchased. Upon arrival, mice were fed either HFD or LFD ad libitum for 20 wk. Mice had free access to 
fresh water and body weight was measured weekly. At 26-wk of age, mice were randomly allotted to the 
following groups: 1) HFD, administrated with dextran-dexamethasone conjugate (5.0 mg/kg BW); 2) HFD, 
administrated with dextran-Texas Red dye conjugate; 3) LFD, administrated with dextran-Texas Red dye 
conjugate, and all the IP administration occurred 24h before euthanasia. Mice were euthanized with CO2 
asphyxiation after 8-h of fasting.  Blood was obtained via cardiac puncture for serum triglyceride 
(Comparative Clinical Pathology Services, Columbia, MO) and cytokines measurements (Bio-Plex ProTM 
Mouse Cytokine Th17 Panel, Bio-Rad, Hercules, CA). Adipose tissues (mesenteric, perirenal, gonadal, and 
subcutaneous fat depots) and liver were dissected and collected for histomorphology and quantitative 
reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis. 
 
Dextran Uptake by Myeloid Cells in Obese Mice. Four 25-wk-old diet induced-obese C57BL/6J mice were 
fed HFD ad libitum for 1 wk after purchase as an acclimation period. At 26-wk of age, mice were i.p.i.p. 
administered with saline or D-70-fluor 24 h before euthanasia. AT was harvested and immediately digested 
in a collagenase buffer. Cells were stained with anti-mouse CD11b (BD 557686) and subjected to flow 
cytometry. Events were gated first on forward and side scatter, followed by TRITC positivity and finally 
on CD11b positivity. 
 
RNA Extraction and RT-PCR. Total RNA from mesenteric, perirenal, gonadal, and subcutaneous fat 
depots of mice administrated with dextran-drug conjugates was isolated using RNeasy Kits (Qiagen, 
Valencia, CA) with DNase digestion (RNase-Free DNase Set, Qiagen, Valencia, CA).  RNA concentration 
was determined using a ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE). cDNA 
was made using SuperScript® III Reverse Transcriptase (Invitrogen, Carlsbad, CA). TaqMan Gene 
Expression Assays primer-probe sets (Applied Biosystems, Foster City, CA) were used for each gene of 
interest: TNFα, IL-6, IL-10, MCP-1, PPARγ, Leptin and Adiponectin. Real-time two-step RT-PCR was 
performed using the Applied Biosystems 7900HT Real-Time PCR System (Applied Biosystems, Foster 







Synthesis of D-10-PNC[83-85]. D-10 (2 g) was added to DMSO/Pyridine (80 mL, v/v, 1/1) with stirring 
at 0°C, followed by slow addition of DMAP (72 mg, 589.3 µmol) and PNC. The reaction mixture was 
stirred at 0°C for 4 hours, and the product was precipitated in excess ethanol/ether (800 mL, v/v, 1/1). D-
10-PNC was then collected by filtration, washed with excess ethanol and diethyl ether, and dried under 
vacuum. Yield: 1.8 g (80%). 1H NMR (DMSO-d6, 500 MHz): δ 7.5 and 8.3 (dd, aromatic protons), 5.3 and 
5.5 (s, dextran glucosidic protons at positions which have nitrophenyl substituents), 4.50, 4.84, and 4.91 (s, 
dextran hydroxyl protons), 4.66 (s, dextran anomeric proton), 3.10 – 3.89 (m, dextran glucosidic protons). 
Synthesis of D-10-Boc. D-10-PNC (0.8 g) was dissolved in DMF (10 mL) containing 1 w/v % of LiCl. 
BocEDA (64 mg, molar ratio of amine to PNC group = 6.5) was dissolved in DMF (1 mL) and added to 
the dextran solution. The reaction was stirred for 12 hr at room temperature. D-10-Boc was recovered by 
precipitation in ethanol, washed several times with ethanol and ether, and finally dried under vacuum. Yield: 
0.6 g (80%). 1H NMR (DMSO-d6, 500 MHz): δ 7.45 and 8.28 (dd, aromatic protons), 4.50, 4.84, and 4.91 
(s, dextran hydroxyl protons), 4.66 (s, dextran anomeric proton), 3.10 – 3.89 (m, dextran glucosidic protons), 
3.33 – 3.52 (m, -CH2-CH2-), 1.37 (s, -C(CH3)3). 
Synthesis of D-10-NH2. D-10-Boc (0.8 g) was deprotected with 0.75 mL of TFA in 8.0 mL deionized water. 
The reaction was allowed to proceed overnight under N2. After neutralized with 4.0 M NaOH to pH 7.0, 
the mixture was dialyzed against water (MWCO 2 kDa). D-10-NH2 was obtained as white solid product 
after lyophilization. Yield: 0.16 g (20%). 1H NMR (D2O, 500 MHz): δ 4.81 (s, dextran anomeric proton), 
3.31 – 3.89 (m, dextran glucosidic protons), 2.97 and 3.46 (m, -CH2-CH2-).  
Synthesis of D-70 Conjugates. D-70 conjugates were synthesized from D-70-NH2, which was purchased 
from a commercial source and used after narrowing of molecular weight distribution. A 40 mg/mL solution 
was prepared by dissolving 400 mg amino-dextran in 900 µL water and 100 µL 10 × PBS. The solution 
was centrifuged at 7,000 g for 10 min and then filtered with 0.22 µm filter. Gel filtration chromatography 
was performed (flow rate: 0.5 mL/min, mobile phase: 1 ×PBS), with fractionation collection, and partial 
sample loop filling was used for sample loading. A 250 µL sample was loaded in a 500 µL sample loop and 
5-8 fractions were combined each time. A total of 160 mL product was obtained, which was concentrated 
and desalted using an Amicon filter with molecular weight cutoff (MWCO) of 30 kDa. A white solid 
polymer was obtained after lyophilization.  
Synthesis of D-70-PNC. D-70 (0.2 g) was suspended in 20 mL DMF (dry) and then LiCl (0.4 g, 2 w/v % 
of DMF) was added. The suspension was heated to 90°C until the solution became clear. Then the reaction 
mixture was cooled to 0°C and pyridine (249 µL, 3.08 mmol) was added, followed by PNC (622 mg, 3.08 





cold ethanol, washed with diethyl ether, and under vacuum[86]. Yield: 0.4 g (50%). Mn = 150 kDa; Mw/Mn 
= 1.24. 1H NMR (DMSO-d6, 500 MHz): δ 7.51 and 8.28 (b, aromatic protons), 5.33 and 5.52 (s, dextran 
glucosidic protons at positions which have nitrophenyl substituents), 4.9, 4.8, and 4.5 (s, dextran hydroxyl 
protons), 4.7 (s, dextran anomeric proton), 3.10 – 3.89 (m, dextran glucosidic protons).  
Synthesis of D-70-PEG-Boc. D-70-PNC (50 mg) was dissolved in anhydrous DMF (4 mL) under N2. Then 
a solution of CH3O-PEG-NH2 (MW = 2 kDa, 367.8 mg) and H2N-PEG-NH-Boc (MW = 3 kDa, 55.17 mg) 
in 1 mL DMF was added in one portion. The mixture was stirred at room temperature for 24 hr. The product 
was purified using an Amicon filter (MWCO 10 kDa) and then freeze-dried to give the product D-70-PEG-
Boc. Yield: 130 mg (30%). Mn = 370 kDa; Mw/Mn = 1.23.   1H NMR (D2O, 500 MHz): δ 4.81 (s, dextran 
anomeric proton), 3.31 – 3.89 (m, dextran glucosidic protons), 3.53 – 3.57 (b, -O-CH2-CH2-), 3.22 (s, -O-
CH3), 1.28 (s, -C(CH3)3). 
Synthesis of D-70-PEG-NH2. D-70-PEG-Boc (130 mg) was deprotected with 0.3 mL of TFA in 3.1 mL of 
deionized water overnight under N2. After neutralized with 4.0 M NaOH to pH = 7.0, the mixture was 
purified by Amicon filter (MWCO 10 kDa). D-70-PEG-NH2 was obtained as white solid product after 
lyophilization. Yield: 80 mg (80%). 1H NMR (D2O, 500 MHz): δ 4.81 (s, dextran anomeric proton), 3.31 – 
3.89 (m, dextran glucosidic protons), 3.53 – 3.57 (b, -O-CH2-CH2-), 3.22 (s, -O-CH3). 
Synthesis of D-Fluor Conjugates[87, 88]. D-70-NH2 (10 mg, 3.14 µmol free amine) was dissolved in 1 
mL anhydrous DMSO with 10 µL TEA for 4 hr. Then 5-TRITC (0.5 mg, 1.13 µmol) in 0.5 mL DMSO 
was added. The mixture stirred for 14 h in h dark. The polymer was purified by repeated concentration 
and dilution (at least 8 times) with an Amicon filter (MWCO 30 kDa) in the dark. The 
tetramethylrhodamine (TR) conjugate was obtained after lyophilization (8 mg).  Syntheses of other TR 
conjugates were similar except dialysis (MWCO 1 kDa) was used for purification. 
Synthesis of D-NOTA Conjugates.  D-NOTA conjugates were synthesized from D-NH2, as depicted in 
Scheme 5-1. D-70-NH2 (40 mg) was dissolved in 2 mL anhydrous DMSO, and 17.53 µL anhydrous TEA 
was added. Then p-SCN-Bn-NOTA (8.4 mg) in 500 µL DMSO was added and the mixture was left at room 
temperature for 16 hr. The product was purified by Amicon filter (MWCO 30 kDa) and the solid D-70-
NOTA was obtained after lyophilizaiton. Yield: 30 mg (70%). 1H NMR (D2O -d6, 500 MHz): δ 7.1 and 7.2 
(dd, aromatic protons), 4.8 (s, dextran anomeric proton), 3.3 – 3.9 (m, dextran glucosidic protons). For other 
NOTA conjugates, dialysis (MWCO 1 kDa) was used for purification and solid samples were obtained after 
lyophilization.  
Synthesis of D-Rad Conjugates. A solution of D-NOTA in NH4OAc buffer (100 µL, 5 mg/mL, pH = 5.5, 





Louis, MO, USA). The mixture was incubated for 10 min at 60°C before nonradioactive copper (equivalent 
molar amount to NOTA in the dextran conjugate) was added to saturate remaining NOTA. The mixture 
was then incubated for 20 min at 60°C. EDTA (2 equivalent of total copper amount) was added to scavenge 
nonspecifically bound copper or free copper and incubated at 60°C for another 10 min. Free copper (64Cu 
and nonradioactive Cu), EDTA, and EDTA-copper chelates were removed and buffer was exchanged to 
1XPBS using an Amicon filter (MWCO 3 kDa). To assess sample purity, a small aliquot (10 µCi) of 
solution was reacted with a large excess of EDTA (1000: 1 molar excess) and incubated at 60°C for 15 min. 
Solutions were then analyzed by radio-TLC in an EtOH/Ammonium Acetate (1:1, v/v) mobile phase. Rf 
(64Cu-EDTA): 0.84; Rf (64Cu-D-10): 0.16; Rf (64Cu-D-70): 0.03; Rf (64Cu-D-500): 0.07, Rf (64Cu-D-70-
PEG): 0.04. Samples with radiochemical purity (RCP) greater than 90% were used for imaging experiments. 
Synthesis of Dexamethasone Succinic Acid (DSA). Dexamethasone (1.0 g, 2.55 mmol) was dissolved in 
pyridine (25 mL). A solution of succinic anhydride (0.77 g, 7.65 mmol) and DMAP (31 mg, 0.255 mmol) 
in pyridine (10 mL) was added to the dexamethasone solution. The reaction was stirred overnight under 
nitrogen at room temperature. The pyridine was then removed under vacuum and 40 mL water was added 
into the residue. Then mixture was stirred for 10 min and then centrifuged. The resulting precipitate was 
washed again with H2O. DSA was collected as a white powder[89]. Yield: 1.0 g (80%). 1H NMR (DMSO-
d6, 500 MHz): δ 7.24 (dd, 1H, -CH=CH-CH2-), 6.19 (dd, 1H, -CH=CH-CH2-), 5.97 (t, 1H, -CH=C<), 5.41 
(s, 1H, -OH), 5.13 (s, 1H, -OH), 5.00 (dd, 2H, -CH2-O-), 4.76 (dd, 1H, -CH2-O-), 4.10 (dd, 1H, >CH-OH), 
2.83 (t, 1H, -C-CH<), 2.60 – 2.48 (m, 2H, -CH2-CH2-, -CO-CH2-CH2-), 2.47 – 2.41 (s, 2H, -CO-CH2-CH2-), 
2.41 – 2.21 (m, 2H, -CH2-CH2-,-CH-CH-), 2.18 – 2.01 (m, 2H, HO-CH-CH2-, -CH-CH2-), 1.73 (dd,  1H, -
CH2-CH2-), 1.65 – 1.42 (m, 5H, -CH3, -CH-CH2-CH2-, HO-CH-CH2-), 1.30 (m, 1H, -CH2-CH2-), 1.03 (dd, 
1H, -CH-CH2-CH2-), 0.84 (s, 3H, >C-CH3), 0.74 (dd, 3H, >CH-CH3). 
Synthesis of D-70-Drug. DSA (0.5 mmol, 0.246 g) and 1,1′-carbonyldiimidazole (0.162 g, 1 mmol) were 
dissolved in anhydrous DMSO (2.5 mL). The resulting mixture was stirred for 1 hr and then a solution of 
dextran (0.75 g, 5%, w/v) in anhydrous DMSO (15 mL) was added. TEA (1.5 mL) was added to catalyze 
the reaction. The solution was sealed under nitrogen and allowed to react for 36 hr. The dextran conjugate 
was precipitated by addition to 30 mL ethanol/ether (50: 50, v/v). The precipitate was dispersed in ethanol 
and centrifuged to collect the polymer, which was then washed with anhydrous ether three times and dried 
under vacuum. The polymer was purified by redissolution in anhydrous DMSO (10 mL) and precipitation 
from ethanol (30 mL). The product was washed with ethanol and ether and dried under vacuum to yield a 
white powder[90]. Yield: 0.9 g (90%). 1H NMR (DMSO-d6, 500 MHz): δ 4.50, 4.84, and 4.91 (s, dextran 
hydroxyl protons), 4.66 (s, dextran anomeric proton), 3.10 – 3.89 (m, dextran glucosidic protons), 7.24 (dd,  





O-), 4.76 (dd, -CH2-O-), 4.10 (dd, >CH-OH), 2.83 (t, -C-CH<), 2.60 – 2.48 (m, -CH2-CH2-, -CO-CH2-
CH2-), 2.47 – 2.41 (m, -CH2-CH2-, -CO-CH2-CH2-), 2.41 – 2.21 (m, -CH2-CH2-,-CH-CH-), 2.18 – 2.01 (m, 
HO-CH-CH2-, -CH-CH2-), 1.73 (dd,  -CH2-CH2-), 1.65 – 1.42 (m, -CH3, -CH-CH2-CH2-, HO-CH-CH2-), 
1.30 (m, -CH2-CH2-), 1.03 (dd, -CH-CH2-CH2-), 0.84 (s, >C-CH3), 0.74 (dd, >CH-CH3).   
Animation Analysis. Quantitative analysis of primary amine incorporation into dextran was performed 
using a fluorescamine assay. Briefly, a 10 mg/mL solution of fluorescamine in anhydrous DMSO was 
freshly prepared, and glycine standards (0 – 1.0 mM) were prepared in deionized water. The assay was 
initiated by mixing 380 µL water, 70 µL fluorescamine solution, 50 µL sample or standard, and 50 µL of 
500 mM sodium borate buffer (pH 8.5). After 20 min of reaction in the dark, the fluorescence intensity at 
470 nm, with 380 nm excitation was measured using a fluorescence microplate reader (BioTek Synergy 
HT).  
Validation of NOTA Percentage with non-radioactive Cu. D-70-NOTA (5 mg, 1.571 µmol of NOTA) was 
dissolved in 1 mL NH4OAc buffer (pH 5.5). Then 40 mM CuCl2 (100 µL, 4 µmol) was added and the 
reaction mixture was stirred overnight at room temperature. Free copper was removed by dialysis against 
distilled water (MWCO 1 kDa). The sample was then lyophilized and weighed, and ICP-MS was performed 
on a sample of known weight.  
Drug Release Kinetics Study. Drug conjugates were dissolved in 1X PBS (pH 7.4) and incubated at 37°C 
in a Pur-A-Lyzer (MWCO 3.5 kDa) (Aldrich, Catalog No. PURD35050-1KT), immersed in 20 mL buffer 
solution. After specific time intervals (0, 1, 4, 7, and 11 days), 1 mL of the buffer solution was withdrawn 
and 1 mL of fresh buffer solution was added to maintain a constant volume. The total concentration of 
dexamethasone and dexamethasone succinic acid was measured by UV-Vis absorption. Each experiment 
was repeated three times. The cumulative drug release percentage (𝐸𝑟) was calculated using the following 
equation: 
𝐸𝑟(%) =




 ×  100% 
Where 𝑚𝐷𝑒𝑥 represents the mass of dexamethasone in the conjugate, 𝑉0 is the total volume (𝑉0 = 20 mL), 
𝑉𝑡 is the volume of the replaced media (Vt =1.0 mL), and 𝐶𝑛 is the total concentration of dexamethasone 
and dexamethasone succinic acid in the sample. 
Flow Cytometric Analysis of Macrophage Endocytosis of Dextran Conjugates. RAW 264.7 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS and 1% P/S at 





were grown in the presence of 100 ng/mL LPS (Sigma Aldrich, Product No. L2880) or 20 ng/mL IL-4 
(PeproTech, Rocky Hill, NJ), respectively, for 24 hr. Then dextran-Texas Red (MW = 70 kDa, Life 
Technologies, Catalog No. D1830, 100 µL, 10 mg/mL) was added to the wells and the cells were incubated 
for an additional 4 hr. Cells were then washed, gently harvested using a cell scraper, and transferred to 
microcentrifuge tubes on ice. The cells were washed with 500 µL cold wash buffer (PBS, 2% FBS, 0.1% 
sodium azide) and collected by centrifugation. This was repeated three times and then the cells were 
resuspended in 500 µL ice cold flow cytometry buffer (PBS, 10% FBS, 0.1% sodium azide). At least 10,000 
cells/sample were analyzed using a BD LSRFortessaTM cell analyzer (BD Biosciences).  
In vitro Cellular Anti-Inflammatory Phenotype Analysis. RAW 264.7 cells were seeded on 24-well plates 
at 2×104 cells/well and cultured for 24 hr. The culture medium was exchanged with complete medium 
supplemented with 100 ng/mL LPS to induce M1 polarization. After 24 hr, the medium was exchanged 
with freshly prepared complete medium supplemented with 100 ng/mL LPS and 1 µM of either free 
dexamethasone solution, D-drug conjugate solution (1 µM free drug concentration) or vehicle as a control. 
Conditioned medium was collected at different time points (1, 6, 12, 24, 48 hr) for quantification of 
extracellular TNF or IL-6 production by enzyme-linked immunosorbent assays (ELISA, R&D, USA). 
The impact of drugs was measured as the percent of TNF or IL-6 detected divided by the percent detected 
in control cells which did not receive drug treatment. 
Tissue Radioactivity Measurements via γ-Counter. Ex vivo measurements of radioactivity were conducted 
using a Wizard2 Automatic γ-counter (Perkin-Elmer, USA). Mice were euthanized and dissected after the 
final micro-PET/CT imaging session (24 hr after injection). All major organs and tissues were collected, 
weighed and measured for radioactivity using the appropriate energy window centered at 511 keV for 64Cu. 
Raw counts were corrected for background, decay, and weight. Corrected counts were converted to micro-
curie (µCi) per gram using a previously determined calibration curve based on 64Cu standards. Activity in 
each collected tissue sample was calculated as percentage of injected dose per gram of tissue (%I.D./g). For 
this calculation, the radioactivity in tissue was corrected for decay at the time of γ-well counting. Data are 
presented as %I.D./g (mean ± standard error). Statistical analysis was performed using a two-tailed 
Student’s t-test, and p-values < 0.05 were considered statistically significant. 
Histologic Evaluation. Portions of VAT were removed at the time of euthanasia and placed in 10% neutral 
buffered formalin for 24 hours at a volume of at least ten parts formalin to one part tissue.  After 24 hours, 
tissues were transferred to 80% ethanol for storage at 4o C until trimming.  Tissues were processed in graded 
alcohols through xylene, then infiltrated and imbedded in paraffin blocks.  Tissues were section at 3 m 





staining procedure.  Slides were evaluated subjectively in blinded fashion by a board-certified veterinary 
pathologist, Matthew A. Wallig from Department of Pathobiology, for the presence or absence of lesions, 
including adipocyte degeneration / necrosis and interstitial inflammation, characterized by increased 
interstitial cellularity due to the presence of macrophages, lymphocytes and/or neutrophils.  
Statistical analysis. All data were analyzed using SAS 9.2 (SAS Institute, Cary, NC) using the Mixed 
Models procedure.  When appropriate, post hoc Tukey’s tests were performed to determine differences 
among treatment groups.  Data are reported as means ± SEM with statistical significant set as p<0.05 and 
p<0.10 considered as trends. 
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